ES2632009T3 - Ligandos de receptores de opioides y métodos para utilizar y obtener los mismos - Google Patents
Ligandos de receptores de opioides y métodos para utilizar y obtener los mismos Download PDFInfo
- Publication number
- ES2632009T3 ES2632009T3 ES12760456.9T ES12760456T ES2632009T3 ES 2632009 T3 ES2632009 T3 ES 2632009T3 ES 12760456 T ES12760456 T ES 12760456T ES 2632009 T3 ES2632009 T3 ES 2632009T3
- Authority
- ES
- Spain
- Prior art keywords
- ethyl
- amine
- oxaspiro
- methyl
- decan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title description 8
- 239000003446 ligand Substances 0.000 title description 7
- 102000003840 Opioid Receptors Human genes 0.000 title description 6
- 108090000137 Opioid Receptors Proteins 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 abstract description 188
- 150000003839 salts Chemical class 0.000 abstract description 16
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 10
- 238000006467 substitution reaction Methods 0.000 abstract description 9
- 125000001072 heteroaryl group Chemical group 0.000 abstract description 8
- 125000002950 monocyclic group Chemical group 0.000 abstract description 5
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract description 4
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- -1 Benzyl ({2- [4- (4-fluorophenyl) -2,2-dimethyloxan-4-yl] ethyl}) amine Chemical class 0.000 description 359
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 157
- 150000001412 amines Chemical class 0.000 description 118
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 101
- 238000005160 1H NMR spectroscopy Methods 0.000 description 90
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 56
- 239000000126 substance Substances 0.000 description 51
- 238000012512 characterization method Methods 0.000 description 48
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 40
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 32
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 26
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 24
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 20
- 238000005481 NMR spectroscopy Methods 0.000 description 20
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 17
- 125000003118 aryl group Chemical group 0.000 description 14
- 238000001228 spectrum Methods 0.000 description 14
- 125000001424 substituent group Chemical group 0.000 description 14
- 125000005843 halogen group Chemical group 0.000 description 13
- 239000004310 lactic acid Substances 0.000 description 13
- 235000014655 lactic acid Nutrition 0.000 description 13
- 125000000217 alkyl group Chemical group 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 9
- 125000000623 heterocyclic group Chemical group 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 5
- 229960003184 carprofen Drugs 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 125000001544 thienyl group Chemical group 0.000 description 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 4
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 4
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 4
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 3
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 3
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 3
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical compound C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 229940121367 non-opioid analgesics Drugs 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- IJVNQJHHXLTQFV-OAHLLOKOSA-N 2-[(9r)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine Chemical compound C([C@@](C1)(CCN)C=2N=CC=CC=2)COC21CCCC2 IJVNQJHHXLTQFV-OAHLLOKOSA-N 0.000 description 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 2
- OAVTYOIOESAJKW-UHFFFAOYSA-N 4-[[2-[4-(2-methoxyphenyl)-2,2-dimethyloxan-4-yl]ethylamino]methyl]-n,n-dimethylaniline Chemical compound COC1=CC=CC=C1C1(CCNCC=2C=CC(=CC=2)N(C)C)CC(C)(C)OCC1 OAVTYOIOESAJKW-UHFFFAOYSA-N 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960003803 meclofenamic acid Drugs 0.000 description 2
- 229960003464 mefenamic acid Drugs 0.000 description 2
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229960000953 salsalate Drugs 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229960000894 sulindac Drugs 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 229960001017 tolmetin Drugs 0.000 description 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- SOQXEYAYCJZLLI-LMNIDFBRSA-N 1-[5-[[2-[(9R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethylamino]methyl]thiophen-2-yl]ethanol Chemical compound N1=C(C=CC=C1)[C@@]1(CCOC2(CCCC2)C1)CCNCC1=CC=C(S1)C(C)O SOQXEYAYCJZLLI-LMNIDFBRSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
- 125000005955 1H-indazolyl group Chemical group 0.000 description 1
- 125000003070 2-(2-chlorophenyl)ethyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000301 2-(3-chlorophenyl)ethyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- IJVNQJHHXLTQFV-UHFFFAOYSA-N 2-(9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl)ethanamine Chemical compound C1C(CCN)(C=2N=CC=CC=2)CCOC21CCCC2 IJVNQJHHXLTQFV-UHFFFAOYSA-N 0.000 description 1
- DPCUAOPGQHVJJN-UHFFFAOYSA-N 2-[2,2-dimethyl-4-(4-methylphenyl)oxan-4-yl]-N-[(2-methoxyphenyl)methyl]-N-methylethanamine Chemical compound CC1(OCCC(C1)(C1=CC=C(C=C1)C)CCN(C)CC1=C(C=CC=C1)OC)C DPCUAOPGQHVJJN-UHFFFAOYSA-N 0.000 description 1
- XRZYWBNYJREUNS-UHFFFAOYSA-N 2-[2,2-dimethyl-4-(4-methylphenyl)oxan-4-yl]-n-[(3-methylphenyl)methyl]ethanamine Chemical compound C1=CC(C)=CC=C1C1(CCNCC=2C=C(C)C=CC=2)CC(C)(C)OCC1 XRZYWBNYJREUNS-UHFFFAOYSA-N 0.000 description 1
- TYCOFFBAZNSQOJ-UHFFFAOYSA-N 2-[4-(3-fluorophenyl)phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC(F)=C1 TYCOFFBAZNSQOJ-UHFFFAOYSA-N 0.000 description 1
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 description 1
- GMSLGZAZRVMEIG-UHFFFAOYSA-N 2-[9-(2-aminoethyl)-6-oxaspiro[4.5]decan-9-yl]-1H-pyridin-4-one Chemical compound NCCC1(CCOC2(CCCC2)C1)C1=NC=CC(=C1)O GMSLGZAZRVMEIG-UHFFFAOYSA-N 0.000 description 1
- RNIWZJBOQXPUAX-UHFFFAOYSA-N 2-[[2-[2,2-dimethyl-4-(4-methylphenyl)oxan-4-yl]ethylamino]methyl]phenol Chemical compound CC1(OCCC(C1)(C1=CC=C(C=C1)C)CCNCC1=C(C=CC=C1)O)C RNIWZJBOQXPUAX-UHFFFAOYSA-N 0.000 description 1
- AZZXQPIFKYDBCE-UHFFFAOYSA-N 2-[[2-[2-ethyl-2-methyl-4-(4-methylphenyl)oxan-4-yl]ethylamino]methyl]phenol Chemical compound C1COC(CC)(C)CC1(C=1C=CC(C)=CC=1)CCNCC1=CC=CC=C1O AZZXQPIFKYDBCE-UHFFFAOYSA-N 0.000 description 1
- FUGFRVYNKAYHJM-UHFFFAOYSA-N 2-[[2-[4-(4-fluorophenyl)oxan-4-yl]ethylamino]methyl]phenol Chemical compound FC1=CC=C(C=C1)C1(CCOCC1)CCNCC1=C(C=CC=C1)O FUGFRVYNKAYHJM-UHFFFAOYSA-N 0.000 description 1
- QXJKYQBYAFLIDP-UHFFFAOYSA-N 2-[[2-[4-(4-methoxyphenyl)-2,2-dimethyloxan-4-yl]ethylamino]methyl]phenol Chemical compound COC1=CC=C(C=C1)C1(CC(OCC1)(C)C)CCNCC1=C(C=CC=C1)O QXJKYQBYAFLIDP-UHFFFAOYSA-N 0.000 description 1
- TYKOFZSXWIUAJX-UHFFFAOYSA-N 2-[[2-[9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-9-yl]ethylamino]methyl]phenol Chemical compound FC1=CC=C(C=C1)C1(CCOC2(CCCC2)C1)CCNCC1=C(C=CC=C1)O TYKOFZSXWIUAJX-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- XKSAJZSJKURQRX-UHFFFAOYSA-N 2-acetyloxy-5-(4-fluorophenyl)benzoic acid Chemical compound C1=C(C(O)=O)C(OC(=O)C)=CC=C1C1=CC=C(F)C=C1 XKSAJZSJKURQRX-UHFFFAOYSA-N 0.000 description 1
- SKNUXEFKQKPIHH-OAQYLSRUSA-N 2-amino-4-chloro-5-[[2-[(9R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethylamino]methyl]thiophene-3-carbonitrile Chemical compound NC=1SC(=C(C=1C#N)Cl)CNCC[C@]1(CCOC2(CCCC2)C1)C1=NC=CC=C1 SKNUXEFKQKPIHH-OAQYLSRUSA-N 0.000 description 1
- NUNHXJYRUDTBFI-JOCHJYFZSA-N 2-chloro-5-[[2-[(9r)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethylamino]methyl]pyridine-3-carbonitrile Chemical compound C1=C(C#N)C(Cl)=NC=C1CNCC[C@]1(C=2N=CC=CC=2)CC2(CCCC2)OCC1 NUNHXJYRUDTBFI-JOCHJYFZSA-N 0.000 description 1
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 description 1
- LLJRZCBWWOFEJC-JOCHJYFZSA-N 2-fluoro-5-[[2-[(9r)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethylamino]methyl]pyridine-3-carbonitrile Chemical compound C1=C(C#N)C(F)=NC=C1CNCC[C@]1(C=2N=CC=CC=2)CC2(CCCC2)OCC1 LLJRZCBWWOFEJC-JOCHJYFZSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- HROSQPIFFBINFG-HSZRJFAPSA-N 2-methoxy-5-[[2-[(9r)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethylamino]methyl]pyridine-3-carbonitrile Chemical compound C1=C(C#N)C(OC)=NC=C1CNCC[C@]1(C=2N=CC=CC=2)CC2(CCCC2)OCC1 HROSQPIFFBINFG-HSZRJFAPSA-N 0.000 description 1
- CCWMKUPBVUNVNH-HSZRJFAPSA-N 2-methyl-5-[[2-[(9r)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethylamino]methyl]pyridine-3-carbonitrile Chemical compound C1=C(C#N)C(C)=NC=C1CNCC[C@]1(C=2N=CC=CC=2)CC2(CCCC2)OCC1 CCWMKUPBVUNVNH-HSZRJFAPSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- MCBAYZFITMKVAF-JOCHJYFZSA-N 3-chloro-5-[[2-[(9r)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethylamino]methyl]pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(Cl)=CC(CNCC[C@@]2(CC3(CCCC3)OCC2)C=2N=CC=CC=2)=C1 MCBAYZFITMKVAF-JOCHJYFZSA-N 0.000 description 1
- DXMYZNGPQMXWOY-JOCHJYFZSA-N 3-fluoro-5-[[2-[(9r)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethylamino]methyl]pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(F)=CC(CNCC[C@@]2(CC3(CCCC3)OCC2)C=2N=CC=CC=2)=C1 DXMYZNGPQMXWOY-JOCHJYFZSA-N 0.000 description 1
- OQOGTOVQKRKTAK-JOCHJYFZSA-N 3-iodo-5-[[2-[(9r)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethylamino]methyl]pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(I)=CC(CNCC[C@@]2(CC3(CCCC3)OCC2)C=2N=CC=CC=2)=C1 OQOGTOVQKRKTAK-JOCHJYFZSA-N 0.000 description 1
- CTNPHUJUKXDAKF-HSZRJFAPSA-N 3-methoxy-5-[[2-[(9r)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethylamino]methyl]pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(OC)=CC(CNCC[C@@]2(CC3(CCCC3)OCC2)C=2N=CC=CC=2)=C1 CTNPHUJUKXDAKF-HSZRJFAPSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- LFRJZZHSMJGAMN-HSZRJFAPSA-N 3-methyl-5-[[2-[(9r)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethylamino]methyl]pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C)=CC(CNCC[C@@]2(CC3(CCCC3)OCC2)C=2N=CC=CC=2)=C1 LFRJZZHSMJGAMN-HSZRJFAPSA-N 0.000 description 1
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical class NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-n-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- UHUDMDSDXOYQQZ-OAQYLSRUSA-N 5-[2-[(9r)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethyl]-4,6-dihydrothieno[2,3-c]pyrrole Chemical compound C([C@@](C1)(CCN2CC=3SC=CC=3C2)C=2N=CC=CC=2)COC21CCCC2 UHUDMDSDXOYQQZ-OAQYLSRUSA-N 0.000 description 1
- ONLPETHQTPVXCI-HSZRJFAPSA-N 5-[[2-[(9r)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethylamino]methyl]pyridine-2,3-dicarbonitrile Chemical compound N1=C(C#N)C(C#N)=CC(CNCC[C@@]2(CC3(CCCC3)OCC2)C=2N=CC=CC=2)=C1 ONLPETHQTPVXCI-HSZRJFAPSA-N 0.000 description 1
- XBYMOBXOAQHWPP-UHFFFAOYSA-N 6-[9-(2-aminoethyl)-6-oxaspiro[4.5]decan-9-yl]-1H-pyridin-2-one Chemical compound NCCC1(CCOC2(CCCC2)C1)C1=CC=CC(=N1)O XBYMOBXOAQHWPP-UHFFFAOYSA-N 0.000 description 1
- IGJLRTNWZONWAG-UHFFFAOYSA-N 6-[9-(2-aminoethyl)-6-oxaspiro[4.5]decan-9-yl]pyridin-3-ol Chemical compound NCCC1(CCOC2(CCCC2)C1)C1=CC=C(C=N1)O IGJLRTNWZONWAG-UHFFFAOYSA-N 0.000 description 1
- SCAKLSOBLMGVOU-UHFFFAOYSA-N 6-[9-[2-[(4,5-dimethylthiophen-2-yl)methylamino]ethyl]-6-oxaspiro[4.5]decan-9-yl]-1H-pyridin-2-one Chemical compound CC=1C=C(SC=1C)CNCCC1(CCOC2(CCCC2)C1)C1=CC=CC(=N1)O SCAKLSOBLMGVOU-UHFFFAOYSA-N 0.000 description 1
- WWDLEXNFZITXFV-UHFFFAOYSA-N 6-[9-[2-[(4,5-dimethylthiophen-2-yl)methylamino]ethyl]-6-oxaspiro[4.5]decan-9-yl]pyridin-3-ol Chemical compound CC=1C=C(SC=1C)CNCCC1(CCOC2(CCCC2)C1)C1=CC=C(C=N1)O WWDLEXNFZITXFV-UHFFFAOYSA-N 0.000 description 1
- JGPUWAQXCLTTBT-UHFFFAOYSA-N 6-oxaspiro[4.5]decan-9-one Chemical compound C1C(=O)CCOC11CCCC1 JGPUWAQXCLTTBT-UHFFFAOYSA-N 0.000 description 1
- YVYXGCYTKXZPQV-UHFFFAOYSA-N 6h-cyclopenta[b]thiophene Chemical compound C1=CSC2=C1C=CC2 YVYXGCYTKXZPQV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 101100439662 Arabidopsis thaliana CHR5 gene Proteins 0.000 description 1
- 101100495914 Arabidopsis thaliana ETL1 gene Proteins 0.000 description 1
- 101100439665 Arabidopsis thaliana SWI2 gene Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- OIRAEJWYWSAQNG-UHFFFAOYSA-N Clidanac Chemical compound ClC=1C=C2C(C(=O)O)CCC2=CC=1C1CCCCC1 OIRAEJWYWSAQNG-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- WFMFBCFBNNHGOJ-UHFFFAOYSA-N N-[2-[2,2-diethyl-4-(4-fluorophenyl)oxan-4-yl]ethyl]-N-propylpropan-1-amine Chemical compound C(C)C1(OCCC(C1)(C1=CC=C(C=C1)F)CCN(CCC)CCC)CC WFMFBCFBNNHGOJ-UHFFFAOYSA-N 0.000 description 1
- FIJIXKIWZLVXAQ-UHFFFAOYSA-N N-benzyl-2-[2,2-dimethyl-4-(4-methylphenyl)oxan-4-yl]-N-methylethanamine Chemical compound C(C1=CC=CC=C1)N(C)CCC1(CC(OCC1)(C)C)C1=CC=C(C=C1)C FIJIXKIWZLVXAQ-UHFFFAOYSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- PDODBKYPSUYQGT-UHFFFAOYSA-N acetic acid;1h-indene Chemical class CC(O)=O.C1=CC=C2CC=CC2=C1 PDODBKYPSUYQGT-UHFFFAOYSA-N 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 150000003934 aromatic aldehydes Chemical class 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 229960005430 benoxaprofen Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004935 benzoxazolinyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000005512 benztetrazolyl group Chemical group 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229950010886 clidanac Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- XSYZCZPCBXYQTE-UHFFFAOYSA-N cyclodecylcyclodecane Chemical compound C1CCCCCCCCC1C1CCCCCCCCC1 XSYZCZPCBXYQTE-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960002679 fentiazac Drugs 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229950007979 flufenisal Drugs 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229950001284 fluprofen Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000004936 isatinoyl group Chemical group N1(C(=O)C(=O)C2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229950001846 mabuprofen Drugs 0.000 description 1
- JVGUNCHERKJFCM-UHFFFAOYSA-N mabuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(=O)NCCO)C=C1 JVGUNCHERKJFCM-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- ANGDWNBGPBMQHW-UHFFFAOYSA-N methyl cyanoacetate Chemical compound COC(=O)CC#N ANGDWNBGPBMQHW-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- VFSRWDUYZSDWRN-OAQYLSRUSA-N n-[(5-bromo-6-chloropyridin-3-yl)methyl]-2-[(9r)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine Chemical compound C1=C(Br)C(Cl)=NC=C1CNCC[C@]1(C=2N=CC=CC=2)CC2(CCCC2)OCC1 VFSRWDUYZSDWRN-OAQYLSRUSA-N 0.000 description 1
- YJLCIHATFYQKPK-JOCHJYFZSA-N n-[(5-bromo-6-methylpyridin-3-yl)methyl]-2-[(9r)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine Chemical compound C1=C(Br)C(C)=NC=C1CNCC[C@]1(C=2N=CC=CC=2)CC2(CCCC2)OCC1 YJLCIHATFYQKPK-JOCHJYFZSA-N 0.000 description 1
- PHLWMLJQXIEDTP-JOCHJYFZSA-N n-[(5-fluoro-6-methylpyridin-3-yl)methyl]-2-[(9r)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine Chemical compound C1=C(F)C(C)=NC=C1CNCC[C@]1(C=2N=CC=CC=2)CC2(CCCC2)OCC1 PHLWMLJQXIEDTP-JOCHJYFZSA-N 0.000 description 1
- NAAGIRMWOVBNMN-HSZRJFAPSA-N n-[(5-methoxy-6-methylpyridin-3-yl)methyl]-2-[(9r)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine Chemical compound N1=C(C)C(OC)=CC(CNCC[C@@]2(CC3(CCCC3)OCC2)C=2N=CC=CC=2)=C1 NAAGIRMWOVBNMN-HSZRJFAPSA-N 0.000 description 1
- BRYHFIGSTGFNAU-OAQYLSRUSA-N n-[(6-chloro-5-fluoropyridin-3-yl)methyl]-2-[(9r)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine Chemical compound N1=C(Cl)C(F)=CC(CNCC[C@@]2(CC3(CCCC3)OCC2)C=2N=CC=CC=2)=C1 BRYHFIGSTGFNAU-OAQYLSRUSA-N 0.000 description 1
- GADLXNKEJIXSPR-JOCHJYFZSA-N n-[(6-chloro-5-methoxypyridin-3-yl)methyl]-2-[(9r)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine Chemical compound N1=C(Cl)C(OC)=CC(CNCC[C@@]2(CC3(CCCC3)OCC2)C=2N=CC=CC=2)=C1 GADLXNKEJIXSPR-JOCHJYFZSA-N 0.000 description 1
- QYBGYELJJOYYHQ-OAQYLSRUSA-N n-[(6-fluoro-5-iodopyridin-3-yl)methyl]-2-[(9r)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine Chemical compound C1=C(I)C(F)=NC=C1CNCC[C@]1(C=2N=CC=CC=2)CC2(CCCC2)OCC1 QYBGYELJJOYYHQ-OAQYLSRUSA-N 0.000 description 1
- WPQVKOJWMFQDLZ-JOCHJYFZSA-N n-[(6-fluoro-5-methylpyridin-3-yl)methyl]-2-[(9r)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine Chemical compound N1=C(F)C(C)=CC(CNCC[C@@]2(CC3(CCCC3)OCC2)C=2N=CC=CC=2)=C1 WPQVKOJWMFQDLZ-JOCHJYFZSA-N 0.000 description 1
- VIGFBTIGLXYZDN-HSZRJFAPSA-N n-[(6-methoxy-5-methylpyridin-3-yl)methyl]-2-[(9r)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine Chemical compound C1=C(C)C(OC)=NC=C1CNCC[C@]1(C=2N=CC=CC=2)CC2(CCCC2)OCC1 VIGFBTIGLXYZDN-HSZRJFAPSA-N 0.000 description 1
- YFXUDGYVQVAYIY-OAQYLSRUSA-N n-[[5,6-bis(trifluoromethyl)pyridin-3-yl]methyl]-2-[(9r)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine Chemical compound N1=C(C(F)(F)F)C(C(F)(F)F)=CC(CNCC[C@@]2(CC3(CCCC3)OCC2)C=2N=CC=CC=2)=C1 YFXUDGYVQVAYIY-OAQYLSRUSA-N 0.000 description 1
- NBXSEADGQTYSNU-HSZRJFAPSA-N n-benzyl-2-[(9r)-9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-9-yl]ethanamine Chemical compound C1=CC(F)=CC=C1[C@@]1(CCNCC=2C=CC=CC=2)CC2(CCCC2)OCC1 NBXSEADGQTYSNU-HSZRJFAPSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical compound C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 description 1
- 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000004928 piperidonyl group Chemical group 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- CYMJPJKHCSDSRG-UHFFFAOYSA-N pyrazolidine-3,4-dione Chemical class O=C1CNNC1=O CYMJPJKHCSDSRG-UHFFFAOYSA-N 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 229950005175 sudoxicam Drugs 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- FQCQGOZEWWPOKI-UHFFFAOYSA-K trisalicylate-choline Chemical compound [Mg+2].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O FQCQGOZEWWPOKI-UHFFFAOYSA-K 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 229960003414 zomepirac Drugs 0.000 description 1
- ZXVNMYWKKDOREA-UHFFFAOYSA-N zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
Un compuesto que tiene una fórmula de Fórmula IV-1 o una sal farmacéuticamente aceptable del mismo:**Fórmula** en donde: R21 y R22 son independientemente H o CH3; A4 es un ciclo opcionalmente sustituido de la fórmula C(CH2)n, en donde n >= 2-5, en donde la sustitución opcional es halo, ciano, alquilo C1-C6, alquilo C1-C6 ramificado, alquilo C1-C6 halogenado, hidroxilo, alquil C1-C6 oxi, amino o alquil C1-C6 amino; B3 es H o un alquilo C1-C6 opcionalmente sustituido, en donde la sustitución opcional es halo, hidroxi o alcoxi C1-C3; B4 es alquileno C1-C6; D1 es un arilo o heteroarilo monocíclico o bicíclico opcionalmente sustituido, en donde cada anillo es un anillo de 5, 6 o 7 miembros y la sustitución opcional es halo, ciano, alquilo C1-C6, alquilo C1-C6 ramificado, alquilo C1-C6 halogenado, hidroxilo, alquil C1-C6 oxi, amino o alquil C1-C6 amino; y B5 es un arilo o heteroarilo monocíclico o bicíclico opcionalmente sustituido, en donde cada anillo es un anillo de 5, 6 o 7 miembros y la sustitución opcional es halo, ciano, alquilo C1-C6, alquilo C1-C6 ramificado, alquilo C1-C6 halogenado, hidroxilo, alquil C1-C6 oxi, amino o alquil C1-C6 amino.
Description
13) Bencil({2-[2-etil-4-(2-metoxifenil)-2-metiloxan-4-il]etil})amina
14) [(3,4-dimetoxifenil)metil]({2-[2-etil-4-(2-metoxifenil)-2-metiloxan-4-il]etil})amina
15) 4-[({2-[4-(2-Metoxifenil)-2,2-dimetiloxan-4-il]etil}amino)metil]-N,N-dimetilanilina
16) Bencil({2-[4-(4-fluorofenil)-2,2-dimetiloxan-4-il]etil})amina
10 17) {2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]etil}(1-feniletil)amina
18) [2-(2,2-Dimetil-4-feniloxan-4-il)etil] [(4-metoxifenil)metil]amina
19) 2-[4-(4-Fluorofenil)-2,2-dimetiloxan-4-il]etil}[(4-metoxifenil)metil]amina
CH2CH3, CH2F, CHF2, CF3, n-Pr, n-Bu, i-Bu, sec-Bu, i-Pr, t-Bu, CN, OH, OMe, OEt, O-iPr, OCF3, NH2, NHMe, NMe2, metoxicarbonilo, Ph, bencilo, formilo o acetilo. Esto es, cada grupo arilo y heteroarilo puede estar múltiplemente sustituido por el mismo sustituyente (es decir, 2 grupos cloro) o solo estar sustituido múltiplemente, aunque con diferentes grupos (por ejemplo, un grupo arilo o heteroarilo con 1 grupo cloro y 1 grupo metilo se consideraría múltiplemente sustituido).
Esta divulgación también describe compuestos que tienen la estructura de Fórmula III:
10 en donde A2 es CH2, CHR5 o CR5R6; A4 es CH2, CHR9, CR9R10 o un ciclo de la fórmula C(CH2)n, en donde n = 2-5.
Además, R5, R6, R9 y R10 son independientemente CH3, CH2CH3, CH2F, CHF2, CF3, n-Pr, n-Bu, i-Bu, sec-Bu, i-Pr, t-Bu o fenilo. R5 y R6 o R9 y R10 pueden formar un carbociclo monocíclico. A2 y A4 pueden estar conectados mediante un puente de carbono. El puente puede ser -CH2-o-CH2CH2-. Además, B3 se selecciona de H, alquilo, alquilo ramificado, arilo, arilalquilo, alquilcarbonilo, alquilcarbonilo ramificado,
15 arilcarbonilo, alcoxicarbonilo o alquilsulfonilo. Además, B4 es nulo, alquilo C1-C6, CH2, CH2CH2, CHR19, CR19R20 o CO. Además, R19 y R20 pueden formar un
monociclo de la fórmula (CH2)n, en donde n = 2-4. B5 es alquilo, alquilo ramificado, carbociclo, alquilo sustituido por carbociclo, arilo o arilalquilo. Además, D1 es un arilo o heteroarilo. Ejemplos de los grupos arilo y heteroarilo se muestran más adelante.
20 Los grupos arilo y heteroarilo pueden estar mono o múltiplemente sustituido por F, Cl, Br, CH3, CH2CH3, CH2F, CHF2, CF3, n-Pr, n-Bu, i-Bu, sec-Bu, i-Pr, t-Bu, CN, OH, OMe, OEt, O-iPr, OCF3, NH2, NHMe, NMe2, metoxicarbonilo, Ph, bencilo, formilo o acetilo.
Esta divulgación también describe compuestos que tienen la estructura de Fórmula IV-1, IV-2 o IV-3, V o VI:
5
10
15
20
25
30
35
40
45
50
55
Alternativamente, el ingrediente activo puede estar en forma de polvo para constitución con un vehículo adecuado, por ejemplo, estéril, agua libre de pirógenos, antes de su uso.
Para la administración mediante inyección, el compuesto puede utilizarse en solución en un vehículo acuoso estéril que también puede contener otros solutos tales como soluciones amortiguadoras o conservantes, así como cantidades suficientes de sales farmacéuticamente aceptables o de glucosa para hacer la solución isotónica. Las composiciones farmacéuticas de los compuestos descritos en la presente pueden formularse con un portador farmacéuticamente aceptable para proporcionar soluciones o suspensiones estériles para una administración inyectable. Los inyectables pueden prepararse en formas convencionales, ya sea como soluciones o suspensiones líquidas, formas sólidas adecuadas para la solución o suspensiones en líquido antes de la inyección o como emulsiones. Excipientes adecuados son, por ejemplo, agua, solución salina, dextrosa, manitol, lactosa, lecitina, albúmina, glutamato de sodio, clorhidrato de cisteína o similares. Además, si se desea, las composiciones farmacéuticas inyectables pueden contener pequeñas cantidades de sustancias auxiliares no tóxicas, tales como agentes humectantes, agentes amortiguadores de pH y similares. Si se desea, pueden utilizarse preparaciones que mejoran la absorción (por ejemplo, liposomas). Se describen portadores farmacéuticamente adecuados en "Remington's pharmaceutical Sciences" por E. W. Martin.
Para la administración por inhalación, los compuestos pueden administrarse de manera conveniente en forma de una presentación de pulverizador en aerosol de paquetes presurizados o un nebulizador, con el uso de un propulsor adecuado, por ejemplo, diclorodifluorometano, triclorofluorometano, diclorotetrafluoroetano, dióxido de carbono u otro gas adecuado. En el caso de un aerosol presurizado, la unidad de dosificación puede determinarse proporcionando una válvula para administrar una cantidad medida. Pueden formularse cápsulas y cartuchos de, por ejemplo, gelatina para utilizar en un inhalador o insuflador que contienen una mezcla de polvo del compuesto y una base de polvo adecuada tal como lactosa o almidón. Para la administración intranasal los compuestos descritos en la presente pueden utilizarse, por ejemplo, como un pulverizador de líquido, como un polvo o en forma de gotas.
Los compuestos también puede ser formulados en composiciones rectales, por ejemplo, supositorios o enemas de retención, por ejemplo, conteniendo bases de supositorios convencionales, por ejemplo, manteca de cacao u otros glicéridos.
Más aun, los compuestos pueden formularse como una preparación de depósito. Dichas formulaciones de acción prolongada pueden administrarse mediante implantación (por ejemplo, subcutáneamente o intramuscularmente) o mediante inyección intramuscular. Por lo tanto, por ejemplo, los compuestos pueden formularse con materiales poliméricos o hidrófobos adecuados (por ejemplo como una emulsión en un aceite aceptable) o resinas de intercambio de iones o como derivados moderadamente solubles, por ejemplo, como una sal moderadamente soluble.
Las composiciones pueden, si se desea, presentarse en un paquete o dispositivo dispensador que puede contener una o más formas de dosificación unitaria que contienen el ingrediente activo. El envase puede comprender, por ejemplo, papel metálico o plástico, tal como un envase de blíster. El paquete o dispositivo dispensador puede incluir instrucciones para la administración.
Los compuestos descritos en la presente también incluyen derivados denominados profármacos, que pueden prepararse al modificar grupos funcionales presentes en los compuestos de manera que las modificaciones se escinden, ya sea en manipulación de rutina o in vivo, a los compuestos parentales. Ejemplos de profármacos incluyen compuestos de la invención como se describe en la presente que contienen uno o más restos moleculares adjuntos a un grupo hidroxilo, amino, sulfhidrilo o carboxilo del compuesto y que cuando se administran a un paciente, se escinden in vivo para formar el grupo hidroxilo, amino, sulfhidrilo o carboxilo libre, respectivamente. Ejemplos de profármacos incluyen, a modo no taxativo, derivados de acetato, formiato y benzoato de grupos funcionales de alcohol y amina en los compuestos de la invención. La preparación y el uso de profármacos se describen en T. Higuchi et al., "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series y en Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association y Pergamon Press, 1987.
Dosificaciones
Los compuestos descritos en la presente pueden administrarse a un paciente a una dosis terapéuticamente efectiva para prevenir, tratar o controlar una o más enfermedades y trastornos mediados, en su totalidad o en parte, por una interacción OR-ligando. Composiciones farmacéuticas que comprenden uno o más de los compuestos descritos en la presente pueden administrarse a un paciente en una cantidad suficiente para provocar una respuesta protectora o terapéutica efectiva en el paciente. Una cantidad adecuada para lograr esto se define como una "dosis terapéuticamente efectiva." La dosis se determinará mediante la eficacia del compuesto particular empleado y la afección del sujeto, así como el peso corporal o área superficial del área a tratar. El tamaño de la dosis también se determinará mediante la existencia, naturaleza y alcance de cualquier efecto adverso que acompañe la administración de un compuesto o vector particular en un sujeto particular.
La toxicidad y eficacia terapéutica de dichos compuestos pueden determinarse mediante procedimientos farmacéuticos estándar en cultivos celulares o animales experimentales, por ejemplo, al determinar la LD50 (la dosis
5
10
15
20
25
30
35
40
45
50
55
60
letal para el 50% de la población) y la ED50 (la dosis terapéuticamente efectiva en el 50% de la población). La relación de la dosis entre los efectos tóxicos y terapéuticos es el índice terapéutico y puede expresarse como la relación LD50/ED50. Se utilizan compuestos que exhiben grandes índices terapéuticos. Aunque pueden utilizarse compuestos que exhiben efectos secundarios tóxicos, se debe tener cuidado al diseñar un sistema de administración que dirija dichos compuestos al sitio del tejido afectado para minimizar el daño potencial a las células normales y, de este modo, reducir los efectos secundarios.
Los datos obtenidos a partir de ensayos de cultivos celulares y estudios animales pueden utilizarse para formular un rango de dosificación para su uso en humanos. La dosificación de dichos compuestos yace dentro de un rango de concentraciones circulantes que incluyen la ED50 con poco o nada de toxicidad. La dosificación puede variar dentro de este rango dependiendo de la forma de dosificación empleada y la ruta de administración. Para cualquier compuesto descrito en la presente, la dosis terapéuticamente efectiva puede estimarse inicialmente a partir de los ensayos de cultivo celular. Una dosis puede formularse en modelos de animales para alcanzar un rango de concentración en plasma circulante que incluye la IC50 (la concentración de los compuestos de prueba que alcanza una inhibición media-máxima de los síntomas), tal como se determina en el cultivo celular. Dicha información puede utilizarse para determinar de manera más precisa la dosis útil en humanos. Los niveles en plasma pueden medirse, por ejemplo, mediante cromatografía líquida de alto rendimiento (HPLC). En general, la dosis equivalente de un modulador es de aproximadamente 1 ng/kg a 10 mg/kg para un sujeto típico.
La cantidad y frecuencia de la administración de los compuestos descritos en la presente y/o las sales farmacéuticamente aceptables de los mismos se regularán de acuerdo con el juicio del médico tratante considerando factores tales como edad, afección y talla del paciente, así como la gravedad de los síntomas tratados. Un médico o veterinario experto en la técnica podrá determinar fácilmente y prescribir la cantidad efectiva del fármaco requerido para prevenir, contrarrestar o detener el avance de la afección. En general se contempla que una cantidad efectiva sería de 0,001 mg/kg a 10 mg/kg de peso corporal y en particular de 0,01 mg/kg a 1 mg/kg de peso corporal. Puede ser apropiado administrar la dosis necesaria como dos, tres, cuatro o más subdosis a intervalos apropiados a lo largo del día. Dichas subdosis pueden formularse como formas de dosificación unitaria, por ejemplo, que contienen 0,01 a 500 mg y en particular 0,1 a 200 mg de ingrediente activo por forma de dosificación unitaria.
En algunos casos, la preparación farmacéutica está en una forma de dosificación unitaria. En dicha forma, la preparación se subdivide en dosis unitarias de tamaño adecuado que contienen cantidades apropiadas del componente activo, por ejemplo, una cantidad efectiva para alcanzar el propósito deseado. La cantidad de compuesto activo en una dosis unitaria de preparación puede variar o ajustarse de aproximadamente 0,01 mg a aproximadamente 1000 mg, de aproximadamente 0,01 mg a aproximadamente 750 mg, de aproximadamente 0,01 mg a aproximadamente 500 mg o de aproximadamente 0,01 mg a aproximadamente 250 mg, de acuerdo con la aplicación particular. La dosificación real empleada puede variar dependiendo de los requisitos del paciente y la gravedad de la afección tratada. La determinación del régimen de dosificación apropiado para una situación particular se encuentra dentro de la técnica. Para conveniencia, la dosificación total puede dividirse y administrarse en porciones durante el día según sea requerido.
En algunos casos, uno o más compuestos descritos en la presente se administran con otro compuesto. La administración puede ser secuencial o simultánea. La combinación puede estar en la misma forma de dosificación o administrarse como una dosis separada. En algunos casos, el otro compuesto es otro analgésico. En algunos casos, el otro compuesto es un analgésico no opioide. Ejemplos de analgésicos no opioides útiles incluyen, a modo no taxativo, agentes antiinflamatorios no esteroideos, tales como aspirina, ibuprofeno, diclofenac, naproxeno, benoxaprofeno, flurbiprofeno, fenoprofeno, flubufeno, ketoprofeno, indoprofeno, piroprofeno, carprofeno, oxaprozina, pramoprofeno, muroprofeno, trioxaprofeno, suprofeno, aminoprofeno, ácido tiaprofénico, fluprofeno, ácido buclóxico, indometacina, sulindac, tolmetina, zomepirac, tiopinac, zidometacina, acemetacina, fentiazac, clidanac, oxpinac, ácido mefenámico, ácido meclofenámico, ácido flufenámico, ácido niflúmico, ácido tolfenámico, diflurisal, flufenisal, piroxicam, sudoxicam, isoxicam y sales farmacéuticamente aceptables de los mismos y mezclas de los mismos. Otros analgésicos no opioides adecuados incluyen los siguientes, a modo no taxativo, clases químicas de analgésicos, antipiréticos, fármacos antiinflamatorios no esteroideos: derivados de ácido salicílico, incluyendo aspirina, salicilato de sodio, trisalicilato de magnesio de colina, salsalato, diflunisal, ácido salicilsalicílico, sulfasalazina y olsalazina; derivados de para-aminofenol incluyendo acetaminofén y fenacetina; ácidos indol e indeno acéticos, incluyendo indometacina, sulindac y etodolac; ácidos acéticos de heteroarilo, incluyendo tolmetina, diclofenaco y ketorolaco; ácidos antranílicos (fenamatos), incluyendo ácido mefenámico y ácido meclofenámico; ácidos enólicos, incluyendo oxicam (piroxicam, tenoxicam) y pirazolidinadionas (fenilbutazona, oxifentartazona); y alcanonas, incluyendo nabumetona. Para una descripción más detallada de los AINEs, ver Paul A. Insel, Analgesic-Antipiretic and Anti-inflammatory Agents and Drugs Employed in the Treatment of Gout, en Goodman & Gilman's The Pharmacological Basis of Therapeutics 617-57 (Perry B. Molinhoff y Raymond W. Ruddon eds., 9th ed 1996); y Glen
R. Hanson, Analgesic, Antipiretic and Anti-Inflammatory Drugs en Remington: The Science and Practice of Pharmacy Vol II 1196-1221 (A. R. Gennaro ed. 19th ed. 1995).
Los compuestos descritos en la presente también pueden ser inhibidores de Cox-II administrados. Ejemplos de inhibidores de Cox-II e inhibidores de 5-lipoxigenase útiles, así como combinaciones de los mismos, se describen en la Patente de los Estados Unidos No. 6.136.839. Ejemplos de inhibidores de Cox-II incluyen, a modo no taxativo, rofecoxib y celecoxib.
5
10
15
20
25
30
35
40
45
50
La expresión "alcoxicarbonilo C1-C4" se refiere a un grupo alcoxi C1-C4 ligado a través de un resto carbonilo.
El término "halo" se refiere a fluoro, cloro, bromo o yodo. En algunos casos, los grupos halo son fluoro, cloro y bromo. En algunos casos, los grupos halo son fluoro y cloro.
Tal como se utiliza en la presente, "carbociclo" o "anillo carbocíclico" pretende significar, a menos que se indique de otra forma, cualquier anillo monocíclico, bicíclico o tricíclico de 3, 4, 5, 6, 7, 8, 9, 10, 11 o 12 miembros estable, pudiendo cualquiera de ellos ser saturado, insaturado (incluyendo parcialmente y completamente insaturado) o aromático. Ejemplos de dichos carbociclos incluyen, a modo no taxativo, ciclopropilo, ciclobutilo, ciclobutenilo, ciclopentilo, ciclopentenilo, ciclohexilo, cicloheptenilo, cicloheptilo, cicloheptenilo, adamantilo, ciclooctilo, ciclooctenilo, ciclooctadienilo, [3.3.0]biciclooctano, [4.3.0]biciclononano, [4.4.0]biciclodecano, [2.2.2]biciclooctano, fluorenilo, fenilo, naftilo, indanilo, adamantilo y tetrahidronaftilo. Tal como se mostró anteriormente, los anillos con puente también se incluyen en la definición de carbociclo (por ejemplo, [2.2.2]biciclooctano). Un anillo con puente ocurre cuando uno o más átomos de carbono enlazan dos átomos de carbono no adyacentes. En algunos casos, los puentes son uno o dos átomos de carbono. Cabe destacar que un puente siempre convierte un anillo monocíclico en un anillo tricíclico. Cuando un anillo tiene puente, los sustituyentes indicados para el anillo también pueden estar presentes en el puente. También se incluyen los anillos fusionados (por ejemplo, naftilo y tetrahidronaftilo) y espiro.
El término "heterociclo" se toma para significar un anillo saturado o insaturado de 5 o 6 miembros que contiene de 1 a 3 heteroátomos que se seleccionan de nitrógeno, oxígeno y azufre, estando dicho anillo opcionalmente benzofusionado. Heterociclos ejemplares incluyen furanilo, tiofenilo (tienilo), pirrolilo, pirrolidinilo, piridinilo, N-metilpirrolilo, oxazolilo, isoxazolilo, pirazolilo, imidazolilo, triazolilo, oxadiazolilo, tiadiazolilo, tiazolilo, tiazolidinilo, N-acetiltiazolidinilo, pirimidinilo, pirazinilo, piridazinilo y similares. Anillos heterocíclicos benzofusionados incluyen isoquinolinilo, benzoxazolilo, benzodioxolilo, benzotiazolilo, quinolinilo, benzofuranilo, benzotiofenilo, indolilo y similares, los cuales pueden ser opcionalmente sustituidos, lo cual también incluye, por supuesto, opcionalmente sustituidos en el anillo benzo cuando el heterociclo está benzofusionado.
El término grupo "ciclo" se toma para que signifique un anillo carbocílico, un carbociclo o a heterocarbocilo.
Tal como se utiliza en la presente, la frase un "ciclo de la fórmula" se refiere a un anillo que puede formarse con la variable referida. Por ejemplo, en la estructura
en donde A puede ser un ciclo de la fórmula C(CH2)n, en donde n = 2-5, significa que A es un carbono y forma un anillo con sí mismo con 2-5 grupos CH2, que también podrían representarse estructuralmente como
La variable "A" no se limita a carbono y puede ser otro átomo, tal como, a modo no taxativo, un heteroátomo, pero el contexto en que la variable se usa indicará el tipo de átomo que "A" puede ser. Este es solamente un ejemplo no taxativo. Además, el anillo que se forma con "A" también puede ser sustituido. Se describen sustituyentes ejemplares en la presente.
Heterociclos incluyen, a modo no taxativo, piridinilo, indolilo, furanilo, benzofuranilo, tiofenilo, benzodioxolilo y tiazolidinilo, los cuales pueden ser opcionalmente sustituidos.
Tal como se utiliza en la presente, la expresión "heterociclo aromático" o "heteroarilo" pretende significar un anillo aromático monocíclico o bicíclico de 5, 6, 7, 8, 9, 10, 11 o 12 miembros estable que consiste en átomos de carbono y uno o más heteroátomos, por ejemplo, 1 o 1-2 o 1-3 o 1-4 o 1-5 o 1-6 heteroátomos, que se seleccionan independientemente de nitrógeno, oxígeno y azufre. En el caso de anillos aromáticos heterocíclicos bicíclicos, solamente uno de los dos anillos debe ser aromático (por ejemplo, 2,3-dihidroindol), aunque ambos pueden serlo (por ejemplo, quinolina). El segundo anillo también puede estar fusionado o tener puente tal como se definió anteriormente para los heterociclos. El átomo de nitrógeno puede sustituirse o no sustituirse (es decir, N o NR en donde R es H u otro sustituyente, tal como se define). Los heteroátomos de nitrógeno y azufre opcionalmente pueden oxidarse (es decir, N→O y S(O)p, en donde p = 1 o 2). En ciertos compuestos, el número total de átomos de S y O en el heterociclo aromático no es mayor que 1.
Ejemplos de heterociclos incluyen, a modo no taxativo, acridinilo, azocinilo, bencimidazolilo, benzofuranilo, benzotiofuranilo, benzotiofenilo, benzoxazolilo, benzoxazolinilo, benztiazolilo, benztriazolilo, benztetrazolilo, bencisoxazolilo, bencisotiazolilo, bencimidazolinilo, carbazolilo, 4aH-carbazolilo, carbolinilo, cromanilo, cromenilo, cinnolinilo, decahidroquinolinilo, 2H,6H-1,5,2-ditiazinilo, dihidrofuro[2,3-b]tetrahidrofurano, furanilo, furazanilo,
5
15
25
35
45
55
imidazolidinilo, imidazolinilo, imidazolilo, 1H-indazolilo, indolnilo, indolinilo, indolizinilo, indolilo, 3H-indolilo, isatinoilo, isobenzofuranilo, isocromanilo, isoindazolilo, isoindolinilo, isoindolilo, isoquinolinilo, isotiazolilo, isoxazolilo, metilendioxifenilo, morfolinilo, naftiridinilo, octahidroisoquinolinilo, oxadiazolilo, 1,2,3-oxadiazolilo, 1,2,4-oxadiazolilo, 1,2,5-oxadiazolilo, 1,3,4-oxadiazolilo, oxazolidinilo, oxazolilo, oxindolilo, pirimidinilo, fenanthridinilo, fenanthrolinilo, fenazinilo, fenotiazinilo, fenoxathinilo, fenoxazinilo, ftalazinilo, piperazinilo, piperidinilo, piperidonilo, 4-piperidonilo, piperonilo, pteridinilo, purinilo, piranilo, pirazinilo, pirazolidinilo, pirazolinilo, pirazolilo, piridazinilo, piridooxazol, piridoimidazol, piridotiazol, piridinilo, piridilo, pirimidinilo, pirrolidinilo, pirrolinilo, 2H-pirrolilo, pirrolilo, quinazolinilo, quinolinilo, 4H-quinolizinilo, quinoxalinilo, quinuclidinilo, tetrahidrofuranilo, tetrahidroisoquinolinilo, tetrahidroquinolinilo, tetrazolilo, 6H-1,2,5-tiadiazinilo, 1,2,3-tiadiazolilo, 1,2,4-tiadiazolilo, 1,2,5-tiadiazolilo, 1,3,4-tiadiazolilo, tianthrenilo, tiazolilo, tienilo, tienotiazolilo, tienooxazolilo, tienoimidazolilo, tiofenilo, triazinilo, 1,2,3-triazolilo, 1,2,4-triazolilo, 1,2,5-triazolilo, 1,3,4-triazolilo y xantenilo.
Alquilo, cicloalquilo, cicloalquilalquilo, alcoxi o alquiltio sustituido significa un grupo alquilo, cicloalquilo, cicloalquilalquilo, alcoxi o alquiltio, respectivamente, sustituido una o más veces independientemente con un sustituyente que se selecciona del grupo que consiste en halo, hidroxi y alcoxi C1-C3. De forma ilustrativa, a modo no taxativo, ejemplos incluyen trifluorometilo, pentafluoroetilo, 5-fluoro-2-bromopentilo, 3-hidroxipropiloxi, 4-hidroxiciclohexiloxi, 2-bromoetiltio, 3-etoxipropiloxi, 3-etoxi-4-clorociclohexilo y similares. Las sustituciones incluyen la sustitución 1-5 veces con halo, cada una independientemente seleccionada o sustitución 1-3 veces con halo y 1-2 veces independientemente con un grupo que se selecciona de hidroxi y alcoxi C1-C3 o sustitución 1-3 veces independientemente con un grupo que se selecciona de hidroxi y alcoxi C1-C3, siempre que no más que un sustituyente de hidroxi y/o alcoxi pueda unirse a través del mismo carbono.
Las expresiones "fenilo sustituido" y "heterociclo sustituido" significan que el resto cíclico en cualquier caso se sustituye. Pueden estar sustituidos independientemente con uno o más sustituyentes. Pueden estar sustituidos independientemente con 1, 2, 3, 4, 5, 1-3, 1-4 o 1-5 sustituyentes. La sustitución puede ser, independientemente, halo, alquilo, tal como, a modo no taxativo, alquilo C1-C4, alcoxi, tal como a modo no taxativo, alcoxi C1-C4 y alquiltio, tal como a modo no taxativo, alquiltio C1-C4, en donde cada sustituyente alquilo, alcoxi y alquiltio puede estar adicionalmente sustituido independientemente por alcoxi C1-C2 o por uno a cinco grupos halo; o sustituido por un sustituyente que se selecciona del grupo que consiste en feniloxi, benciloxi, feniltio, benciltio y pirimidiniloxi, en donde el resto feniloxi, benciloxi, feniltio, benciltio y pirimidiniloxi puede estar adicionalmente sustituido por uno a dos sustituyentes que se seleccionan del grupo que consiste en halo, alquilo C1-C2 y alcoxi C1-C2; o sustituido por un sustituyente que se selecciona del grupo que consiste en acilo C1-C4 y alcoxi C1-C4 carbonilo y adicionalmente sustituido por cero a un sustituyente que se selecciona del grupo que consiste en halo, alquilo C1-C4, alcoxi C1-C4 y alquiltio C1-C4. Cuando un sustituyente es halo, en algunos casos, los grupos halo son fluoro, cloro y bromo. El halo también puede ser yodo.
DMF significa N,N-dimetilformamida.
Tal como se utiliza en la presente, la expresión "farmacéuticamente aceptable" se refiere a aquellos compuestos, materiales, composiciones y/o formas de dosificación que sean, dentro del alcance de un juicio médico razonable, adecuados para su uso en contacto con los tejidos de seres humanos y animales sin excesiva toxicidad, irritación, respuestas alérgicas ni otro problema o complicación, acorde con una relación riesgo/beneficio razonable.
Por "formulación farmacéutica" se entiende, además, que el portador, disolvente, excipientes y sal deben ser compatibles con el ingrediente activo de la formulación (por ejemplo un compuesto descrito en la presente). Un experto en la técnica comprenderá que las expresiones "formulación farmacéutica" y "composición farmacéutica" son generalmente intercambiables y, por lo tanto, se usan de este modo en esta divulgación.
Tal como se utiliza en la presente, “sales farmacéuticamente aceptables” se refiere a derivados de los compuestos revelados, en donde el compuesto base se modifica mediante la obtención de sales ácidas o básicas del mismo. Ejemplos de sales farmacéuticamente aceptables incluyen, a modo no taxativo, sales de ácidos minerales u orgánicas de residuos básicos tales como aminas; sales alcalinas u orgánicas de residuos ácidos tales como ácidos carboxílicos; y similares. Las sales farmacéuticamente aceptables incluyen las sales no tóxicas convencionales o las sales de amonio cuaternario del compuesto base formado, por ejemplo, a partir de ácidos no tóxicos inorgánicos u orgánicos. Por ejemplo, dichas sales no tóxicas convencionales incluyen, a modo no taxativo, aquellas derivadas de ácidos inorgánicos y orgánicos que se seleccionan de 2-acetoxibenzoico, sulfónico de 2-hidroxietano, acético, ascórbico, sulfónico de benceno, benzoico, bicarbónico, carbónico, cítrico, edético, etanodisulfónico, etanosulfónico, fumárico, glucoheptónico, glucónico, glutámico, glicólico, glicoliarsanílico, hexilresorcínico, hidrabámico, hidrobrómico, clorhídrico, hidroyoduro, hidroximaleico, hidroxinaftoico, isetiónico, láctico, lactobiónico, laurilsulfónico, maleico, málico, mandélico, metanosulfónico, napsílico, nítrico, oxálico, pamoico, pantoténico, fenilacético, fosfórico, poligalacturónico, propiónico, salicílico, esteárico, subacético, succínico, sulfámico, sulfanílico, sulfúrico, tánico, tartárico y toluenosulfónico. La presente divulgación incluye sales farmacéuticamente aceptables de cualquier compuesto descrito en la presente.
Las sales farmacéuticamente aceptables pueden sintetizarse a partir del compuesto base que contiene un resto básico o ácido mediante métodos químicos convencionales. En general, dichas sales pueden prepararse haciendo reaccionar las formas de ácido o base libre de estos compuestos con una cantidad estequiométrica de la base o ácido
Los compuestos reivindicados en esta invención pueden prepararse a partir de los procedimientos descritos en los esquemas a continuación.
Esquemas
Los siguientes esquemas representativos ilustran cómo pueden prepararse los compuestos descritos en la presente. Los disolventes y condiciones de reacción específicos mencionados también son ilustrativos y no pretenden ser limitantes. Los compuestos no descritos están comercialmente disponibles o son preparados fácilmente por un experto en la técnica utilizando materiales de partida disponibles.
Siguiendo el Esquema 8, 2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]decan-9-il]etan-1-amina, que puede prepararse siguiendo una secuencia como se describe para el Compuesto 81 (Compuesto 4) y una secuencia similar a la del Intermediario 11, se hace reaccionar con un aldehído heteroaromático apropiadamente sustituido o aldehído
5 aromático apropiadamente sustituido (1 equivalente) en presencia de un disolvente orgánico (es decir DCM, MeOH, EtOH) para formar una imina correspondiente, que se reduce mediante un agente de reducción apropiado para proporcionar el compuesto. La (R)n y la Rm se refiere a los sustituyentes opcionales. Además, los grupos fenilo pueden reemplazarse por otros grupos arilo o ciclos como se describe en la presente.
Ejemplo 11: Procedimientos básicos para preparar compuestos de la fórmula:
10
Siguiendo el Esquema 9, 9-1, que puede prepararse siguiendo una secuencia descrita para el Compuesto 81 (Compuesto 4) y una secuencia similar a la del Intermediario 11, se hace reaccionar con un aldehído heteroaromático apropiadamente sustituido o aldehído aromático apropiadamente sustituido (1 equivalente) en presencia de un
15 disolvente orgánico (es decir DCM, MeOH, EtOH y etc.) para formar una imina correspondiente, que se reduce mediante un agente de reducción apropiado (es decir NaBH4) para proporcionar el compuesto. La (R)n y la Rm se refiere a los sustituyentes opcionales. Además, los grupos fenilo pueden reemplazarse por otros grupos arilo o ciclos como se describe en la presente.
Ejemplo 12: Ligandos de receptores de opioides
20 Los ligandos de receptores de opioides y compuestos que figuran en las siguientes tablas pueden preparase o se prepararon de acuerdo con los procedimientos descritos anteriormente a partir de materiales de partida apropiados y reactivos apropiados. Los compuestos que se han preparado incluyen datos de NMR, mientras que los ejemplos teóricos no incluyen datos de NMR.
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 1
- 2-[9-(piridin-2-il)-6-oxaspiro[4.5]decan-9-il] etan-1-amina 261,1 δ 8,58 (ddd, J = 4,8, 1,9, 0,9, 1H), 7,63 (m, 1H), 7,30 (m, 1H), 7,12 (ddd, J = 7,4, 4,8, 1,0, 1H), 3,76 (m, 2H), 2,55 (td, J = 11,6, 5,1, 1H), 2,46 (ddd, J = 13,7, 5,1, 2,7, 1H), 2,37 (dd, J = 13,7, 2,1, 1H), 2,14 (td, J = 11,6, 5,0, 1H), 1,92 (m, 2H), 1,70 (m, 4H), 1,46 (m, 4H), 1,13 (m, 1H), 0,71 (dt, J = 13,4, 8,8, 1H).
- 2
- 2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]decan -9-il]etan-1-amina 261,2 δ 8,58 (ddd, J = 4,8, 1,7, 0,7,1H), 7,64 (td, J = 7,8, 1,9, 1H), 7,28 (m, 1H), 7,12 (ddd, J = 7,4, 4,8, 0,9, 1H), 3,76 (m, 2H), 2,55 (m, 1H), 2,46 (ddd, J = 13,7, 5,1, 2,7,1H), 2,37 (m, 1H), 2,14 (m, 1H), 1,91 (m, 2H), 1,71 (m, 4H), 1,47 (m, 4H), 1,13 (m, 1H), 0,71 (m, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 3
- 2-[9-(2-aminoetil)-6oxaspiro[4.5]decan-9-il]piridin-4-ol 277,1 δ 7,60 (d, J = 6,8, 1H), 7,60 (d, J = 6,8, 1H), 7,21 (s, 2H), 6,79 (d, J = 332,9, 3H), 6,54 (m, 5H), 6,37 (s, 1H), 6,29 (d, J = 6,5,1H), 5,97 (m, 6H), 4,84 (d, J = 169,9, 3H), 3,69 (dt, J = 23,7, 11,7, 3H), 3,69 (dt, J = 23,7, 11,7, 3H), 3,40 (s, 2H), 3,40 (s, 2H), 2,64 (s, 1H), 2,64 (s, 1H), 2,32 (d, J = 12,0, 1H), 2,26 (dd, J = 46,7, 13,0, 2H), 2,20 (d, J = 13,9, 1H), 2,09 (d, J = 13,8, 1H), 2,09 (d, J = 13,8, 1H), 1,84 (t, J = 15,9, 2H), 1,60 (m, 15H), 1,55 (m, 11H), 0,89 (m, 2H), 0,89 (m, 1H).
- 4
- 6-[9-(2-aminoetil)-6-oxaspiro[4.5]decan-9-il ]piridin-3-ol 277,1 δ 8,05 (m, 1H), 7,01 (d, J = 8,6, 1H), 6,87 (dd, J = 8,6, 2,9, 1H), 5,37 (s, 2H), 3,66 (dd, J = 13,7, 7,2, 2H), 2,60 (ddd, J = 12,3, 10,1, 5,6, 1H), 2,22 (m, 3H), 1,88 (tt, J = 10,0, 7,9, 1H), 1,77 (d, J = 13,6, 1H), 1,58 (m, 4H), 1,37 (m, 5H), 1,08 (dd, J = 15,4, 4,9, 1H), 0,63 (dt, J = 13,7, 8,9, 1H).
- 5
- 6-[9-(2-aminoetil)-6-oxaspiro[4.5]decan-9-il ]piridin-2-ol 277,1 δ 7,38 (dd, J = 9,0, 7,1, 1H), 6,40 (d, J = 9,0, 1H), 6,09 (d, J = 7,1, 1H), 5,28 (s, 1H), 3,73 (s, 2H), 2,69 (m, 1H), 2,37 (m, 2H), 2,13 (m, 2H), 1,66 (m, 12H), 0,97 (dt, J = 12,4, 7,6, 1H).
- 6
- 2-[(9R)-9-(2-aminoetil)-6-oxaspiro[4.5]deca n-9-il]-1-oxidopiridin-1-io 277,1 δ 8,23 (m, 1H), 7,31 (dd, J = 5,8, 2,0, 2H), 7,23 (m, 1H), 4,03 (s, 2H), 3,81 (s, 2H), 3,27 (d, J = 13,9, 1H), 2,95 (td, J = 12,8, 5,1, 1H), 2,65 (td, J = 11,8, 5,1, 1H), 2,25 (s, 2H), 1,65 (ddd, J = 38,7, 17,6, 11,7, 9H), 1,24 (s, 1H), 0,84 (dt, J = 13,1, 8,8, 1H).
- 7
- bencil({2-[1-(4-fluorofenil)ciclohexil]etil})am ina 312,2 δ 9,72 (t, J = 1,5, 1H), 7,91 (m, 2H), 7,23 (m, 3H), 7,06 (m, 2H), 6,92 (m, 2H), 2,91 (t, J = 6,9, 2H), 2,44 (m, 4H), 2,09 (dd, J = 13,2, 5,3, 2H), 1,68 (m, 4H), 1,46 (m, 1H), 1,33 (dd, J = 15,4, 6,7, 4H).
- 8
- bencil({2-[4-(4-fluorofenil)oxan-4-il]etil})ami na 314,2 δ 7,38 -7,16 (m, 7H), 7,09 -6,99 (m, 2H), 3,79 (ddd, J = 11,5, 5,7, 3,6, 2H), 3,64 (s, 2H), 3,56 (ddd, J = 11,6, 8,8, 2,8, 2H), 2,39 2,29 (m, 2H), 2,24 -2,01 (m, 4H), 1,86 (ddd, J = 13,8, 7,9, 3,5, 2H).
- 9
- [(2-metilfenil)metil]({2-[4-(4-metilfenil)oxan4-il]etil})amina 324,2 δ 7,16 (m, 8H), 3,79 (ddd, J = 11,5, 5,2, 3,8, 2H), 3,58 (m, 4H), 2,41 (m, 2H), 2,36 (s, 3H), 2,27 (s, 3H), 2,16 (m, 2H), 1,86 (ddd, J = 12,3, 8,6, 4,6, 4H), 1,58 (s, 1H)
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 10
- N-{2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]eti l}anilina 324,3 δ 7,25 (dt, J = 5,9, 2,9, 3H), 7,11 (m, 2H), 6,98 (dd, J = 25,0, 8,2, 4H), 3,65 (dd, J = 8,9, 6,7, 2H), 2,95 (d, J = 4,6, 1H), 2,50 (d, J = 4,7, 1H), 2,23 (s, 3H), 2,10 (d, J = 13,9, 1H), 1,89 (m, 3H), 1,43 (m, 2H), 1,21 (m, 1H), 1,05 (s, 3H), 0,53 (s, 3H).
- 11
- 2-[({2-[4-(4-metilfenil)oxan-4-il]etil}amino)m etil]fenol 326,2 δ 7,15 (m, 5H), 6,88 (dd, J = 7,4, 1,3, 1H), 6,79 (dd, J = 8,1, 1,0, 1H), 6,73 (td, J = 7,4, 1,1, 1H), 3,76 (m, 4H), 3,54 (ddd, J = 11,7, 9,4, 2,5, 2H), 2,37 (m, 5H), 2,13 (m, 2H), 1,82 (m, 4H)
- 12
- 2-[({2-[4-(4-fluorofenil)oxan-4-il]etil}amino) metil]fenol 330,2 δ 8,26 (s, 2H), 7,07 (m, 3H), 6,95 (dd, J = 14,3, 5,8, 2H), 6,86 (d, J = 6,3, 1H), 6,78 (d, J = 8,1, 1H), 6,71 (t, J = 7,4, 1H), 3,96 (d, J = 7,0, 2H), 3,80 (s, 2H), 3,64 (dt, J = 8,8, 3,9, 2H), 3,41 (t, J = 9,3, 2H), 2,45 (s, 2H), 1,95 (d, J = 14,7, 2H), 1,85 (m, 2H), 1,67 (m, 2H).
- 13
- bencil({2-[3-(piridin-2-il)-1-oxaspiro[4,4]non an-3-il]etil})amina 337,1 6 9,76 (s, 2H), 8,59 (d, J = 4,7, 1H), 8,11 (t, J = 7,8, 1H), 7,69 (d, J = 8,1, 1H), 7,63 -7,52 (m, 1H), 7,35 (s, 5H), 4,13 (d, J = 9,7, 1H), 4,03 (s, 2H), 3,91 (d, J = 9,7, 1H), 2,92 (d, J = 26,5, 2H), 2,53 (ddd, J = 14,6, 9,5, 5,4, 1H), 2,38 (dd, J = 19,0, 8,5, 2H), 2,28 (d, J = 13,6, 1H), 1,99 -1,81 (m, 1H), 1,84 -1,52 (m, 6H), 1,51 -1,35 (m, 1H).
- 14
- bencil({2-[2,2-dimetil-4-(4-metilfenil)oxan-4 -il]etil})amina 338,3 δ 8,54 (d, J = 226,0, 2H), 7,22 (q, J = 6,7, 3H), 7,03 (dd, J = 19,0, 8,3, 6H), 6,23 (d, J = 186,3, 2H), 3,69 (m, 4H), 2,66 (s, 1H), 2,25 (s, 4H), 2,10 (dd, J = 22,7, 13,3, 2H), 1,83 (m, 1H), 1,64 (m, 1H), 1,49 (m, 2H), 1,11 (s, 3H), 0,57 (s, 3H).
- 15
- {2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]etil}( piridin-2-ilmetil)amina 339,3 δ 8,48 (dd, J = 5,2, 0,9, 1H), 8,26 (s, 1H), 7,98 (dd, J = 7,8, 1,6, 1H), 7,59 (d, J = 7,9, 1H), 7,54 (m, 1H), 7,07 (s, 4H), 4,17 (q, J = 13,9, 2H), 3,73 (m, 2H), 2,88 (d, J = 4,8, 1H), 2,42 (d, J = 4,8, 1H), 2,21 (m, 4H), 2,10 (dd, J = 13,9, 2,1, 1H), 2,00 (d, J = 4,6, 1H), 1,78 (d, J = 4,6, 1H), 1,58 (m, 2H), 1,12 (s, 3H), 0,59 (s, 3H).
- 16
- {2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]etil}( piridin-3-ilmetil)amina 339,3 δ 8,92 (s, 1H), 8,52 (s, 1H), 8,25 (d, J = 8,0, 1H), 7,67 (m, 1H), 7,08 (m, 4H), 5,92 (s, 4H), 4,09 (s, 2H), 3,71 (m, 2H), 2,85 (dd, J = 12,0, 7,9, 1H), 2,34 (m, 1H), 2,23 (m, 4H), 2,10 (d, J = 13,9, 1H), 1,94 (m, 1H), 1,74 (dd, J = 12,5, 4,3, 1H), 1,55 (m, 2H), 1,10 (s, 3H), 0,57 (s, 3H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 17
- [(2-metoxifenil)metil]({2-[4-(4-metilfenil)oxa n-4-il]etil})amina 340,2 δ 7,21 (m, 1H), 7,13 (s, 4H), 7,07 (dd, J = 7,4, 1,7, 1H), 6,84 (ddd, J = 12,1, 9,3, 4,6, 2H), 3,78 (m, 5H), 3,63 (s, 2H), 3,54 (ddd, J = 11,6, 9,1, 2,7, 2H), 2,38 (d, J = 1,3, 1H), 2,32 (m, 5H), 2,10 (m, 2H), 1,84 (m, 4H)
- 18
- (furan-3-ilmetil)({2-[(9R)-9-(piridin-2-il)-6-ox aspiro[4.5]decan-9-il]etil})amina 341,1 δ 8,72 (d, J = 4,6, 1H), 8,23 (t, J = 7,3, 1H), 7,84 -7,57 (m, 2H), 7,46 (s, 1H), 7,38 (t, J = 1,6, 1H), 7,28 (s, 1H), 3,89 (s, 2H), 3,82 (dt, J = 12,4, 4,2, 1H), 3,72 (dd, J = 16,1, 6,2, 1H), 2,96 (d, J = 4,4, 1H), 2,40 (ddd, J = 36,0, 24,7, 12,8, 4H), 2,20 (dd, J = 12,7, 4,8, 1H), 2,01 (d, J = 14,2, 1H), 1,95 -1,77 (m, 2H), 1,69 (dd, J = 9,6, 4,4, 1H), 1,63 -1,39 (m, 4H), 1,21 -1,08 (m, 1H), 0,91-0,60 (m, 1H).
- 19
- (1H-imidazol-2-ilmetil)({2-[(9R)-9-(piridin-2il)-6-oxaspiro[4.5]decan-9-il]etil})amina 341,1 δ 8,70 (d, J = 5,1, 1H), 8,40 (t, J = 7,9, 1H), 7,92 (d, J = 8,2, 1H), 7,87 -7,74 (m, 1H), 7,31 (d, J = 18,0, 2H), 4,66 (d, J = 14,3, 1H), 4,49 (d, J = 14,3, 1H), 4,02 -3,81 (m, 1H), 3,74 (d, J = 9,7, 1H), 3,10 (d, J = 4,9, 1H), 2,84 -2,48 (m, 2H), 2,37 (t, J = 12,7, 3H), 2,17 -2,00 (m, 1H), 2,00 -1,82 (m, 2H), 1,70 (s, 1H), 1,65 -1,41 (m, 4H), 1,21 (s, 1H), 0,82 (d, J = 13,1, 1H).
- 20
- (1,3-oxazol-4-ilmetil)({2-[(9R)-9-(piridin-2-il) -6-oxaspiro[4.5]decan-9-il]etil})amina 342,1 δ 8,77 (dd, J = 5,5, 1,4, 1H), 8,26 (td, J = 8,0, 1,7, 1H), 7,90 (s, 1H), 7,82 (s, 1H), 7,79 7,60 (m, 2H), 4,08 (s, 2H), 3,86 (d, J = 12,9, 1H), 3,81-3,66 (m, 1H), 3,13 (d, J = 5,6, 1H), 2,76 -2,60 (m, 1H), 2,48 (s, 1H), 2,42 -2,25 (m, 3H), 2,16 -2,01 (m, 1H), 1,89 (dd, J = 9,6, 4,0, 2H), 1,79 -1,63 (m, 1H), 1,63 -1,35 (m, 4H), 1,19 (s, 1H), 0,80 (d, J = 13,2, 1H).
- 21
- {2-[3-(piridin-2-il)-1-oxaspiro[4,4]nonan-3-il] etil}(tiofen-2-ilmetil)amina 343 δ 10,01 (s, 3H), 8,62 (d, J = 4,5, 1H), 8,11 (td, J = 8,0, 1,4, 1H), 7,70 (d, J = 8,1, 1H), 7,63 -7,46 (m, 1H), 7,33 (dd, J = 5,1, 1,0, 1H), 7,16 (d, J = 2,8,1H), 7,00 (dd, J = 5,1, 3,6, 1H), 4,29 (s, 2H), 4,14 (d, J = 9,7, 1H), 3,92 (d, J = 9,7, 1H), 2,97 (qd, J = 18,1, 12,2, 2H), 2,53 (ddd, J = 14,4, 9,0, 5,7, 1H), 2,45 2,21 (m, 3H), 2,00 -1,82 (m, 1H), 1,67 (tt, J = 22,6, 8,0, 6H), 1,44 (dd, J = 14,3, 10,0, 1H).
- 22
- {2-[3-(piridin-2-il)-1-oxaspiro[4,4]nonan-3-il] etil}(tiofen-3-ilmetil)amina 343 δ 11,15 (s, 2H), 9,70 (s, 2H), 8,64 (d, J = 4,4, 1H), 8,17 (td, J = 8,0, 1,5, 1H), 7,74 (d, J = 8,1,1H), 7,63 (dd, J = 6,7, 5,7, 1H), 7,40 (dd, J = 2,8, 1,1, 1H), 7,33 (dd, J = 5,0, 3,0, 1H), 7,10 (dd, J = 5,0, 1,2, 1H), 4,23 -4,07 (m, 3H), 3,94 (d, J = 9,8, 1H), 2,90 (d, J = 33,7, 2H), 2,67 -2,50 (m, 1H), 2,50 -2,24 (m, 3H), 1,91 (dd, J = 13,7, 4,9, 1H), 1,83 -1,52 (m, 6H), 1,43 (td, J = 7,7, 3,9, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 23
- (ciclopentilmetil)({2-[(9R)-9-(piridin-2-il)-6-o xaspiro[4.5]decan-9-il]etil})amina 343,3 δ 8,77 (d, J = 4,6, 2H), 8,26 (t, J = 7,6, 1H), 7,89 -7,60 (m, 2H), 3,85 (dd, J = 8,5, 4,2,1H), 3,73 (t, J = 10,1, 1H), 3,00 (s, 1H), 2,81 (s, 2H), 2,42 (dt, J = 23,0, 9,5, 4H), 2,25 (t, J = 10,8, 1H), 2,19 -1,98 (m, 2H), 1,98 1,33 (m, 13H), 1,16 (s, 3H), 0,76 (dt, J = 13,1, 8,9, 1H).
- 24
- {2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]etil}( tiofen-2-ilmetil)amina 344,2 δ 8,87 (d, J = 194,4, 2H), 3,91 (s, 3H), 3,69 (m, 2H), 2,66 (d, J = 7,9, 1H), 2,24 (m, 4H), 2,10 (ddd, J = 30,6, 14,0, 2,1, 2H), 1,84 (td, J = 12,5, 4,9, 1H), 1,65 (m, 1H), 1,49 (m, 2H), 1,11 (d, J = 6,1, 3H), 0,57 (s, 3H).
- 25
- (2-[4-(4-fluorofenil)oxan-4-il]etil}[(2-metoxif enil)metil]amina 344,2 δ 7,20 (ddd, J = 7,6, 4,8, 2,0, 3H), 7,03 (m, 3H), 6,84 (ddd, J = 11,7, 9,1, 4,5, 2H), 3,77 (m, 5H), 3,61 (s, 2H), 3,54 (ddd, J = 11,6, 8,8, 2,8, 2H), 2,27 (m, 2H), 2,08 (m, 2H), 1,84 (ddd, J = 10,5, 8,4, 3,0, 4H), 1,58 (s, 1H)
- 26
- {2-[9-(1H-pirazol-1-il)-6-oxaspiro[4.5]decan -9-il]etil}(tiofen-2-ilmetil)amina 346 δ 9,87 (s, 1H), 9,00 (d, J = 145,4, 2H), 7,46 (dd, J = 12,7, 2,1, 2H), 7,28 (dd, J = 5,1, 1,1, 1H), 7,01 (d, J = 0,8, 1H), 6,93 (dd, J = 5,1, 3,5, 1H), 6,34 -6,24 (m, 1H), 5,22 (s, 1H), 4,10 (q, J = 14,2, 2H), 3,68 (d, J = 2,7, 2H), 2,94 (s, 1H), 2,50 (s, 1H), 2,31 (s, 2H), 2,24 2,08 (m, 1H), 1,99 (dt, J = 14,7, 7,3, 1H), 1,93 -1,76 (m, 2H), 1,75 -1,63 (m, 1H), 1,57 (ddd, J = 23,2, 14,0, 8,1, 1H), 1,51 (s, 4H), 1,17 -1,04 (m, 1H), 0,69 (dt, J = 13,3, 8,7, 1H).
- 27
- bencil({2-[(9S)-9-(piridin-2-il)-6-oxaspiro[4. 5]decan-9-il]etil})amina 351,1 δ 8,67 (d, J = 4,7,1H), 8,17 (t, J = 7,7, 1H), 7,64 (m, 2H), 7,35 (m, 5H), 6,51 (s, 4H), 4,72 (s, 1H), 3,94 (s, 2H), 3,75 (m, 2H), 2,95 (s, 1H), 2,49 (s, 1H), 2,33 (m, 3H), 2,19 (m, 1H), 1,98 (d, J = 14,1, 1H), 1,81 (dt, J = 13,4, 7,5, 2H), 1,68 (m, 1H), 1,49 (ddd, J = 20,8,14,7, 7,2, 4H), 1,15 (s, 1H), 0,75 (m, 1H).
- 28
- bencil({2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4. 5]decan-9-il]etil})amina 351,1 δ 8,61 (s, 1H), 8,18 (t, J = 7,7,1H), 7,65 (m, 2H), 7,26 (m, 5H), 6,90 (d, J = 26,0, 4H), 3,88 (s, 2H), 3,72 (d, J = 12,7, 1H), 3,60 (t, J = 10,0, 1H), 2,90 (s, 1H), 2,39 (d, J = 34,6, 2H), 2,20 (t, J = 13,3, 3H), 1,92 (d, J = 14,8, 2H), 1,75 (m, 2H), 1,59 (d, J = 4,9, 1H), 1,41 (m, 4H), 1,08 (s, 1H), 0,68 (dt, J = 13,2, 9,0, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 29
- bencil({2-[3-(piridin-2-il)-1-oxaspiro[4.5]dec an-3-il]etil})amina 351,1 δ 9,67 (s, 2H), 8,61 (s, 1H), 8,19 (t, J = 7,5, 1H), 7,80 (d, J = 8,1, 1H), 7,64 (s, 1H), 7,36 (s, 5H), 4,22 (d, J = 10,0, 1H), 4,05 (s, 2H), 3,98 (d, J = 10,0, 1H), 3,00 (s, 1H), 2,84 (s, 1H), 2,64 (s, 1H), 2,39 (d, J = 8,7, 1H), 2,18 (d, J = 13,6,1H), 2,09 (d, J = 13,6, 1H), 1,75 1,52 (m, 4H), 1,33 (dd, J = 28,9, 16,2, 7H).
- 30
- bencil({2-[9-(piridin-2-il)-6-oxaspiro[4.5]dec an-9-il]etil})amina 351,2 δ 8,49 (s, 1H), 8,03 (s, 1H), 7,53 (d, J = 8,0, 2H), 7,18 (m, 5H), 3,82 (s, 2H), 3,63 (s, 1H), 3,53 (dd, J = 23,8, 13,7, 1H), 2,84 (s, 1H), 2,38 (s, 1H), 2,27 (d, J = 7,4, 1H), 2,13 (d, J = 14,1, 3H), 1,84 (d, J = 14,2, 1H), 1,67 (m, 2H), 1,52 (d, J = 5,0, 1H), 1,32 (m, 4H), 1,01 (s, 1H), 0,61 (dt, J = 13,0, 8,9, 1H).
- 31
- {2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]etil}[ (2-metilfenil)metil]amina 352,2 δ 7,09 (d, J = 8,3, 2H), 7,02 (ddd, J = 8,1, 6,1, 3,3, 6H), 3,69 (m, 2H), 3,47 (s, 2H), 2,41 (td, J = 10,8, 5,4, 1H), 2,25 (m, 4H), 2,11 (m, 5H), 1,75 (ddd, J = 13,2, 10,4, 5,2, 1H), 1,56 (m, 4H), 1,11 (s, 3H), 0,59 (s, 3H).
- 32
- {2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]etil}[ (3-metilfenil)metil]amina 352,3 δ 9,13 (s, 1H), 8,69 (s, 1H), 7,04 (m, 6H), 6,86 (m, 2H), 3,65 (m, 6H), 2,59 (s, 1H), 2,12 (m, 9H), 1,83 (td, J = 12,4, 4,5, 1H), 1,64 (m, 1H), 1,48 (m, 2H), 1,10 (s, 3H), 0,57 (s, 3H).
- 33
- {2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]etil}[ (4-metilfenil)metil]amina 352,3 δ 8,68 (d, J = 205,9, 2H), 7,02 (dd, J = 16,8, 9,0, 6H), 6,93 (d, J = 8,1, 2H), 3,67 (dd, J = 6,6, 2,7, 2H), 3,57 (s, 2H), 3,44 (s, 3H), 2,61 (s, 1H), 2,25 (d, J = 11,2, 3H), 2,17 (s, 3H), 2,08 (dd, J = 20,3, 14,0, 2H), 1,84 (m, 1H), 1,67 (d, J = 7,6, 1H), 1,48 (m, 2H), 1,09 (s, 3H), 0,56 (s, 3H).
- 34
- {2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]etil)[ (1R)-1-feniletil]amina 352,3 δ 9,07 (dd, J = 228,2, 166,6, 2H), 7,24 (ddd, J = 9,3, 6,4, 3,4, 3H), 7,15 (m, 2H), 6,94 (m, 4H); 3,91 (s, 1H), 3,61 (dd, J = 7,0, 4,0, 2H), 2,42 (d, J = 33,9, 1H), 2,21 (d, J = 11,7, 6H), 2,00 (m, 2H), 1,82 (m, 1H), 1,62 (dd, J = 8,6, 4,1, 1H), 1,42 (m, 5H), 1,05 (s, 3H), 0,53 (d, J = 3,4, 3H).
- 35
- {2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]etil}[ (1S)-1-feniletil]amina 352,3 δ 8,92 (dd, J = 238,8, 174,0, 2H), 7,24 (m, 3H), 7,14 (td, J = 7,5, 2,2, 2H), 6,95 (m, 4H), 3,89 (d, J = 19,3, 1H), 3,62 (m, 2H), 2,96 (s, 2H), 2,42 (m, 1H), 2,21 (d, J = 11,6, 3H), 2,00 (m, 3H), 1,82 (m, 1H), 1,63 (m, 1H), 1,40 (m, 5H), 1,06 (s, 3H), 0,53 (d, J = 3,6, 3H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 36
- bencil({2-[2,2-dimetil-4-(4-metilfenil)oxan-4 -il]etil})metilamina 352,3 δ 11,09 (s, 2H), 7,39 (m, 3H), 7,23 (m, 1H), 7,15 (m, 5H), 4,19 (dd, J = 25,7, 12,6, 1H), 3,91 (dd, J = 17,4, 8,4, 1H), 3,78 (m, 2H), 2,91 (d, J = 127,4, 1H), 2,56 (dd, J = 17,7, 7,2, 3H), 2,37 (d, J = 4,8, 3H), 2,24 (ddd, J = 22,0, 12,2, 2,2, 3H), 2,05 (m, 1H), 1,88 (td, J = 12,5, 4,7, 1H), 1,64 (m, 2H), 1,21 (s, 3H), 382,30,67 (d, J = 1,2, 3H).
- 37
- {2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]etil}( 2-feniletil)amina 352,3 δ 9,06 (d, J = 128,6, 2H), 7,17 (m, 3H), 7,02 (m, 6H), 3,68 (dd, J = 11,8, 10,1, 2H), 2,77 (dt, J = 36,5, 30,4, 7H), 2,19 (m, 5H), 1,99 (m, 1H), 1,89 (td, J = 12,5, 4,6, 1H), 1,69 (m, 1H), 1,49 (m, 2H), 1,00 (s, 3H), 0,52 (s, 3H).
- 38
- (pirazin-2-ilmetil)({2-[(9R)-9-(piridin-2-il)-6oxaspiro[4.5]decan-9-il]etil})amina 353,1 δ 8,79 (dd, J = 5,6, 1,4, 1H), 8,68 -8,54 (m, 2H), 8,51 (dd, J = 2,3, 1,6, 1H), 8,32 (td, J = 8,0, 1,6, 1H), 7,93 -7,66 (m, 3H), 4,30 (s, 2H), 3,85 (dt, J = 12,3, 4,2,1H), 3,72 (t, J = 9,9, 1H), 3,19 (td, J = 11,7, 5,2, 1H), 2,72 (td, J = 11,8, 4,0,1H), 2,62 -2,45 (m, 1H), 2,45 2,27 (m, 3H), 2,10 (d, J = 14,2, 1H), 2,00 1,79 (m, 2H), 1,69 (dt, J = 9,9, 6,6, 1H), 1,63 -1,41 (m, 4H), 1,19 (dd, J = 12,6, 6,5, 1H), 0,78 (dt, J = 13,1, 8,9, 1H).
- 39
- bencil({2-[2,2-dietil-4-(piridin-2-il)oxan-4-il] etil})amina 353,3 δ 8,71 (dd, J = 5,5, 1,4, 1H), 8,21 (td, J = 8,0, 1,7, 1H), 7,67 (m, 2H), 7,33 (m, 5H), 3,95 (s, 2H), 3,79 (m, 1H), 3,67 (d, J = 10,8, 1H), 3,01 (d, J = 5,2, 1H), 2,40 (m, 4H), 2,10 (s, 1H), 1,73 (t, J = 16,5, 2H), 1,55 (dd, J = 14,1, 7,5,1H), 1,39 (dd, J = 14,1, 7,4,1H), 0,81 (m, 5H), 0,56 (t, J = 7,3, 3H).
- 40
- bencil({2-[2,2,6,6-tetrametil-4-(piridin-2-il)o xan-4-il]etil})amina 353,3 δ 8,74 -8,62 (m, 1H), 8,24 (td, J = 8,1, 1,5, 1H), 7,87 (d, J = 8,2, 1H), 7,76-7,65 (m, 1H), 7,47 -7,18 (m, 7H), 3,96 (s, 2H), 2,75 (s, 2H), 2,50 (d, J = 14,7, 2H), 2,43 -2,28 (m, 2H), 1,89 (d, J = 14,8, 2H), 1,30 (s, 6H), 0,97 (s, 6H).
- 41
- 4-[({2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]e til}amino)metil]fenol 354,2 δ 8,58 (d, J = 187,3, 2H), 7,05 (q, J = 8,3, 4H), 6,91 (d, J = 8,3, 2H), 6,58 (d, J = 8,4, 2H), 3,67 (d, J = 10,4, 2H), 3,58 (s, 2H), 2,63 (d, J = 18,2, 1H), 2,26 (s, 4H), 2,07 (d, J = 14,3, 4H), 1,84 (t, J = 10,2, 1H), 1,49 (d, J = 13,9, 3H), 1,09 (s, 3H), 0,56 (s, 3H).
- 42
- 2-[({2-[2,2-dimetil-4-(4-metilfenil)oxan-4il]etil}amino)metil]fenol 354,3 δ 8,15 (d, J = 107,7, 2H), 7,03 (dt, J = 26,2, 8,3, 5H), 6,82 (m, 2H), 6,64 (t, J = 7,4, 1H), 3,68 (m, 6H), 2,58 (s, 1H), 2,24 (d, J = 6,8, 4H), 2,05 (dd, J = 21,0,14,9, 2H), 1,78 (d, J = 4,4, 1H), 1,58 (s, 1H), 1,44 (dd, J = 21,2, 9,8, 2H), 1,10 (d, J = 18,7, 3H), 0,57 (d, J = 24,3, 3H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 43
- 3-[({2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]e til}amino)metil]fenol 354,3 δ 8,50 (d, J = 165,4, 2H), 7,02 (m, 5H), 6,68 (d, J = 7,5, 2H), 6,47 (d, J = 7,4, 1H), 3,67 (d, J = 9,4, 2H), 3,59 (s, 2H), 2,63 (s, 2H), 2,23 (s, 4H), 2,09 (dd, J = 27,3, 13,5, 2H), 1,84 (d, J = 7,8, 1H), 1,66 (d, J = 8,6, 1H), 1,52 (d, J = 13,9, 2H), 1,09 (s, 3H), 0,56 (s, 3H).
- 44
- [(5-metilfuran-2-il)metil]({2-[(9R)-9-(piridin2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 355,1 δ 8,73 (d, J = 4,2, 1H), 8,18 (td, J = 8,0, 1,5, 1H), 7,80 -7,53 (m, 2H), 7,29 (s, 1H), 4,00 (d, J = 1,4, 2H), 3,83 (dt, J = 12,4, 4,3, 1H), 3,79 -3,63 (m, 1H), 3,10 -2,86 (m, 1H), 2,64 -2,44 (m, 1H), 2,45 -2,27 (m, 3H), 2,27 2,11 (m, 4H), 2,02 (d, J = 14,2, 1H), 1,95 -1,77 (m, 2H), 1,68 (dd, J = 9,5, 4,1, 1H), 1,62 -1,39 (m, 4H), 1,26 -1,05 (m, 1H), 0,77 (dt, J = 13,3, 9,0, 1H).
- 45
- [(5-metilfuran-2-il)metil]({2-[9-(pirazin-2-il)6-oxaspiro[4.5]decan-9-il]etil})amina 356,1 δ 8,66 (s, 1H), 8,56 (s, 1H), 8,50 (s, 1H), 6,27 (d, J = 3,2, 1H), 6,05 -5,83 (m, 1H), 3,94 (d, J = 1,9, 2H), 3,85 -3,59 (m, 2H), 2,89 (d, J = 5,0,1H), 2,49 (d, J = 5,1, 1H), 2,38 (t, J = 16,0, 2H), 2,24 (s, 4H), 2,02 (dd, J = 18,2, 6,8, 2H), 1,96 -1,88 (m, 2H), 1,59 -1,37 (m, 5H), 1,09 (s, 1H), 0,66 (d, J = 13,4, 1H).
- 46
- bencil({2-[9-(tiofen-2-il)-6-oxaspiro[4.5]dec an-9-il]etil})amina 356,2 δ 9,56 (s, 1H), 9,11 (s, 1H), 7,31 (m, 3H), 7,23 (m, 2H), 7,19 (dd, J = 5,1, 1,0, 1H), 6,91 (dd, J = 5,1, 3,6, 1H), 6,74 (d, J = 3,5, 1H), 3,72 (m, 4H), 2,74 (m, 1H), 2,44 (m, 1H), 2,01 (d, J = 13,9, 2H), 1,95 (dd, J = 11,7, 5,0, 1H), 1,87 (m, 2H), 1,73 (s, 5H), 1,66 (m, 2H), 1,50 (m, 3H), 1,00 (dd, J = 13,6, 8,5, 1H).
- 47
- {2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]etil}[ (2-fluorofenil)metil]amina 356,3 δ 7,15 (m, 1H), 7,06 (m, 5H), 6,94 (dt, J = 18,3, 8,1, 2H), 3,69 (t, J = 7,7, 2H), 3,60 (s, 2H), 2,44 (dd, J = 11,0, 5,2, 1H), 2,22 (d, J = 20,4, 4H), 2,11 (m, 2H), 1,77 (dd, J = 6,6, 4,0, 1H), 1,57 (qd, J = 10,9, 5,5, 3H), 1,11 (s, 3H), 0,59 (s, 3H).
- 48
- {2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]etil}[ (3-fluorofenil)metil]amina 356,3 δ 8,79 (d, J = 198,9, 2H), 7,19 (m, 2H), 7,05 (d, J = 8,2, 2H), 7,00 (d, J = 8,4, 2H), 6,94 (td, J = 8,4, 2,2, 1H), 6,86 (d, J = 7,6, 1H), 6,79 (d, J = 8,9, 1H), 6,36 (s, 2H), 3,69 (m, 4H), 2,65 (s, 1H), 2,24 (s, 3H), 2,11 (ddd, J = 18,3, 15,7, 11,3, 3H), 1,81 (dt, J = 12,3, 6,2, 1H), 1,63 (m, 1H), 1,48 (m, 2H), 1,10 (s, 3H), 0,56 (s, 3H).
- 49
- {2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]etil}[ (4-fluorofenil)metil]amina 356,3 δ 8,73 (d, J = 173,6, 2H), 7,03 (m, 6H), 6,88 (t, J = 8,5, 2H), 5,32 (s, 2H), 3,68 (m, 4H), 2,61 (s, 1H), 2,24 (s, 3H), 2,11 (m, 3H), 1,78 (dt, J = 12,3, 6,2, 1H), 1,61 (m, 1H), 1,47 (m, 2H), 1,10 (s, 3H), 0,56 (s, 3H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 50
- bencil(2-{9-ciclohexil-6-oxaspiro[4.5]decan -9-il}etil)amina 356,3 δ 9,09 (d, J = 38,9, 2H), 7,35 (m, 5H), 6,43 (s, 2H), 3,93 (s, 2H), 3,54 (m, 2H), 2,85 (s, 2H), 1,63 (m, 16H), 1,10 (m, 7H), 0,84 (q, J = 11,8, 2H).
- 51
- {2-[3-(piridin-2-il)-1-oxaspiro[4.5]decan-3-il] etil}(tiofen-2-ilmetil)amina 357 δ 9,79 (s, 2H), 8,66 (s, 1H), 8,21 (t, J = 7,5, 1H), 7,80 (d, J = 8,1, 1H), 7,66 (s, 1H), 7,33 (d, J = 5,0,1H), 7,16-(s, 1H), 7,06 -6,98 (m, 1H), 4,29 (s, 2H), 4,23 (d, J = 9,9, 1H), 3,99 (d, J = 10,0, 1H), 3,00 (s, 1H), 2,87 (s, 1H), 2,63 (t, J = 9,5, 1H), 2,39 (d, J = 8,6, 1H), 2,20 (d, J = 13,5,1H), 2,10 (d, J = 13,6,1H), 1,77 -1,49 (m, 4H), 1,47-1,19 (m, 6H).
- 52
- {2-[3-(piridin-2-il)-1-oxaspiro[4.5]decan-3-il] etil}(tiofen-3-ilmetil)amina 357 δ 9,72 (s, 2H), 8,64 (s, 1H), 8,21 (t, J = 7,5, 1H), 7,80 (d, J = 8,1, 1H), 7,66 (t, J = 5,9, 1H), 7,44-7,31 (m, 2H), 7,09 (d, J = 4,8, 1H), 4,23 (d, J = 9,9, 1H), 4,10 (s, 2H), 3,99 (d, J = 10,0, 1H), 2,95 (s, 1H), 2,80 (s, 1H), 2,64 (s, 1H), 2,39 (d, J = 8,7, 1H), 2,21 (d, J = 13,7, 1H), 2,10 (d, J = 13,6, 1H), 1,77 -1,50 (m, 4H), 1,49 -1,22 (m, 6H).
- 53
- {2-[9-(piridin-2-il)-6-oxaspiro[4.5]decan-9-il] etil}(tiofen-2-ilmetil)amina 357,1 δ 8,67 (d, J = 4,3, 1H), 8,14 (s, 1H), 7,66 (d, J = 8,2, 1H), 7,59 (s, 1H), 7,33 (dd, J = 5,1, 1,1, 1H), 7,12 (d, J = 2,7, 1H), 7,00 (dd, J = 5,1, 3,5, 1H), 4,22 (s, 2H), 3,80 (s, 1H), 3,72 (t, J = 9,8, 1H), 3,33 -2,70 (m, 1H), 2,70 2,50 (m, 1H), 2,30 (d, J = 14,0, 3H), 2,19 (dd, J = 18,0, 7,1, 1H), 1,98 (d, J = 14,1, 1H), 1,83 (d, J = 4,6, 2H), 1,76 -1,62 (m, 1H), 1,50 (dd, J = 20,1, 13,3, 5H), 1,16 (s, 1H), 0,75 (dt, J = 13,1, 9,1, 1H).
- 54
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]deca n-9-il]etil}(tiofen-2-ilmetil)amina 357,2 δ 8,67 (d, J = 4,3, 1H), 8,14 (s, 1H), 7,66 (d, J = 8,2, 1H), 7,59 (s, 1H), 7,33 (dd, J = 5,1, 1,1, 1H), 7,12 (d, J = 2,7, 1H), 7,00 (dd, J = 5,1, 3,5, 1H), 4,22 (s, 2H), 3,80 (s, 1H), 3,72 (t, J = 9,8, 1H), 3,33 -2,70 (m, 1H), 2,70 2,50 (m, 1H), 2,30 (d, J = 14,0, 3H), 2,19 (dd, J = 18,0, 7,1,1H), 1,98 (d, J = 14,1,1H), 1,83 (d, J = 4,6, 2H), 1,76 -1,62 (m, 1H), 1,50 (dd, J = 20,1, 13,3, 5H), 1,16 (s, 1H), 0,75 (dt, J = 13,1, 9,1, 1H).
- 55
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]deca n-9-il]etil}(tiofen-3-ilmetil)amina 357,2 δ 8,73 (d, J = 5,0,1H), 8,27 (t, J = 7,5, 2H), 7,88-7,62 (m, 2H), 7,48 -7,23 (m, 1H), 7,04 (dd, J = 4,9, 1,0, 1H), 4,02 (s, 2H), 3,90 3,76 (m, 1H), 3,69 (t, J = 10,0, 1H), 2,95 (s, 1H), 2,62 -2,12 (m, 4H), 2,13 -1,95 (m, 1H), 1,95 -1,76 (m, 2H), 1,68 (dt, J = 13,5, 7,9, 1H), 1,62 -1,30 (m, 5H), 1,16 (dd, J = 13,2, 6,6, 1H), 0,76 (dt, J = 13,0, 8,9, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 56
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]deca n-9-il]etil}(1,3-tiazol-2-ilmetil)amina 358 δ 8,77 (d, J = 4,3, 1H), 8,27 (t, J = 7,3, 1H), 7,86-7,65 (m, 2H), 7,43 (d, J = 3,1, 1H), 7,28 (s, 1H), 4,56 -4,39 (m, 2H), 3,79 (dddd, J = 21,9, 19,5, 10,8, 7,1, 2H), 3,19 (td, J = 11,5, 5,3, 1H), 2,81 -2,63 (m, 1H), 2,62 -2,43 (m, 1H), 2,43 -2,26 (m, 3H),,14 -1,99 (m, 1H), 2,00 -1,79 (m, 2H), 1,79 -1,63 (m, 1H), 1,63 -1,38 (m, 4H), 1,20 (dd, J = 13,0, 6,5, 1H), 0,79 (dt, J = 13,0, 8,9,1H).
- 57
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]deca n-9-il)etil}(1,3-tiazol-5-ilmetil)amina 358 δ 8,76 (d, J = 4,7, 1H), 8,37 (td, J=8,1, 1,4, 1H), 8,12 -7,72 (m, 3H), 7,29 (s, 1H), 4,37 (s, 2H), 3,93 -3,58 (m, 2H), 3,05 (td, J = 11,7, 5,1, 1H), 2,66-2,43 (m, 2H), 2,42-2,22 (m, 3H), 2,18-1,96 (m, 1H), 1,96-1,79 (m, 2H), 1,79 -1,39 (m, 5H), 1,18 (dd, J = 12,1, 5,5, 1H), 0,77 (dt, J = 12,9, 8,9, 1H).
- 58
- {2-[9-(pirazin-2-il)-6-oxaspiro[4.5]decan-9-il ]etil}(tiofen-2-ilmetil)amina 358 δ 8,63 (s, 1H), 8,55 (s, 1H), 8,49 (d, J = 2,3, 1H), 7,33 (dd, J = 5,1, 1,1, 1H), 7,08 (d, J = 2,6, 1H), 7,05 -6,97 (m, 1H), 3,73 (d, J = 36,7, 2H), 3,17 -2,73 (m, 1H), 2,54 -2,43 (m, 1H), 2,35 (d, J = 13,0, 2H), 2,24 -2,11 (m, 1H), 2,05-2,15 (m, 4H), 1,51 (s, 5H), 1,14 1,01 (m, 1H), 0,66 (s, 1H).
- 59
- {2-[2,2-dietil-4-(piridin-2-il)oxan-4-il]etil}(tiof en-3-ilmetil)amina 359,2 δ 8,72 (dd, J = 5,5, 1,4, 1H), 8,21 (td, J = 8,0, 1,7, 1H), 7,68 (m, 2H), 7,35 (dd, J = 2,9, 1,2, 1H), 7,30 (m, 2H), 7,04 (dd, J = 5,0, 1,3, 1H), 4,02 (s, 2H), 3,80 (dd, J = 10,0, 6,3, 1H), 3,68 (d, J = 10,8, 1H), 3,00 (m, 1H), 2,42 (m, 4H), 2,08 (d, J = 4,4, 1H), 1,78 (s, 1H), 1,71 (d, J = 14,5, 1H), 1,56 (dd, J = 14,1, 7,5, 1H), 1,40 (dd, J = 14,1, 7,4,1H), 0,81 (m, 5H), 0,57 (t, J = 7,3, 3H).
- 60
- {2-[2,2-dietil-4-(piridin-2-il)oxan-4-il]etil}(tiof en-2-ilmetil)amina il)metil)amina 359,2 δ 8,70 (dd, J = 5,4,1,4, 1H), 8,15 (d, J = 1,6, 1H), 7,66 (d, J = 8,2, 1H), 7,60 (dd, J = 6,7, 5,5, 1H), 7,33 (dd, J = 5,1, 1,2, 1H), 7,11 (d, J = 2,6, 1H), 6,99 (dd, J = 5,1, 3,6, 1H), 3,73 (d, J = 44,0, 4H), 4,02 (s, 2H), 3,80 (dd, J = 10,0, 6,3, 1H), 3,68 (d, J = 10,8, 1H), 3,00 (m, 1H), 2,42 (m, 4H), 2,08 (d, J = 4,4, 1H), 1,78 (s, 1H), 1,71 (d, J = 14,5, 1H), 1,56 (dd, J = 14,1, 7,5, 1H), 1,40 (dd, J = 14,1, 7,4, 1H), 0,81 (m, 5H), 0,57 (t, J = 7,3, 3H).
- 61
- {2-[2,2,6,6-tetrametil-4-(piridin-2-il)oxan-4-il ]etil}(tiofen-2-ilmetil)amina 359,2 δ 8,63 (dd, J = 5,6, 1,3, 1H), 8,18 (td, J = 8,1, 1,6, 1H), 7,81 (d, J = 8,2, 1H), 7,63 (dd, J = 6,8, 5,8, 1H), 7,36 -7,16 (m, 2H), 7,05 -6,96 (m, 2H), 6,88 (dd, J = 5,1, 3,6, 2H), 4,13 (s, 2H), 2,80 -2,60 (m, 2H), 2,43 (d, J = 14,7, 2H), 2,33 -2,17 (m, 2H), 1,81 (d, J = 14,8, 2H), 1,21 (d, J = 12,2, 6H), 0,89 (s, 6H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 62
- {2-[2,2,6,6-tetrametil-4-(piridin-2-il)oxan-4-il ]etil}(tiofen-3-ilmetil)amina 359,2 δ 8,62 (dd, J = 5,6, 1,4, 1H), 8,19 (td, J = 8,0, 1,7, 1H), 7,81 (d, J = 8,2, 2H), 7,67 -7,60 (m, 1H), 7,27 (dd, J = 2,9, 1,2, 1H), 7,23 -7,17 (m, 2H), 6,95 (dd, J = 5,0, 1,3, 1H), 3,95 (s, 2H), 2,62 (d, J = 8,1, 2H), 2,41 (d, J = 14,7, 2H), 2,34 -2,08 (m, 2H), 1,82 (d, J = 14,8, 2H), 1,21 (d, J = 13,1, 6H), 0,89 (s, 6H).
- 63
- {2-[9-(tiofen-2-il)-6-oxaspiro[4.5]decan-9-il] etil}(tiofen-2-ilmetil)amina 362,2 δ 9,60 (s, 1H), 9,27 (s, 1H), 7,29 (dd, J = 5,1, 1,1, 2H), 7,21 (dd, J = 5,1, 1,0, 1H), 7,03 (d, J = 2,6, 1H), 6,94 (ddd, J = 9,9, 5,1, 3,6, 2H), 6,77 (dd, J = 3,6, 1,1, 1H), 4,03 (s, 2H), 3,74 (m, 2H), 2,80 (td, J = 11,9, 4,9, 1H), 2,50 (td, J = 11,8, 5,0, 1H), 1,96 (m, 4H), 1,71 (m, 4H), 1,48 (m, 6H), 1,00 (dt, J = 12,7, 8,1, 1H).
- 64
- {2-[9-(tiofen-2-il)-6-oxaspiro[4.5]decan-9-il] etil}(tiofen-3-ilmetil)amina 362,2 δ 9,46 (s, 1H), 9,23 (s, 1H), 7,27 (m, 2H), 7,21 (dd, J = 5,1, 1,0, 1H), 7,00 (dt, J = 7,5, 4,4,1H), 6,93 (dd, J = 5,1, 3,5, 1H), 6,75 (dd, J = 3,6, 1,1, 1H), 3,85 (s, 2H), 3,74 (m, 2H), 2,73 (m, 1H), 2,43 (s, 1H), 2,12 (m, 1H), 2,03 (m, 2H), 1,96 (dd, J = 12,4, 7,6, 1H), 1,87 (m, 2H), 1,70 (m, 3H), 1,48 (m, 5H), 1,00 (dt, J = 12,8, 8,1,1H).
- 65
- (ciclopentilmetil)({2-[2,2-dietil-4-(4-fluorofe nil)oxan-4-il]etil})amina 362,3 δ 9,23 (m, 1H), 8,73 (m, 1H), 7,25 (dd, J = 8,9, 5,2, 2H), 7,07 (t, J = 8,6, 2H), 3,73 (d, J = 10,9, 2H), 2,69 (s, 2H), 2,10 (m, 4H), 1,78 (d, J = 18,1, 3H), 1,64 (m, 7H), 1,38 (s, 2H), 1,28 (s, 1H), 1,10 (d, J = 16,3, 3H), 0,84 (s, 4H), 0,53 (s, 3H).
- 66
- (ciclopentilmetil)({2-[4-(4-fluorofenil)-2,2,6, 6-tetrametiloxan-4-il]etil})amina 362,3 δ 8,64 (s, 2H), 7,22 (dd, J = 8,9, 5,1, 2H), 6,95 (t, J = 8,6, 2H), 3,25 (s, 2H), 2,61 (s, 2H), 2,43 (s, 2H), 2,24 (d, J = 14,3, 2H), 1,91 (m, 2H), 1,68 (m, 2H), 1,60 (d, J = 14,3, 2H), 1,49 (m, 4H), 1,18 (s, 6H), 1,03 (dd, J = 12,4, 7,3, 2H), 0,93 (s, 6H).
- 67
- (2-{9-ciclohexil-6-oxaspiro[4.5]decan-9-il}et il)(tiofen-2-ilmetil)amina 362,3 δ 9,21 (d, J = 25,7, 2H), 7,33 (dd, J = 5,1, 1,1, 2H), 7,14 (d, J = 2,7, 1H), 7,00 (dd, J = 5,1, 3,6, 1H), 4,19 (s, 2H), 3,56 (m, 2H), 2,92 (s, 2H), 1,65 (m, 17H), 1,12 (m, 7H), 0,87 (dd, J = 23,8, 11,9, 2H).
- 68
- (2-{9-ciclohexil-6-oxaspiro[4.5]decan-9-il}et il)(tiofen-3-ilmetil)amina 362,3 δ 9,07 (d, J = 31,8, 2H), 7,37 (ddd, J = 7,9, 3,9, 2,1, 2H), 7,10 (dd, J = 5,0, 1,3, 1H), 6,37 (s, 2H), 4,04 (s, 2H), 3,55 (m, 2H), 2,87 (s, 2H), 1,64 (m, 16H), 1,12 (m, 7H), 0,85 (q, J = 11,8, 2H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 69
- 2-{2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]de can-9-il]etil}-2,3-dihidro-1H-isoindol 363,1 δ 8,77 (d, J = 4,0, 1H), 8,09 (td, J = 8,0, 1,7, 1H), 7,64 (d, J = 8,1, 1H), 7,55 (dd, J = 7,1, 5,8, 1H), 7,35 (dd, J = 5,6, 3,2, 2H), 7,24 (d, J = 3,6, 2H), 4,76 (m, 4H), 4,21 (brs, 1H), 3,77 (m, 2H), 3,30 (m, 1H), 2,80 (td, J = 12,3, 4,4, 1H), 2,49 (td, J = 12,9, 4,5, 1H), 2,38 (t, J = 15,1, 2H), 2,23 (td, J = 12,9, 4,2, 1H), 2,07 (d, J = 14,0, 1H), 1,87 (ddd, J = 24,1, 11,9, 7,1, 2H), 1,69 (m, 1H), 1,51 (dt, J = 24,2, 10,9, 4H), 1,15 (m, 1H), 0,78 (dt, J = 13,4, 9,0, 1H).
- 70
- {2-[2,2-dietil-4-(4-fluorofenil)oxan-4-il]etil}di propilamina 364,4 δ 11,44 (s, 1H), 7,28 (m, 2H), 7,10 (m, 2H), 3,75 (m, 2H), 2,88 (m, 5H), 2,27 (m, 3H), 1,97 (td, J = 12,7, 3,9, 1H), 1,80 (td, J = 12,6, 4,9, 1H), 1,66 (m, 2H), 1,46 (m, 6H), 1,04 (m, 1H), 0,88 (m, 10H), 0,55 (m, 3H).
- 71
- (2-feniletil)({2-[(9R)-9-(piridin-2-il)-6-oxaspi ro[4.5]decan-9-il]etil})amina 365,1 δ 8,51 (dd, J = 5,3, 1,3, 1H), 8,04 (td, J = 7,9, 1,7, 1H), 7,56 (d, J = 8,1, 1H), 7,49 (dd, J = 7,1, 5,8, 1H), 7,25 -7,12 (m, 6H), 7,10 -7,03 (m, 2H), 3,88 -3,47 (m, 3H), 3,01 (d, J = 7,5, 2H), 2,85 (t, J = 7,8, 2H), 2,44 (s, 1H), 2,38-2,17 (m, 3H), 2,17-1,99 (m, 1H), 1,92 (d, J = 14,1,1H), 1,84 -1,66 (m, 3H), 1,58 (d, J = 5,1, 1H), 1,40 (ddd, J = 15,2, 12,1, 8,9, 4H), 1,05 (d, J = 6,5, 1H), 0,65 (d, J=13,4,1H).
- 72
- (2-feniletil)({2-[9-(piridin-2-il)-6-oxaspiro[4.5 ]decan-9-il]etil})amina 365,3 δ 8,58 (d, J = 4,8,1H), 8,07 (t, J = 7,9, 1H), 7,61 (s, 1H), 7,52 (dd, J = 12,0, 6,3, 1H), 7,27 (m, 3H), 7,20 (m, 2H), 4,04 (d, J = 3,2, 2H), 3,76 (ddd, J = 19,4, 12,6, 8,9, 2H), 3,05 (s, 1H), 2,53 (m, 2H), 2,29 (d, J = 43,6, 5H), 1,96 (d, J = 13,9, 1H), 1,80 (m, 2H), 1,68 (s, 1H), 1,50 (ddd, J = 20,5, 13,1, 7,0, 4H), 1,17 (s, 1H), 0,75 (m, 1H).
- 73
- bencil({2-[9-(6-metilpiridin-2-il)-6-oxaspiro[ 4.5]decan-9-il]etil})amina 365,7 δ 9,49 (s, 2H), 8,18 (t, J = 7,9, 1H), 7,55 (dd, J = 23,1, 7,8, 2H), 7,35 (s, 5H), 5,87 (s, 3H), 4,00 (s, 2H), 3,88 -3,66 (m, 2H), 3,00 (s, 1H), 2,80 (s, 3H), 2,65 (d, J = 12,5, 1H), 2,53 (s, 1H), 2,31 (d, J = 14,3, 2H), 2,20 (d, J = 13,5, 1H), 2,11-2,00 (m, 1H), 1,97 -1,80 (m, 2H), 1,70 (d, J = 5,3, 1H), 1,52 (ddd, J = 29,7, 17,1, 7,4, 4H), 1,28 (t, J = 7,1, 1H), 0,95 -0,79 (m, 1H). (ddd, J = 29,7, 17,1, 7,4, 4H), 1,28 (t, J = 7,1, 1H), 0,92-0,77 (m, 1H).
- 74
- {2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]etil}( 2-fenilpropan-2-il)amina 366,3 1H NMR (400 MHz324,3, CDCl3) δ 8,50 (d, J = 223,4, 2H), 7,25 (s, 5H), 6,95 (d,338,3 J = 8,1, 2H), 6,87 (d, J = 8,3, 2H), 5,69 (s, 3H), 3,62 (dd, J = 6,8, 2,5, 2H), 2,38 (dd, J = 15,7, 13,2, 1H), 2,22 (s, 3H), 1,98 (m, 2H), 1,80 (m, 2H), 1,63 (m, 1H), 1,56 (s, 3H), 1,51 (s, 3H), 1,47 (d, J = 14,1, 1H), 1,39 (dd, J = 10,5, 4,0, 1H), 1,06 (s, 3H), 0,53 (s, 3H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 75
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]deca n-9-il]etil}[2-(piridin-3-il)etil]amina 367,1 δ 8,90 (s, 1H), 8,75 (d, J = 4,4, 1H), 8,61 (d, J = 5,2, 1H), 8,41-8,28 (m, 2H), 7,87 -7,70 (m, 3H), 3,81 (s, 1H), 3,71 (s, 1H), 3,29 (t, J = 10,5, 3H), 2,97 (d, J = 7,3, 1H), 2,44 (s, 2H), 2,33 (t, J = 11,9, 2H), 2,21 (dt, J = 24,1, 11,9, 1H), 2,07 (d, J = 14,3, 1H), 1,88 (d, J = 10,3, 2H), 1,65 (dd, J = 16,4, 9,9, 1H), 1,60 -1,44 (m, 5H), 1,19 (s, 1H), 0,81 (d, J = 13,1, 1H).
- 76
- [(2-metilpirimidin-5-il)metil]({2-[(9R)-9-(pirid in-2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 367,1 δ 8,57 (s, 2H), 7,83 -7,66 (m, 1H), 7,33 (s, 4H), 7,21 (dt, J = 10,8, 2,9, 1H), 3,93 (s, 1H), 3,69 (s, 2H), 2,65 (s, 1H), 2,40 -2,20 (m, 3H), 2,09 (s, 2H), 1,87 (s, 2H), 1,76 -1,50 (m, 3H), 1,42 (ddd, J = 33,3, 13,0, 3,9, 2H), 1,22 (td, J = 7,3, 1,9, 1H), 1,02 (s, 1H), 0,71 0,54 (m, 1H).
- 77
- {2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]etil}[ (2-metoxifenil)metil]amina 368,3 δ 7,16 (m, 6H), 6,85 (dd, J = 18,0, 7,8, 2H), 3,80 (s, 3H), 3,61 (d, J = 1,9, 2H), 3,51 (s, 2H), 2,45 (d, J = 5,2, 1H), 2,35 (s, 4H), 2,15 (m, 2H), 1,81 (m, 1H), 1,66 (s, 4H), 1,20 (s, 3H), 0,69 (s, 3H).
- 78
- {2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]etil}[ (3-metoxifenil)metil]amina 368,3 δ 9,28 (s, 1H), 8,80 (s, 1H), 7,10 (m, 1H), 7,01 (q, J = 8,4, 4H), 6,74 (dd, J = 8,2, 2,0,1H), 6,65 (dd, J = 15,6, 4,8, 2H), 3,66 (m, 7H), 2,64 (s, 4H), 2,24 (s, 3H), 2,09 (m, 3H), 1,82 (m, 1H), 1,64 (m, 1H), 1,48 (ddd, J = 13,4, 9,8, 8,8, 2H), 1,10 (s, 3H), 0,57 (s, 3H).
- 79
- bencil({2-[9-(4-fluorofenil)-6-oxaspiro[4.5]d ecan-9-il]etil})amina 368,3 δ 8,82 (d, J = 134,2, 2H), 7,31 (m, 3H), 7,16 (m, 4H), 7,00 (dd, J = 10,7, 6,5, 2H), 3,72 (m, 4H), 2,70 (s, 1H), 2,28 (s, 1H), 1,92 (m, 6H), 1,62 (m, 2H), 1,46 (m, 4H), 1,23 (m, 1H), 0,77 (dt, J = 13,6, 8,8, if)
- 80
- bencil({2-[(9S)-9-(4-fluorofenil)-6-oxaspiro[ 4.5]decan-9-il]etil})amina 368,3 δ 9,09 (s, 1H), 8,74 (s, 1H), 7,31 (m, 3H), 7,16 (m, 4H), 7,00 (t, J = 8,6, 2H), 3,73 (m, 4H); 2,67 (s, 1H), 2,26 (s, 1H), 2,02 (s, 2H), 1,94 (td, J = 12,6, 4,7, 1H), 1,85 (d, J = 13,9, 3H), 1,62 (s, 2H), 1,46 (dd, J = 7,8, 4,0, 4H), 1,24 (d, J = 12,7, 1H), 0,77 (dt, J = 13,6, 8,7, 1H)
- 81
- bencil({2-[(9R)-9-(4-fluorofenil)-6-oxaspiro[ 4.5]decan-9-il]etil})amina 368,3 δ 7,24-7,17 (m, 2H), 7,16 -7,09 (m, 3H), 7,01 (d, J = 7,8, 2H), 6,89 (d, J = 8,0, 2H), 3,68 (ddd, J = 11,8, 5,0, 1,3, 1H), 3,62 -3,49 (m, 3H), 2,32 (t, J = 7,3, 2H), 2,25 (s, 3H), 2,22 -2,13 (m, 1H), 1,93 (dtd, J = 15,7, 7,7, 3,8, 1H), 1,81 -1,66 (m, 2H), 1,65 -1,56 (m, 1H), 1,37 (d, J = 20,2, 1H), 1,20 -1,05 (m, 2H), 1,01-1,02 (m, 2H), 0,86 (t, J = 12,7, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 82
- 2-[(9R)-9-(2-{4H,5H,6H-tieno[2,3-c]pirrol-5il}etil)-6-oxaspiro[4.5]decan-9-il]piridina 369 δ 8,59 (ddd, J = 4,8, 1,9, 0,9, 1H), 7,64 (m, 1H), 7,32 (t, J = 5,9,1H), 7,15 (d, J = 4,9,1H), 7,12 (ddd, J = 7,5, 4,8, 1,0, 1H), 6,74 (d, J = 4,9, 1H), 3,80 (m, 4H), 3,68 (m, 2H), 2,63 (td, J = 11,6, 5,1, 1H), 2,49 (dd, J = 13,8, 2,2, 1H), 2,37 (dd, J = 13,7, 2,0, 1H), 2,16 (td, J = 11,6, 4,4,1H), 2,05 (m, 1H), 1,79 (m, 3H), 1,62 (d, J = 7,8, 2H), 1,50 (m, 3H), 1,40 (m, 1H), 1,14 (ddd, J = 9,7, 7,6, 3,2, 1H), 0,72 (dt, J = 13,4, 8,9,1H).
- 83
- [(4,5-dimetilfuran-2-il)metil]({2-[(9R)-9-(piri din-2-il)-6-oxaspiro[4.5]decan-9-il]etil})amin a 369,1 δ 10,28 (brs, 1H), 9,39 (brs, 1H), 8,70 (d, J = 4,6, 1H), 8,12 (t, J = 7,5, 1H), 7,65 (d, J = 8,1, 1H), 7,58 (m, 1H), 6,14 (s, 1H), 3,91 (q, J = 14,4, 2H), 3,75 (m, 2H), 2,95 (dd, J = 10,9, 5,9, 1H), 2,51 (t, J = 9,7, 1H), 2,33 (m, 3H), 2,10 (s, 3H), 1,99 (d, J = 14,1, 1H), 1,82 (m, 5H), 1,68 (m, 1H), 1,48 (m, 4H), 1,15 (m, 1H), 0,74 (dt, J = 13,2, 8,9, 1H).
- 84
- {2-[(9R)-9-(4-fluorofenil)-6-oxaspiro[4.5]de can-9-il]etil}(piridin-4-ilmetil)amina 369,2 δ 8,53 (s, 2H), 7,78 (s, 3H), 7,29 -7,05 (m, 6H), 6,96 (t, J = 8,4, 3H), 4,07 (s, 2H), 3,66 (d, J = 12,5, 2H), 2,83 (s, 1H), 2,37 (s, 1H), 2,11 (d, J = 13,7, 1H), 2,01 (d, J = 13,3, 2H), 1,83 (d, J = 14,0, 2H), 1,49 (t, J = 61,9, 9H), 1,17 (s, 2H), 0,70 (dt, J = 17,4, 8,9, 1H).
- 85
- 2-[({2-[4-(4-metoxifenil)-2,2-dimetiloxan-4-il ]etil}amino)metil]fenol 370,3 δ 8,05 (d, J = 152,9, 2H), 7,08 (m, 1H), 7,01 (d, J = 8,9, 2H), 6,82 (m, 2H), 6,76 (d, J = 8,8, 2H), 6,69 (t, J = 7,3, 1H), 4,00 (s, 2H), 3,77 (s, 2H), 3,70 (s, 3H), 3,65 (dd, J = 6,9, 2,6, 2H), 2,61 (s, 1H), 2,23 (s, 1H), 2,04 (dd, J = 23,7, 13,9, 2H), 1,93 (s, 1H), 1,81 (td, J = 12,5, 4,9, 1H), 1,60 (td, J = 12,7, 4,8, 1H), 1,48 (d, J = 13,9, 2H), 1,08 (s, 3H), 0,55 (s, 3H).
- 86
- bencil({2-[2,2-dietil-4-(4-fluorofenil)oxan-4-i l]etil})amina 370,3 δ 7,26 -7,14 (m, 3H), 7,13 -7,02 (m, 4H), 6,91 (t, J = 8,6, 2H), 3,69 -3,47 (m, 4H), 2,51 (td, J = 12,2, 4,7, 1H), 2,14 -1,94 (m, 3H), 1,83 (td, J = 12,7, 4,3, 1H), 1,64 (td, J = 12,6, 4,7, 1H), 1,56 -1,35 (m, 3H), 1,27 (tt, J = 27,2, 13,7, 1H), 0,95 (dq, J = 14,7, 7,4, 1H), 0,84 -0,58 (m, 4H), 0,43 (t, J = 7,4, 3H).
- 87
- bencil({2-[4-(4-fluorofenil)-2,2,6,6-tetrametil oxan-4-il]etil})amina 370,3 δ 9,15 (s, 2H), 7,32 (m, 3H), 7,25 (m, 2H), 7,18 (dd, J = 7,3, 2,1, 2H), 6,99 (dd, J = 12,0, 5,3, 2H), 3,72 (s, 2H), 2,34 (dd, J = 53,2, 23,4, 2H), 1,91 (dd, J = 10,4, 6,5, 2H), 1,68 (d, J = 14,3, 2H), 1,27 (s, 6H), 1,02 (s, 6H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 88
- [(2,3-dimetoxifenil)metil]({2-[4-(4-metilfenil) oxan-4-il]etil})amina 370,3 δ 7,13 (s, 4H), 6,95 (m, 1H), 6,80 (dd, J = 8,2,1,4, 1H), 6,72 (dd, J = 7,6, 1,4, 1H), 3,83 (s, 3H), 3,75 (m, 5H), 3,63 (s, 2H), 3,54 (ddd, J = 11,6, 9,1, 2,7, 2H), 2,31 (m, 5H), 2,10 (m, 3H), 1,82 (ddd, J = 13,3, 8,3, 3,7, 4H)
- 89
- [(3-metiltiofen-2-il)metil]({2-[(9R)-9-(piridin2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 371,1 δ 9,68 (s, 1H), 8,75 (s, 1H), 8,16 (m, 1H), 7,74 (d, J = 27,0, 2H), 7,27 (d, J = 1,5, 1H), 6,85 (d, J = 5,1, 1H), 4,10 (m, 2H), 3,84 (d, J = 12,7, 1H), 3,66 (d, J = 10,3, 1H), 2,96 (m, 1H), 2,69 (m, 1H), 2,54 (m, 3H), 2,35 (m, 4H), 2,11 (d, J = 14,0, 1H), 1,87 (d, J = 10,3, 3H), 1,57 (m, 5H), 1,06 (m 1H), 0,78 (d, J = 12,8, 1H).
- 90
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]deca n-9-il]etil}[2-(tiofen-2-il)etil]amina 371,1 δ 8,80-8,66 (m, 1H), 8,45 -8,25 (m, 1H), 7,84-7,63 (m, 2H), 7,16 (dd, J = 5,1, 1,1, 1H), 6,91 (dd, J = 5,1, 3,5, H), 6,83 (dd, J = 3,4, 0,9, 1H), 3,83 (tt, J = 13,7, 6,9, 1H), 3,69 (dd, J = 20,1, 10,1, 1H), 3,16 (s, 4H), 3,02 (s, 1H), 2,61 -2,22 (m, 5H), 2,20 -1,98 (m, 1H), 1,98 -1,77 (m, 2H), 1,76 -1,63 (m, 1H), 1,50 (tdd, J = 12,3, 10,9, 5,3, 4H), 1,17 (dd, J = 7,9, 5,2, 1H), 0,76 (dt, J = 13,0, 8,8, 1H).
- 91
- [(2-metiltiofen-3-il)metil]({2-[(9R)-9-(piridin2-il)-6-oxaspiro[4.5]decan-9-il]etil))amina 371,1 δ 8,68 (d, J = 5,4, 1H), 8,26 (s, 1H), 7,82 7,63 (m, 2H), 7,05 (t, J = 10,0, 1H), 6,94 (d, J = 5,3, 1H), 3,96 (s, 2H), 3,82 (s, 1H), 3,72 (s, 1H), 3,03 (s, 1H), 2,50 (d, J = 15,9, 2H), 2,39 (s, 3H), 2,30 (dd, J = 12,6, 7,5, 3H), 2,02 (d, J = 14,2, 1H), 1,92 -1,79 (m, 2H), 1,70 (dt, J = 14,5, 10,2, 1H), 1,64 -1,38 (m, 4H), 1,25 1,13 (m, 1H), 0,79 (d, J = 13,2, 1H).
- 92
- [(5-metiltiofen-2-il)metil]({2-[(9R)-9-(piridin2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 371,2 δ 8,71 (d, J = 4,7, 1H), 8,14 (t, J = 7,6, 1H), 7,78-7,48 (m, 2H), 6,86 (d, J = 3,4, 1H), 6,78 -6,53 (m, 1H), 4,09 (s, 2H), 3,76 (ddd, J = 40,6,14,3, 7,2, 2H), 3,17 -2,85 (m, 1H), 2,64 -2,23 (m, 4H), 2,16 (dd, J = 16,4, 8,6, 1H), 1,99 (d, J = 14,2, 1H), 1,89 -1,75 (m, 2H), 1,75 -1,61 (m, 1H), 1,61 -1,35 (m, 4H), 1,24-1,05 (m, 1H), 0,74 (dt, J = 13,2, 8,9, 1H).
- 93
- {2-[9-(6-metilpiridin-2-il)-6-oxaspiro[4.5]dec an-9-il]etil}(tiofen-3-ilmetil)amina 371,2 δ 9,47 (d, J = 86,3, 2H), 8,17 (t, J = 8,0,1H), 7,58 (d, J = 8,0, 1H), 7,52 (d, J = 7,8, 1H), 7,39 (d, J = 1,9, 1H), 7,31 -7,29 (m, 1H), 7,08 (dd, J = 5,0, 1,0, 1H), 6,43 (s, 3H), 4,11 -3,95 (m, 2H), 3,91 -3,67 (m, 2H), 2,97 (s, 1H), 2,81 (s, 3H), 2,61 (t, J = 12,6,1H), 2,47 (t, J = 10,1, 1H), 2,43 -2,15 (m, 3H), 2,15 1,99 (m, 1H), 1,87 (dd, J = 12,2, 6,8, 2H), 1,70 (dt, J = 12,7, 6,2, 1H), 1,63 -1,40 (m, 4H), 1,28 -1,20 (m, 1H), 0,84 (dt, J = 13,3, 9,0, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 94
- {2-[4-(4-fluorofenil)-1-oxaspiro[5,5]undecan -4-il]etil}(1H-pirrol-2-ilmetil)amina 371,3 δ 7,09 (dd, J = 8,9, 5,1, 2H), 6,93 (dd, J = 11,7, 5,5, 2H), 6,71 (d, J = 2,3, 1H), 5,98 (s, 2H), 3,83 (s, 2H), 3,61 (m, 2H), 2,56 (m, 1H), 2,08 (t, J = 12,1, 3H), 1,68 (s, 3H), 1,48 (d, J = 14,6, 2H), 1,40 (d, J = 14,1, 2H), 1,29 (m, 3H), 1,05 (m, 3H), 0,58 (s, 1H).
- 95
- {2-[9-(6-metilpiridin-2-il)-6-oxaspiro[4.5]dec an-9-il]etil}(tiofen-2-ilmetil)amina 371,3 δ 9,48 (s, 1H), 8,08 (t, J = 7,9,1H), 7,48 (d, J = 8,0, 1H), 7,42 (d, J = 7,8, 1H), 7,22 (dd, J = 5,1, 0,8, 1H), 7,04 (d, J = 2,9,1H), 6,88 (dd, J = 5,1, 3,5,1H), 5,95 (s, 3H), 4,13 (s, 2H), 3,66 (ddd, J = 18,7, 12,8, 9,1, 2H), 2,91 (s, 1H), 2,71 (s, 3H), 2,60 -2,40 (m, 2H), 2,18 (dd, J = 48,6, 14,1, 3H), 1,96 (d, J = 14,2, 1H), 1,88 -1,68 (m, 2H), 1,71 -1,54 (m, 1H), 1,56 -1,31 (m, 4H), 1,20 -1,05 (m, 1H), 0,83 -0,63 (m, 1H).
- 96
- [(4-metiltiofen-2-il)metil]({2-[(9R)-9-(piridin2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 371,3 δ 9,63 (s, 1H), 8,61 (d, J = 4,1, 1H), 8,08 (t, J = 7,8, 1H), 7,61 (d, J = 8,1, 1H), 7,53 (dd, J = 7,0, 5,6, 1H), 6,91 (s, 1H), 6,88 (s, 1H), 4,14 (m, 2H), 3,75 (dt, J = 19,0, 11,1, 2H), 3,02 (m, 1H), 2,61 (m, 1H), 2,40 (brs, 1H), 2,27 (m, 4H), 2,19 (d, J = 0,8, 3H), 1,95 (d, J = 14,0, 1H), 1,79 (m, 2H), 1,66 (dd, J = 12,1, 5,9, 1H), 1,47 (m, 4H), 1,16 (m, 1H), 0,74 (dt, J = 13,1, 8,9, 1H).
- 97
- {2-[(9R)-9-(4-fluorofenil)-6-oxaspiro[4.5]de can-9-il]etil}[(5-metilfuran-2-il)metil]amina 372 δ 7,12 (dd, J = 8,9, 5,2, 2H), 6,94 (t, J = 8,6, 2H), 6,10 (d, J = 3,1, 1H), 5,79 (dd, J = 3,1, 0,9, 1H), 3,77 (m, 2H), 3,72 -3,49 (m, 2H), 2,63 (s, 1H), 2,19 (s, 1H), 2,13 -2,08 (m, 3H), 2,06 (s, 1H), 1,98 (dd, J = 13,8, 1,3, 1H), 1,89 (td, J = 12,7, 4,5, 1H), 1,80 (dd, J = 13,1, 7,1, 2H), 1,71 (dd, J = 13,2, 6,0, 1H), 1,59 (ddd, J = 14,2, 9,4, 5,4, 2H), 1,50 -1,28 (m, 4H), 1,25 -1,09 (m, 1H), 0,71 (dt, J = 13,5, 8,8,1H).
- 98
- [(4-metil-1,3-tiazol-2-il)metil({2-[(9R)-9-(piri din-2-il)-6-oxaspiro[4.5]decan-9-il]etil})amin a 372,1 δ 8,68 (dd, J = 5,3, 1,2, 1H), 8,25 (s, 1H), 8,09 (td, J = 8,0, 1,7, 1H), 7,63 (d, J = 8,1,1H), 7,54 (dd, J = 7,1, 5,7, 1H), 6,94 (d, J = 0,9, 1H), 4,37 (m, 2H), 3,76 (m, 2H), 3,14 (td, J = 11,2, 5,9, 1H), 2,73 (td, J = 11,4, 4,7, 1H), 2,40 (m, 4H), 2,27 (m, 3H), 2,00 (m, 1H), 1,83 (ddd, J = 13,8, 9,3, 4,4, 2H), 1,66 (m, 1H), 1,49 (m, 4H), 1,19 (m, 1H), 0,78 (dt, J = 13,3, 9,0, 1H).
- 99
- [(2-metil-1,3-tiazol-5-il)metil]({2-[(9R)-9-(piri din-2-il)-6-oxaspiro[4.5]decan-9-il]etil})amin a 372,1 δ 8,71 (d, J = 4,3, 1H), 8,33 (td, J = 8,0, 1,5, 1H), 7,77 (m, 2H), 7,69 (s, 1H), 5,53 (s, 1H), 4,28 (m, 2H), 3,78 (m, 2H), 3,04 (td, J = 11,4, 5,4,1H), 2,73 (s, 3H), 2,56 (m, 2H), 2,30 (t, J = 15,3, 3H), 2,04 (m, 1H), 1,88 (ddd, J = 19,6, 11,5, 7,0, 2H), 1,68 (m, 1H), 1,49 (m, 4H), 1,18 (m, 1H), 0,77 (dt, J = 13,1, 9,0, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 100
- [(4-metil-1,3-tiazol-5-il)metil]({2-[(9R)-9-(piri din-2-il)-6-oxaspiro[4.5]decan-9-il]etil})amin a 372,1 δ 13,17 (s, 1H), 9,91 (s, 1H), 8,88 (s, 1H), 8,69 (d, J = 4,9,1H), 8,31 (t, J = 7,4, 1H), 7,75 (t, J = 7,9, 2H), 4,25 (m, 2H), 3,77 (m, 2H), 3,04 (td, J = 11,5, 5,0, 1H), 2,57 (dt, J = 10,7, 7,9,1H), 2,34 (m, 7H), 2,02 (m, 1H), 1,86 (ddd, J = 26,5, 13,3, 8,2, 2H), 1,66 (dt, J = 13,6, 8,4,1H), 1,50 (m, 4H), 1,15 (dd, J = 13,2, 6,6, 1H), 0,73 (dt, J = 13,0, 8,9, 1H).
- 101
- [(2-clorofenil)metil]({2-[2,2-dimetil-4-(4-meti lfenil)oxan-4-il]etil})amina 372,2 δ 7,21 (m, 1H), 7,07 (m, 5H), 7,02 (d, J = 8,2, 2H), 3,69 (m, 2H), 3,58 (d, J = 1,0, 2H), 2,37 (td, J = 10,9, 5,3, 1H), 2,22 (m, 4H), 2,07 (ddd, J = 14,2, 9,9, 3,8, 2H), 1,74 (ddd, J = 13,2, 10,5, 5,1, 1H), 1,55 (m, 3H), 1,43 (s, 2H), 1,10 (s, 3H), 0,58 (s, 3H).
- 102
- [(3-clorofenil)metil]({2-[2,2-dimetil-4-(4-meti lfenil)oxan-4-il]etil})amina 372,2 δ 9,27 (d, J = 168,2, 2H), 7,19 (m, 2H), 7,11 (m, 2H), 7,04 (d, J = 8,2, 2H), 6,99 (d, J = 8,2, 3H), 3,67 (m, 2H), 3,58 (s, 2H), 2,57 (s, 1H), 2,33 (d, J = 12,1, 2H), 2,23 (s, 3H), 2,07 (m, 3H), 1,80 (td, J = 12,5, 4,6, 1H), 1,62 (m, 1H), 1,47 (m, 2H), 1,09 (s, 3H), 0,56 (s, 3H).
- 103
- [(4-clorofenil)metil]({2-[2,2-dimetil-4-(4-meti lfenil)oxan-4-il]etil})amina 372,2 δ 8,80 (d, J = 192,6, 2H), 7,19 (t, J = 4,2, 3H), 7,02 (m, 6H), 4,06 (s, 3H), 3,68 (dd, J = 12,4, 10,2, 4H), 2,62 (s, 1H), 2,24 (d, J = 13,6, 3H), 2,11 (ddd, J = 21,2, 15,6, 7,6, 3H), 1,80 (dt, J = 12,3, 6,3, 1H), 1,64 (m, 1H), 1,49 (m, 2H), 1,11 (s, 3H), 0,57 (s, 3H).
- 104
- 6-[9-{2-[(tiofen-2-ilmetil)amino]etil}-6-oxasp iro[4.5]decan-9-il]piridin-3-ol 373 1H NMR (400 MHz, CD3CN) δ 8,18 (t, J = 1,7, 1H), 8,11 (brs, 1H), 7,49 (dd, J = 5,1, 1,1, 1H), 7,34 (d, J = 1,7, 2H), 7,18 (d, J = 2,7,1H), 7,06 (dd, J = 5,1, 3,6, 1H), 4,24 (s, 2H), 3,67 (m, 2H), 2,95 (m, 1H), 2,73 (brs, 1H), 2,51 (d, J = 4,3, 1H), 2,29 (t, J = 11,0, 2H), 2,08 (m, 2H), 1,84 (m, 2H), 1,72 (t, J = 8,5, 1H), 1,62 (dd, J = 14,4, 6,5, 2H), 1,48 (dt, J = 23,5, 7,0, 4H), 1,15 (m, 1H), 0,73 (dt, J = 12,7, 8,7, 1H).
- 105
- 6-[9-{2-[(tiofen-2-ilmetil)amino]etil}-6-oxasp iro[4.5]decan-9-il]piridin-2-ol 373 δ 7,52 (d, J = 16,2,1H), 7,29 (d, J = 1,1,1H), 7,12 (d, J = 2,7, 1H), 6,97 (dd, J = 5,1, 3,6, 1H), 6,51 (d, J = 8,9, 1H), 6,27 (d, J = 7,2, 1H), 4,16 (s, 2H), 3,71 (s, 2H), 2,85 (dd, J = 13,9, 7,6, 1H), 2,68 (dd, J = 18,4, 9,5,1H), 2,31 (m, 2H), 1,94 (d, J = 13,6, 2H), 1,59 (m, 10H), 0,90 (m, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 106
- [(5-metiltiofen-2-il)metil]({2-[2,2,6,6-tetrame til-4-(piridin-2-il)oxan-4-il]etil})amina 373,2 δ 8,73 (dd, J = 5,5, 1,4, 2H), 8,24 (td, J = 8,0, 1,6, 1H), 7,87 (d, J = 8,2, 1H), 7,69 (dd, J = 7,0, 6,1, 1H), 6,83 (dd, J = 20,2, 3,4, 1H), 6,67 -6,48 (m, 1H), 4,09 (s, 2H), 2,83 -2,69 (m, 2H), 2,52 (dd, J = 19,1, 11,7, 3H), 2,41 (d, J = 0,5, 3H), 2,37 -2,21 (m, 2H), 1,89 (d, J = 14,8, 2H), 1,31 (s, 6H), 0,98 (s, 6H).
- 107
- 2-(9-{2-[(tiofen-2-ilmetil)amino]etil}-6-oxasp iro[4.5]decan-9-il)piridin-4-ol 373,2 δ 9,46 (m, 2H), 7,95 (d, J = 6,6, 1H), 7,25 (d, J = 5,1, 1H), 7,10 (s, 1H), 7,03 (t, J = 5,8, 2H), 6,90 (dd, J = 5,1, 3,6, 1H), 4,10 (s, 2H), 3,62 (m, 2H), 2,84 (s, 1H), 2,49 (s, 1H), 2,28 (s, 1H), 2,06 (dd, J = 44,3, 14,1, 3H), 1,66 (m, 4H), 1,35 (ddd, J = 72,6, 39,8, 18,9, 6H), 0,68 (s, 1H).
- 108
- [(4-metiltiofen-2-il)metil]({2-[2,2,6,6-tetrame til-4-(piridin-2-il)oxan-4-il]etil})amina 373,3 δ 8,75 (d, J = 4,6, 1H), 8,35 (td, J = 8,1, 1,3, 1H), 7,96 (d, J = 8,2, 1H), 7,86 -7,74 (m, 1H), 6,95 -6,80 (m, 2H), 4,14 (s, 2H), 2,87 2,68 (m, 2H), 2,52 (d, J = 14,8, 2H), 2,45 2,29 (m, 2H), 2,18 (d, J = 0,7, 3H), 1,93 (d, J = 14,9, 2H), 1,31 (s, 6H), 0,98 (s, 6H).
- 109
- dibutil({2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4. 5]decan-9-il]etil})amina 373,4 δ 8,78 (d, J = 4,6,1H), 8,05 (t, J = 7,5, 1H), 7,62 (d, J = 8,0, 1H), 7,50 (m, 1H), 3,80 (m, 2H), 3,06 (t, J = 10,5, 1H), 2,90 (s, 4H), 2,42 (m, 4H), 2,02 (m, 2H), 1,83 (m, 2H), 1,68 (tt, J = 13,3, 6,8, 1H), 1,43 (m, 12H), 1,15 (dd, J = 13,2, 5,7, 1H), 0,91 (dt, J = 11,8, 7,1, 6H), 0,72 (dt, J = 13,3, 9,0, 1H).
- 110
- {2-[(9R)-9-(4-fluorofenil)-6-oxaspiro[4.5]de can-9-il]etil}(tiofen-3-ilmetil)amina 374,2 δ 7,33 -7,23 (m, 7H), 7,19 (dd, J = 8,9, 5,2, 2H), 7,04 (t, J = 8,6, 2H), 6,98 (dd, J = 5,0, 1,3, 1H), 3,84 (s, 2H), 3,79 -3,69 (m, 2H), 2,67 (s, 1H), 2,19 -1,74 (m, 22H), 1,66 (ddd, J = 14,0, 9,3, 4,6, 3H), 1,48 (ddd, J = 23,7, 15,2, 8,6, 4H), 1,28 (s, 1H), 0,99-0,64 (m, 1H).
- 111
- {2-[(9R)-9-(4-fluorofenil)-6-oxaspiro[4.5]de can-9-il]etil}(tiofen-2-ilmetil)amina 374,2 δ 9,04 (d, J = 106,1, 2H), 7,21 (dd, J=5,1, 1,1, 1H), 7,10 (m, 2H), 6,92 (m, 3H), 6,86 (dd, J = 5,1, 3,6, 1H), 3,93 (s, 2H), 3,64 (m, 3H), 2,63 (d, J = 7,9, 1H), 2,22 (t, J = 9,7,1H), 2,05 (d, J = 14,1,1H), 1,97 (d, J = 13,9, 1H), 1,88 (td, J = 12,7, 4,6, 1H), 1,75 (m, 3H), 1,57 (m, 2H), 1,38 (m, 3H), 1,17 (dd, J = 14,1, 6,1, 1H), 0,70 (dt, J = 13,6, 8,8, 1H).
- 112
- (ciclopentilmetil)({2-[4-(4-fluorofenil)-1-oxa spiro[5,5]undecan-4-il]etil})amina 374,3 δ 7,15 (dd, J = 8,9, 5,2, 2H), 6,96 (s, 2H), 3,64 (d, J = 13,0, 3H), 2,59 (s, 3H), 2,11 (m, 3H), 1,94 (dd, J = 10,4, 5,7, 2H), 1,68 (dd, J = 12,4, 4,8, 2H), 1,53 (m, 8H), 1,31 (d, J = 19,9, 4H), 1,03 (s, 7H), 0,65 (m, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 113
- {2-[2,2-dietil-4-(4-fluorofenil)oxan-4-il]etil}(ti ofen-3-ilmetil)amina 376,2 δ 7,20 -7,13 (m, 8H), 7,09 (dd, J = 8,9, 5,2, 2H), 6,93 (t, J = 8,6, 2H), 6,87 (dd, J = 4,9, 1,3, 1H), 3,70 (s, 2H), 3,61 (d, J = 2,3, 2H), 2,56 (s, 1H), 2,02 (d, J = 14,1, 3H), 1,75 (s, 11H), 1,44 (d, J = 14,2, 5H), 0,95 (dd, J = 14,5, 7,4,1H), 0,73 (t, J = 7,5, 5H), 0,43 (t, J = 7,4, 4H).
- 114
- {2-[2,2-dietil-4-(4-fluorofenil)oxan-4-il]etil}(ti ofen-2-ilmetil)amina 376,2 δ 7,25 -7,15 (m, 3H), 7,15 -7,02 (m, 4H), 6,91 (t, J = 8,6, 2H), 3,82 -3,36 (m, 4H), 2,51 (td, J = 12,2, 4,7, 1H), 2,12 -1,94 (m, 3H), 1,83 (td, J = 12,7, 4,3, IH), 1,64 (td, J = 12,6, 4,7, 1H), 1,55 -1,35 (m, 3H), 1,28 (dq, J = 14,7, 7,4, 1H), 0,95 (dq, J = 14,7, 7,4, 1H), 0,80 -0,64 (m, 4H), 0,43 (t, J = 7,4, 3H).
- 115
- {2-[4-(4-fluorofenil)-2,2,6,6-tetrametiloxan4-il]etil}(tiofen-3-ilmetil)amina 376,2 δ 7,28 (m, 4H), 7,00 (ddd, J = 6,7, 6,3, 3,2, 3H), 3,82 (s, 3H), 2,46 (s, 1H), 2,28 (d, J = 14,3, 1H), 1,92 (m, 1H), 1,57 (m, 2H), 1,69 (d, J = 14,4, 2H), 1,28 (s, 6H), 1,02 (s, 6H).
- 116
- {2-[4-(4-fluorofenil)-2,2,6,6-tetrametiloxan4-il]etil}(tiofen-2-ilmetil)amina 376,2 δ 7,29 (m, 3H), 7,01 (s, 4H), 3,98 (s, 2H), 2,50 (m, 2H), 2,30 (d, J = 14,2, 2H), 1,94 (m, 2H), 1,69 (d, J = 14,4, 2H), 1,28 (s, 6H), 1,03 (s, 6H).
- 117
- bencil({2-[9-(2-metoxifenil)-6-oxaspiro[4.5] decan-9-il]etil})amina 380,3 δ 8,86 (d, J = 149,6, 2H), 7,25 -7,19 (m, 3H), 7,18 -7,12 (m, 1H), 7,09 (dd, J = 7,4, 2,0, 2H), 6,96 (dd, J = 7,8, 1,5, 1H), 6,85 -6,75 (m, 2H), 3,74 -3,63 (m, 7H), 2,55 (dd, J = 15,6, 7,9, 3H), 2,11 (d, J = 14,8, 2H), 1,75 1,46 (m, 5H), 1,46 -1,32 (m, 3H), 1,32 -1,22 (m, 1H), 1,17 (d, J = 4,1, 1H), 0,74 -0,60 (m, 1H).
- 118
- bencil({2-[9-(6-metoxipiridin-2-il)-6-oxaspir o[4.5]decan-9-il]etil})amina 381,3 δ 9,43 (s, 1H), 9,20 (s, 1H), 7,52 (m, 2H), 7,30 (dd, J = 5,1, 1,8, 3H), 7,21 (m, 2H), 6,78 (d, J = 7,3,1H), 6,57 (d, J = 8,1, 1H), 3,83 (s, 3H), 3,77 (s, 2H), 3,71 (dd,J = 7,8, 2,7, 2H), 2,77(s, 1H), 2,32 (d, J = 13,6, 2H), 2,25 (d, J = 11,5, 1H), 2,06 (td, J = 11,9, 4,8,1H), 1,76 (m, 3H), 1,59 (m, 3H), 1,47 (m, 3H), 1,38 (m, 1H), 1,15 (m, 1H), 0,70 (m, 1H).
- 119
- {2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]etil}[ (2-metoxifenil)metil]metilamina 382,3 δ 10,17 (m, 3H), 7,41 (tdd, J = 8,3, 4,8, 1,6, 1H), 7,13 (m, 5H), 6,93 (m, 2H), 4,20 (dd, J = 14,9, 5,8, 1H), 3,98 (ddd, J = 32,2, 12,9, 4,8, 1H), 3,80 (dd, J = 7,4, 2,6, 5H), 2,94 (d, J = 114,3, 1H), 2,35 (m, 9H), 2,05 (ddd, J = 17,1, 12,7, 6,5, 1H), 1,89 (dt, J = 12,8, 6,2, 1H), 1,67 (ddd, J = 22,2, 14,2, 5,0, 2H), 1,23 (d, J = 10,7, 3H), 0,69 (t, J = 9,5, 3H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 120
- {2-[9-(4-fluorofenil)-6-oxaspiro[4.5]decan-9 -il]etil}[(3-metilfenil)metil]amina 382,3 δ 8,90 (d, J = 138,8, 2H), 7,15 (tt, J = 13,7, 7,6, 4H), 6,97 (m, 4H), 3,70 (m, 4H), 2,67 (s, 1H), 2,27 (s, 4H), 2,00 (m, 3H), 1,82 (m, 3H), 1,63 (m, 2H), 1,46 (m, 4H), 1,24 (d, J = 9,6,1H), 0,78 (dt, J = 13,6, 8,8, 1H)
- 121
- {2-[(9S)-9-(4-fluorofenil)-6-oxaspiro[4.5]dec an-9-il]etil}[(3-metilfenil)metil]amina 382,3 δ 8,73 (d, J = 138,2, 2H), 7,16 (m, 4H), 7,00 (dd, J = 10,5, 6,7, 2H), 6,94 (m, 2H), 3,72 (m, 4H), 2,69 (m, 1H), 2,27 (s, 4H), 2,05 (m, 2H), 1,94 (td, J = 12,6, 4,7, 1H), 1,83 (m, 3H), 1,63 (ddd, J = 14,1, 9,6, 4,6, 2H), 1,47 (m, 4H), 1,23 (m, 1H), 0,78 (dt, J = 13,9, 8,9, 1H)
- 122
- {2-[(9R)-9-(4-fluorofenil)-6-oxaspiro[4.5]de can-9-il]etil}[(3-metilfenil)metil]amina 382,3 δ 8,96 (d, J = 123,7, 2H), 7,15 (m, 4H), 6,98 (m, 4H), 3,71 (m, 4H), 2,66 (s, 1H), 2,25 (d, J = 14,0, 4H), 2,05 (m, 2H), 1,94 (td, J = 12,7, 4,6, 1H), 1,81 (m, 3H), 1,63 (ddd, J = 14,2, 7,7, 3,4, 2H), 1,47 (m, 4H), 1,23 (m, 1H), 0,77 (dt, J = 13,7, 8,9, 1H)
- 123
- bencil({2-[4-(4-fluorofenil)-1-oxaspiro[5,5]u ndecan-4-il]etil})amina 382,3 δ 7,23 (m, 3H), 7,10 (dd, J = 4,6, 2,6, 4H), 6,92 (s, 2H), 3,64 (s, 2H), 2,63 (m, 1H), 2,07 (t, J = 13,9, 3H), 1,74 (s, 2H), 1,48 (d, J = 8,3, 3H), 1,40 (d, J = 14,0, 2H), 1,29 (m, 3H), 1,06 (m, 4H), 0,57 (m, 1H).
- 124
- {2-[(9R)-9-(4-fluorofenil)-6-oxaspiro[4.5]de can-9-il]etil}[(1R)-1-feniletil]amina 382,3 δ 7,47 -7,32 (m, 3H), 7,31-7,22 (m, 2H), 7,11 (dd, J = 8,9, 5,2, 2H), 6,98 (t, J = 8,6, 2H), 6,28 (s, 2H), 4,03 (s, 1H), 3,79 -3,58 (m, 2H), 2,51 (s, 1H), 2,19 (d, J =
- 14,5, 1H), 2,07 -1,90 (m, 3H), 1,89 -1,71 (m, 3H), 1,72 -1,32 (m, 9H), 1,32 -1,10 (m, 1H), 0,78 (dt, J = 13,6, 8,8, 1H).
- 125
- {2-[(9R)-9-(4-fluorofenil)-6-oxaspiro[4.5]de can-9-il]etil}[(1S)-1-feniletil]amina 382,3 δ 7,47 -7,32 (m, 3H), 7,31 -7,22 (m, 2H), 7,11 (dd, J = 8,9, 5,2, 2H), 6,98 (t, J = 8,6, 2H), 6,28 (s, 2H), 4,03 (s, 1H), 3,79 -3,58 (m, 2H), 2,51 (s, 1H), 2,19 (d, J = 14,5, 1H), 2,07 -1,90 (m, 3H), 1,89 -1,71 (m, 3H), 1,72 -1,32 (m, 9H), 1,32 -1,10 (m, 1H), 0,78 (dt, J = 13,6, 8,8, 1H).
- 126
- {2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]etil}[ (2-nitrofenil)metil]amina 383,3 δ 7,94 (dd, J = 8,1, 1,2, 1H), 7,53 (td, J = 7,6, 1,3, 1H), 7,40 (m, 2H), 7,15 (m, 4H), 3,80 (m, 4H), 2,48 (td, J = 10,9, 5,4,1H), 2,32 (m, 4H), 2,18 (ddd, J = 12,7, 7,8, 3,7, 2H), 1,84 (ddd, J = 13,2, 10,4, 5,1, 1H), 1,63 (m, 4H), 1,21 (s, 3H), 0,69 (s, 3H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 127
- {2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]etil}[ (3-nitrofenil)metil]amina 383,3 δ 9,09 (d, J = 219,1, 2H), 8,12 (dd, J = 8,2, 1,6, 1H), 8,01 (s, 1H), 7,45 (dt, J = 15,6, 7,7, 2H), 7,03 (q, J = 8,5, 4H), 3,87 (s, 2H), 3,69 (m, 2H), 3,42 (s, 1H), 3,22 (s, 2H), 2,73 (d, J = 4,5, 1H), 2,24 (d, J = 8,2, 4H), 2,12 (m, 2H), 1,85 (m, 1H), 1,69 (dd, J = 12,1, 4,5, 1H), 1,52 (m, 2H), 1,11 (s, 3H), 0,57 (s, 3H).
- 128
- 2-[({2-[9-(4-fluorofenil)-6-oxaspiro[4.5]deca n-9-il]etil}amino)metil]fenol 384,2 δ 8,36 (d, J = 129,4, 2H), 7,20 (dd, J = 11,0, 4,6, 1H), 7,14 (dd, J = 8,9, 5,1, 2H), 7,00 (t, J = 8,6, 2H), 6,92 (m, 2H), 6,79 (t, J = 7,1, 1H), 3,88 (s, 2H), 3,68 (m, 2H), 2,67 (m, 1H), 2,29 (m, 1H), 1,98 (m, 3H), 1,79 (m, 3H), 1,51 (m, 6H), 1,20 (s, 1H), 0,74 (dt, J = 13,8, 8,9, 1H)
- 129
- {2-[4-(4-metoxifenil)-2,2-dimetiloxan-4-il]etil }[(2-metoxifenil)metil]amina 384,3 δ 8,47 (d, J = 196,5, 2H), 7,36 (td, J = 8,3, 1,7, 1H), 7,12 (dd, J = 9,5, 2,6, 2H), 7,08 (dd, J = 7,5, 1,6, 1H), 6,91 (td, J = 7,5, 0,8, 1H), 6,86 (d, J = 8,8, 3H), 5,77 (s, 2H), 3,91 (s, 2H), 3,82 (s, 3H), 3,79 (s, 3H), 3,77 (m, 2H), 2,76 (s, 1H), 2,33 (s, 1H), 2,16 (m, 2H), 1,96 (d, J = 4,6, 1H), 1,77 (d, J = 4,7, 1H), 1,59 (m, 2H), 1,19 (s, 3H), 0,66 (s, 3H).
- 130
- [(5-etiltiofen-2-il)metil]({2-[(9R)-9-(piridin-2-i l)-6-oxaspiro[4.5]decan-9-il]etil})amina 385,1 δ 8,73 (d, J = 4,6, 1H), 8,20 (t, J = 7,7, 2H), 7,80 -7,55 (m, 2H), 6,88 (d, J = 3,4, 1H), 6,64 (d, J = 3,4, 1H), 4,11 (s, 2H), 3,81 (dd, J = 8,4, 4,3, 1H), 3,70 (t, J = 10,0, 1H), 3,00 (d, J = 4,6, 1H), 2,86 -2,70 (m, 2H), 2,53 (t, J = 10,1, 1H), 2,45 -2,25 (m, 3H), 2,18 (t, J = 10,0, 1H), 2,00 (d, J = 14,2, 1H), 1,93 -1,75 (m, 2H), 1,68 (dd, J = 9,5, 4,4, 1H), 1,62 -1,38 (m, 4H), 1,26 (t, J = 7,5, 3H), 1,20 -1,07 (m, 1H), 0,75 (dt, J = 12,9, 8,8, 1H).
- 131
- [(3,5-dimetiltiofen-2-il)metil]({2-[(9R)-9-(piri din-2-il)-6-oxaspiro[4.5]decan-9il]etil})amina 385,1 δ 9,45 (brs, 1H), 8,70 (d, J = 5,0, 1H), 8,26 (t, J = 7,7, 1H), 7,75 (d, J = 8,1, 1H), 7,70 (m, 1H), 6,46 (d, J = 0,8,1H), 4,07 (s, 2H), 3,76 (ddd, J = 44,9, 13,9, 7,2, 2H), 3,05 (m, 1H), 2,58 (m, 1H), 2,43 (t, J = 10,6,1H), 2,36 (d, J = 0,7, 3H), 2,24 (dd, J = 31,9, 17,7, 3H), 2,03 (m, 4H), 1,85 (m, 2H), 1,66 (dd, J = 13,8, 8,8, 1H), 1,48 (m, 4H), 1,15 (d, J = 7,9, 1H), 0,75 (dt, J = 13,1, 8,9, 1H).
- 132
- {2-[2,2-dietil-4-(4-fluorofenil)oxan-4-il]etil}[( 6-metilpiridin-3-il)metil]amina 385,3 δ 8,84 (s, 1H), 8,24 (d, J = 8,2, 1H), 7,53 (d, J = 8,2, 1H), 7,17 (m, 3H), 6,96 (t, J = 8,6, 2H), 4,08 (d, J = 13,9, 2H), 3,63 (d, J = 10,5, 2H), 2,84 (dd, J = 12,0, 8,2, 1H), 2,68 (s, 3H), 2,24 (m, 2H), 2,07 (d, J = 14,1, 1H), 1,96 (m, 1H), 1,74 (dd, J = 12,5, 8,6, 1H), 1,57 (m, 1H), 1,48 (d, J = 14,2, 1H), 1,41 (m, 1H), 1,28 (dd, J = 14,0, 7,4, 1H), 0,96 (dd, J = 14,5, 7,4, 1H), 0,73 (td, J = 7,3, 3,9, 4H), 0,44 (t, J = 7,4, 3H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 133
- {2-[4-(4-fluorofenil)-2,2,6,6-tetrametiloxan4-il]etil}[(6-metilpiridin-3-il)metil]amina 385,3 δ 8,85 (s, 1H), 8,24 (d, J = 8,2, 1H), 7,54 (d, J = 8,3, 2H), 7,24 (dd, J = 8,9, 5,1, 1H), 6,92 (m, 2H), 4,12 (s, 2H), 2,61 (m, 5H), 2,25 (d, J = 14,3, 2H), 1,91 (dd, J = 10,4, 6,2, 2H), 1,65 (d, J = 14,4, 2H), 1,19 (d, J = 8,9, 6H), 0,94 (s, 6H).
- 134
- [(4,5-dimetiltiofen-2-il)metil]({2-[(9R)-9-(piri din-2-il)-6-oxaspiro[4.5]decan-9-il]etil})amin a 385,3 δ 9,46 (s, 1H), 8,62 (d, J = 4,2, 1H), 8,07 (t, J = 7,3, 1H), 7,60 (d, J = 8,1, 1H), 7,52 (m, 1H), 6,76 (s, 1H), 4,06 (q, J = 13,9, 2H), 3,75 (m, 2H), 3,01 (m, 1H), 2,57 (s, 1H), 2,29 (m, 7H), 2,19 (m, 1H), 2,04 (s, 3H), 1,95 (d, J = 14,0, 1H), 1,81 (m, 2H), 1,67 (d, J = 8,2, 1H), 1,47 (m, 4H), 1,15 (m, 1H), 0,74 (dt, J = 13,1, 8,8, 1H).
- 135
- [(2,4-dimetil-1,3-tiazol-5-il)metil]({2-[(9R)-9(piridin-2-il)-6-oxaspiro[4.5]decan-9-il]etil}) amina 386,1 δ 9,59 (s, 1H), 8,68 (dd, J = 5,6, 1,4, 1H), 8,35 (td, J = 8,0, 1,6, 1H), 7,80 (dd, J = 12,0, 7,0, 2H), 4,22 (m, 2H), 3,83 (dt, J = 12,5, 4,4, 1H), 3,72 (m, 1H), 3,05 (dt, J = 11,2, 5,6, 1H), 2,73 (s, 3H), 2,57 (m, 2H), 2,31 (m, 6H), 2,04 (m, 1H), 1,88 (ddd, J = 19,2, 11,4, 6,9, 2H), 1,68 (m, 1H), 1,52 (m, 4H), 1,19 (dd, J = 12,2, 5,9, 1H), 0,76 (dt, J = 13,1, 8,9, 1H).
- 136
- {2-[9-(pirazin-2-il)-6-oxaspiro[4.5]decan-9-il ]etil}(tiofen-2-ilmetil)amina 386,1 δ 8,90 (s, 1H), 8,55 (s, 1H), 8,40 (s, 1H), 6,60 (s, 1H), 3,88 (d, J = 12,3, 2H), 3,79 -3,66 (m, 1H), 3,58 (dd, J = 16,8, 6,5, 1H), 2,81 (s, 1H), 2,40 (s, 1H), 2,35 -2,22 (m, 2H), 2,16 (s, 3H), 2,12 -2,00 (m, 1H), 1,97 -1,88 (m, 4H), 1,85 (t, J = 9,1, 1H), 1,75 -1,49 (m, 3H), 1,49 -1,27 (m, 4H), 0,98 (d, J = 11,4, 1H), 0,55 (dt, J = 13,3, 9,0, 1H).
- 137
- [(4,5-dimetilfuran-2-il)metil]({2-[(9R)-9-(4-fl uorofenil)-6-oxaspiro[4.5]decan-9-il]etil})a mina 386,1 δ 9,14 (s, 1H), 8,85 (s, 1H), 7,24 (ddd, J = 11,5, 6,2, 3,3, 2H), 7,05 (s, 2H), 6,06 (s, 1H), 3,89 -3,66 (m, 4H), 2,72 (s, 1H), 2,29 (s, 1H), 2,22 -2,13 (m, 1H), 2,11 (s, 4H), 1,85 (s, 7H), 1,76 -1,62 (m, 2H), 1,60 -1,36 (m, 4H), 1,33 -1,24 (m, 1H), 0,82 (dt, J = 13,6, 8,8, 1H).
- 138
- {2-[9-(2-metoxifenil)-6-oxaspiro[4.5]decan9-il]etil}(tiofen-2-ilmetil)amina 386,2 δ 8,90 (d, J = 150,1, 2H), 7,19 (dd, J = 3,7, 1,4, 1H), 7,18 -7,14 (m, 1H), 6,99 (dd, J = 7,8, 1,5, 1H), 6,94-6,76 (m, 4H), 4,66 (s, 2H), 3,94 (s, 2H), 3,80 -3,63 (m, 5H), 2,73 -2,45 (m, 3H), 2,30 -2,08 (m, 2H), 1,76 -1,48 (m, 5H), 1,39 (dt, J = 7,0, 6,3, 3H), 1,30 (d, J = 5,2, 1H), 1,18 (d, J = 4,1, 1H), 0,68 (dd, J = 8,7, 5,0, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 139
- {2-[9-(2-metoxifenil)-6-oxaspiro[4.5]decan9-il]etil}(tiofen-3-ilmetil)amina 386,2 δ 9,28 (d, J = 95,5, 2H), 7,18 -7,12 (m, 3H), 6,97 (dd, J = 7,8, 1,5, 1H), 6,93 -6,86 (m, 1H), 6,86 -6,71 (m, 2H), 3,80 -3,61 (m, 7H), 2,55 (dd, J = 19,5, 5,1, 3H), 2,12 (d, J = 12,8, 2H), 1,85 (s, 2H), 1,76 -1,47 (m, 5H), 1,46 1,32 (m, 3H), 1,31-1,22 (m, 1H), 1,17 (d, J = 4,2, 1H), 0,74 -0,60 (m, 1H).
- 140
- [(3-metoxitiofen-2-il)metil]({2-[(9R)-9-(piridi n-2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 387 δ 11,70 (brs, 1H), 9,14 (d, J = 66,6, 2H), 8,72 (d, J = 4,3, 1H), 8,19 (td, J = 8,0, 1,4, 1H), 7,70 (d, J = 8,1, 1H), 7,63 (dd, J = 7,0, 5,8,1H), 7,22 (d, J = 5,5, 1H), 6,78 (d, J = 5,6, 1H), 4,08 (m, 2H), 3,80 (m, 4H), 3,69 (dd, J = 11,2, 8,7, 1H), 2,99 (d, J = 4,8, 1H), 2,51 (t, J = 9,9, 1H), 2,35 (m, 3H), 2,18 (td, J = 13,5, 5,4, 1H), 1,99 (d, J = 14,2, 1H), 1,82 (m, 2H), 1,65 (m, 1H), 1,47 (m, 4H), 1,14 (m, 1H), 0,73 (dt, J = 13,2, 8,9, 1H).
- 141
- [(3-metoxitiofen-2-il)metil]({2-[9-(piridin-2-il) -6-oxaspiro[4.5]decan-9-il]etil})amina 387 δ 9,03 (d, J = 80,0, 2H), 8,75 (d, J = 5,3, 1H), 8,31 (t, J = 7,9, 1H), 7,76 (m, 2H), 7,26 (t, J = 4,0, 1H), 6,81 (d, J = 5,6, 1H), 4,12 (s, 2H), 3,82 (s, 4H), 3,69 (dd, J = 24,9, 14,9, 1H), 3,04 (s, 1H), 2,56 (s, 1H), 2,45 (dd, J = 17,7, 7,6, 1H), 2,29 (ddd, J = 17,8, 13,5, 5,8, 3H), 2,05 (d, J = 14,3, 1H), 1,87 (dt, J = 14,4, 6,7, 2H), 1,67 (ddd, J = 27,6, 16,0, 6,9, 1H), 1,52 (m, 4H), 1,20 (m, 1H), 0,78 (dt, J = 13,0, 8,9, 1H).
- 142
- {2-[9-(6-metoxipiridin-2-il)-6-oxaspiro[4.5]d ecan-9-il]etil}(tiofen-2-ilmetil)amina 387,2 δ 9,37 (s, 1H), 9,11 (s, 0H), 7,55 (dd, J = 8,2, 7,5, 1H), 7,30 (dd, J = 5,1, 1,1, 1H), 7,03 (d, J = 2,6, 1H), 6,96 (dd, J = 5,1, 3,6, 1H), 6,81 (d, J = 7,3, 1H), 6,60 (d, J = 8,0, 1H), 4,07 (s, 2H), 3,86 (s, 3H), 3,73 (dd, J = 7,7, 2,7, 2H), 2,87 (m, 1H), 2,75 (brs, 1H), 2,47 (m, 1H), 2,32 (dd, J = 24,5, 13,6, 2H), 2,09 (m, 1H), 1,80 (m, 3H), 1,63 (dt, J = 15,1, 7,4, 2H), 1,49 (m, 3H), 1,39 (d, J = 4,5, 1H), 1,16 (m, 1H), 0,72 (dt, J = 13,4, 8,8, 1H).
- 143
- {2-[9-(6-metoxipiridin-2-il)-6-oxaspiro[4.5]d ecan-9-il]etil}(tiofen-3-ilmetil)amina 387,2 δ 9,40 (s, 1H), 9,21 (s, 1H), 7,53 (m, 1H), 7,28 (d, J = 3,0, 2H), 6,99 (dd, J = 4,8, 1,4, 1H), 6,80 (d, J = 7,4, 1H), 6,59 (d, J = 8,2, 1H), 3,86 (d, J = 6,4, 5H), 3,72 (dd, J = 7,7, 2,7, 2H), 2,78 (m, 1H), 2,30 (dd, J = 28,1, 12,5, 3H), 2,09 (m, 1H), 2,02 (brs, 1H), 1,79 (m, 3H), 1,61 (m, 2H), 1,47 (m, 4H), 1,16 (m, 1H), 0,71 (dt, J = 13,4, 8,7, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 144
- {2-[4-(4-clorofenil)-2,2-dimetiloxan-4-il]etil}[ (2-metoxifenil)metil]amina 388,2 δ 8,48 (d, J = 152,7, 2H), 7,28 (td, J = 8,3, 1,7, 1H), 7,22 (dd, J = 6,6, 4,8, 2H), 7,06 (m, 2H), 6,97 (dd, J = 7,5, 1,6, 1H), 6,81 (ddd, J = 19,8, 13,2, 4,6, 2H), 6,03 (s, 1H), 3,82 (s, 2H), 3,66 (m, 5H), 2,64 (s, 1H), 2,15 (s, 1H), 2,05 (ddd, J = 22,5, 14,1, 2,1, 2H), 1,85 (m, 1H), 1,72 (dd, J = 12,5, 4,7, 1H), 1,53 (m, 2H), 1,11 (s, 3H), 0,57 (s, 3H).
- 145
- {2-[(9R)-9-(4-fluorofenil)-6-oxaspiro[4.5]de can-9-il]etil}[(5-metiltiofen-2-il)metil]amina 388,2 δ 7,28 (s, 4H), 7,25 -7,15 (m, 2H), 7,04 (t, J = 8,6, 2H), 6,77 (d, J = 3,5, 1H), 6,59 (dd, J = 3,4, 1,1, 1H), 3,91 (s, 2H), 3,85 -3,64 (m, 2H), 2,73 (t, J = 9,7, 1H), 2,41 (d, J = 0,7, 3H), 2,37 -1,75 (m, 18H), 1,67 (dd, J = 11,7, 7,1, 2H), 1,59 -1,34 (m, 4H), 1,26 (s, 1H), 0,81 (dt, J = 14,0, 8,9, 1H).
- 146
- {2-[4-(4-fluorofenil)-1-oxaspiro[5,5]undecan -4-il]etil}(tiofen-3-ilmetil)amina 388,2 δ 7,18 (s, 1H), 7,15 (s, 1H), 7,10 (dd, J = 8,9, 5,2, 2H), 6,92 (dd, J = 10,8, 6,4, 2H), 6,87 (m, 1H), 3,67 (d, J = 35,8, 3H), 2,66 (m, 1H), 2,07 (s, 3H), 1,83 (m, 2H), 1,56 (s, 3H), 1,41 (d, J = 13,9, 2H), 1,33 (m, 3H), 1,02 (m, 4H), 0,58 (m, 1H).
- 147
- {2-[(9R)-9-(4-fluorofenil)-6-oxaspiro[4.5]de can-9-il]etil}[(3-metiltiofen-2-il)metil]amina 388,2 δ 9,01 (d, J = 137,9, 2H), 7,15 -7,02 (m, 3H), 6,94 (t, J = 8,6, 2H), 6,77 -6,63 (m, 1H), 4,82 (s, 1H), 3,83 (d, J = 19,1, 2H), 3,73 -3,54 (m, 2H), 2,64 (s, 1H), 2,18 (d, J = 10,4, 1H), 2,12 -1,64 (m, 9H), 1,65 -1,50 (m, 2H), 1,50 1,27 (m, 4H), 1,27 -1,08 (m, 1H), 0,69 (dt, J = 13,5, 8,8, 1H).
- 148
- {2-[(9R)-9-(4-fluorofenil)-6-oxaspiro[4.5]de can-9-il]etil}[(4-metiltiofen-2-il)metil]amina 388,2 δ 9,31 (d, J = 89,1, 2H), 7,15 -7,05 (m, 2H), 6,93 (t, J = 8,6, 2H), 6,80 -6,65 (m, 2H), 3,80 (s, 2H), 3,73 -3,57 (m, 2H), 2,93 (s, 1H), 2,60 (s, 1H), 2,17 (s, 1H), 2,04 (dd, J = 16,0, 3,3, 4H), 1,91 (ddd, J = 17,5, 16,7, 9,1, 2H), 1,84 -1,65 (m, 3H), 1,57 (ddd, J = 13,2, 9,0, 4,4, 2H), 1,50 -1,25 (m, 4H), 1,17 (dd, J = 14,9, 5,0, 1H), 0,70 (dt, J = 13,6, 8,8, 1H).
- 149
- {2-[4-(4-fluorofenil)-1-oxaspiro[5,5]undecan -4-il]etil}(tiofen-2-ilmetil)amina 388,3 δ 7,28 (s, 3H), 7,22 (dd, J = 8,6, 4,9, 2H), 7,01 (m, 2H), 4,01 (s, 2H), 3,74 (s, 1H), 2,26 (m, 1H), 1,73 (m, 11H), 1,52 (d, J = 14,1, 2H), 1,39 (m, 2H), 1,13 (s, 2H), 0,69 (m, 1H).
- 150
- {2-[(9R)-9-(4-fluorofenil)-6-oxaspiro[4.5]de can-9-il]etil}[(4-metil-1,3-tiazol-2-il)metil]am ina 389 δ 7,22 (dd, J = 8,9, 5,2, 2H), 7,02 (dd, J = 14,0, 5,4, 2H), 6,92 (d, J = 0,9, 1H), 4,25 (q, J = 14,7, 2H), 3,73 (m, 2H), 2,89 (td, J = 11,8, 4,8, 1H), 2,50 (td, J = 11,7, 5,0, 1H), 2,38 (d, J = 0,8, 3H), 2,15 (m, 1H), 2,08 (m, 2H), 1,98 (m, 1H), 1,91 (d, J = 13,9, 1H), 1,79 (d, J = 9,3, 1H), 1,69 (m, 2H), 1,48 (m, 5H), 1,25 (m, 1H), 0,81 (dt, J = 13,3, 8,7, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 151
- {2-[2,2-dietil-4-(4-fluorofenil)oxan-4-il]etil}[( 5-metiltiofen-2-il)metil]amina 390,2 δ 7,15 -7,02 (m, 2H), 6,94 (t, J = 8,6, 2H), 6,67 (d, J = 3,5, 1H), 6,49 (s, 1H), 3,78 (s, 2H), 3,62 (dd, J = 10,4, 8,1, 3H), 2,61 (s, 1H), 2,30 (s, 4H), 2,08 (dd, J = 31,6, 14,0, 4H), 1,88 (d, J = 4,6, 1H), 1,79 -1,34 (m, 19H), 1,29 (dd, J = 14,0, 7,4, 2H), 0,96 (dd, J = 14,5, 7,3, 1H), 0,74 (t, J = 7,5, 5H), 0,44 (t, J = 7,4, 4H).
- 152
- [(5-clorotiofen-2-il)metil]({2-[(9R)-9-(piridin2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 391 δ 8,75 (d, J = 4,8, 1H), 8,24 (t, J = 7,7, 1H), 7,86 -7,58 (m, 2H), 6,44 (d, J = 3,3, 1H), 6,28 (d, J = 3,3, 1H), 4,07 (s, 2H), 3,94 -3,79 (m, 1H), 3,72 (t, J = 10,1, 1H), 3,01 (dd, J = 11,1, 6,0, 1H), 2,56 (t, J = 9,9, 1H), 2,49 2,11 (m, 4H), 2,05 (d, J = 14,1, 1H), 1,88 (ddd, J = 18,8, 11,0, 6,5, 2H), 1,78 -1,31 (m, 5H), 1,31 -1,07 (m, 1H), 0,77 (dt, J = 13,1, 8,9, 1H)
- 153
- dibutil({2-[4-(4-fluorofenil)-2,2,6,6-tetrametil oxan-4-il]etil})amina 392,4 δ 7,37 (m, 2H), 7,07 (m, 2H), 2,83 (dd, J = 16,3, 9,4, 4H), 2,68 (m, 2H), 2,38 (d, J = 14,3, 2H), 2,09 (s, 4H), 1,93 (m, 2H), 1,77 (d, J = 14,3, 2H), 1,33 (m, 10H), 1,05 (d, J = 8,6, 6H), 0,91 (t, J = 7,2, 6H).
- 154
- {2-[(9R)-9-(4-fluorofenil)-6-oxaspiro[4.5]de can-9-il]etil}(2-fenilpropan-2-il)amina 396,3 δ 7,37 (s, 5H), 7,28 (s, 0H), 7,17 -6,99 (m, 3H), 6,93 (t, J = 8,6, 2H), 3,81 -3,57 (m, 2H), 2,45 (d, J = 9,0, 1H), 2,04 -1,72 (m, 7H), 1,66 (t, J = 10,7, 6H), 1,62 -1,53 (m, 2H), 1,52 -1,34 (m, 4H), 1,23 (s, 1H), 0,78 (d, J = 13,8, 1H).
- 155
- {4H,5H,6H-ciclopenta[b]tiofen -2-ilmetil}({2-[(9R)-9-(piridin-2-il)-6-oxaspir o[4.5]decan-9-il]etil})amina 397,1 δ 9,57 (brs, 1H), 8,62 (d, J = 3,9, 1H), 8,02 (t, J = 7,1, 1H), 7,57 (d, J = 8,1, 1H), 7,48 (dd, J = 6,9, 5,5, 1H), 6,80 (s, 1H), 5,30 (brs, 1H), 4,06 (q, J = 14,1, 2H), 3,74 (m, 2H), 2,99 (m, 1H), 2,82 (t, J = 7,2, 2H), 2,65 (t, J = 7,2, 2H), 2,57 (m, 1H), 2,34 (ddd, J = 33,3, 21,0, 10,4, 5H),,2,16 (dd, J = 9,9, 5,6, 1H), 1,94 (d, J = 13,9, 1H), 1,78 (m, 2H), 1,66 (d, J = 8,0, 1H), 1,46 (ddd, J = 16,6, 12,7, 5,7, 4H), 1,14 (m, 1H), 0,72 (dt, J = 13,4, 9,0, 1H).
- 156
- {2-[4-(4-fluorofenil)-1-oxaspiro[5,5]undecan -4-il]etil}[(6-metilpiridin-3-il)metil]amina 397,3 δ 8,22 (d, J = 8,0, 1H), 7,49 (t, J = 16,4,1H), 7,17 (m, 8H), 6,96 (t, J = 8,6, 2H), 4,09 (s, 2H), 3,66 (s, 4H), 2,84 (s, 1H), 2,68 (s, 3H), 2,29 (s, 1H), 2,20 (d, J = 13,2, 1H), 2,10 (d, J = 14,1, 1H), 1,93 (s, 1H), 1,73 (s, 1H), 1,59 (m, 1H), 1,45 (d, J = 14,0, 3H), 1,30 (m, 2H), 1,10 (m, 3H), 0,62 (d, J = 11,1, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 157
- [(2,3-dimetoxifenil)metil]({2-[2,2-dimetil-4-( 4-metilfenil)oxan-4-il]etil})amina 398,3 δ 7,05 (dd, J = 19,6, 8,3, 4H), 6,88 (m, 1H), 6,74 (dd, J = 8,2, 1,4, 1H), 6,62 (dd, J = 7,6, 1,4, 1H), 3,77 (s, 3H), 3,68 (m, 5H), 3,55 (d, J = 2,3, 2H), 2,37 (m, 1H), 2,22 (m, 4H), 2,06 (ddd, J = 13,8, 8,6, 4,1, 2H), 1,73 (dd, J = 6,6, 4,3, 1H), 1,56 (m, 4H), 1,10 (s, 3H), 0,58 (s, 3H).
- 158
- [(2,4-dimetoxifenil)metil]({2-[2,2-dimetil-4-( 4-metilfenil)oxan-4-il]etil})amina 398,3 δ 8,09 (s, 1H), 7,68 (d, J = 33,5, 1H), 7,55 (s, 1H), 7,02 (q, J = 8,4, 4H), 6,86 (m, 1H), 6,32 (dd, J = 6,6, 2,2, 2H), 3,77 (d, J = 10,4, 2H), 3,69 (m, 8H), 2,67 (s, 1H), 2,24 (s, 4H), 2,10 (m, 2H), 1,87 (d, J = 4,5, 1H), 1,67 (d, J = 4,4, 1H), 1,51 (m, 2H), 1,10 (s, 3H), 0,57 (s, 3H).
- 159
- {2-[9-(4-fluorofenil)-6-oxaspiro[4.5]decan-9 -il]etil}[(4-metoxifenil)metil]amina 398,3 δ 9,06 (d, J = 131,9, 2H), 7,17 (m, 2H), 7,08 (d, J = 8,7, 2H), 7,00 (t, J = 8,6, 2H), 6,79 (d, J = 8,7, 2H), 3,69 (m, 7H), 2,62 (s, 1H), 2,20 (s, 1H), 1,99 (m, 3H), 1,81 (m, 3H), 1,62 (m, 2H), 1,46 (m, 4H), 1,24 (d, J = 9,5, 1H), 0,77 (dt, J = 13,4, 8,8, 1H)
- 160
- [(5-propiltiofen-2-il)metil]({2-[(9R)-9-(piridin -2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 399,1 δ 9,43 (s,2H), 8,72 (d, J = 4,6, 1H), 8,21 (t,J = 7,3, 1H), 7,72 (d, J = 8,1, 2H), 6,88 (d, J = 3,5,1H), 6,63 (d, J = 3,5, 1H), 4,11 (s, 2H), 3,87 -3,65 (m, 2H), 3,00 (s, 1H), 2,71 (t, J = 7,5, 2H), 2,54 (s, 1H), 2,32 (s, 3H), 2,27 2,11 (m, 1H), 2,02 (s, 1H), 1,84 (dd, J = 16,6, 7,3, 2H), 1,64 (dd, J = 15,0, 7,4, 7H), 1,22 1,10 (m, 1H), 0,95 (t, J = 7,3, 3H), 0,83 -0,72 (m, 1H).
- 161
- 1-{5-[({2-[(9R)-9(piridin-2-il)-6-oxaspiro[4.5] decan-9-il]etil}amino)metil]tiofen-2-il}etan-1 -ol 401,1 δ 9,38 (s, 2H), 8,76 (d, J = 4,6,1H), 8,29 (t, J = 7,9, 1H), 7,84-7,69 (m, 2H), 6,92-6,74 (m, 4H), 5,02 (d, J = 6,4, 1H), 4,13 (s, 2H), 3,87 3,60 (m, 2H), 3,03 (s, 1H), 2,52 (s, 1H), 2,34 (t, J = 15,7, 3H), 2,20 (t, J = 12,6, 1H), 2,03 (dd, J = 14,2, 4,7, 1H), 1,96 -1,78 (m, 2H), 1,81 -1,65 (m, 1H), 1,65 -1,43 (m, 7H), 1,15 (s, 1H), 0,77 (s, 1H).
- 162
- 6-[9-(2-{[(4,5-dimetiltiofen-2-il)metil]amino} etil)-6-oxaspiro[4.5]decan-9-il]piridin-3-ol 401,1 1H NMR (400 MHz, CD3CN) δ 8,18 (dd, J = 2,3, 1,2, 1H), 7,72 (s, 1H), 7,32 (d, J = 2,3, 2H), 6,82 (s, 1H), 4,10 (s, 2H), 3,67 (m, 2H), 2,95 (m, 1H), 2,50 (m, 1H), 2,32 (s, 3H), 2,27 (d, J = 13,9, 2H), 2,09 (m, 4H), 2,03 (m, 1H), 1,88 (m, 1H), 1,83 (t, J = 9,2, 2H), 1,71 (m, 1H), 1,63 (m, 2H), 1,48 (ddd, J = 16,6, 12,3, 7,6, 4H), 1,13 (dd, J = 11,7, 5,4,1H), 0,72 (dt, J = 13,7, 9,0, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 163
- 6-[9-(2-{[(4,5-dimetiltiofen-2-il)metil]amino} etil)-6-oxaspiro[4.5]decan-9-il]piridin-2-ol 401,1 δ 7,49 (m, 1H), 6,76 (s, 1H), 6,51 (d, J = 8,9, 1H), 6,25 (d, J = 7,0, 1H), 3,99 (s, 2H), 3,71 (m, 2H), 2,83 (dd, J = 16,5, 11,3, 1H), 2,61 (dd, J = 17,0, 5,8, 1H), 2,27 (d, J = 21,1, 5H), 1,99 (m, 6H), 1,65 (m, 10H), 0,98 (dd, J = 18,1, 5,5, 1H).
- 164
- 2-[9-(2-{[(4,5-dimetiltiofen-2-, il)metil]amino}etil)-6-oxaspiro[4.5]decan-9-i l]piridin-4-ol 401,2 δ 9,21 (d, J = 64,7, 2H), 8,00 (s, 1H), 7,07 (m, 2H), 6,67 (s, 1H), 3,95 (s, 2H), 3,62 (m, 2H), 2,84 (s, 1H), 2,44 (s, 1H), 2,27 (d, J = 12,2, 1H), 2,16 (s, 4H), 2,03 (d, J = 13,5, 2H), 1,94 (s, 3H), 1,83 (d, J = 13,9, 1H), 1,65 (m, 3H), 1,37 (m, 5H), 0,75 (s, 1H).
- 165
- [(5-nitrotiofen-2-il)metil]({2-[(9R)-9-(piridin2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 402 δ 8,59 (d, J = 4,0, 1H), 8,15 (t, J = 7,0, 1H), 7,79 (d, J = 4,1, 1H), 7,66 (d, J = 8,2, 1H), 7,60 (m, 1H), 7,16 (d, J = 4,2, 1H), 4,23 (s, 2H), 3,78 (m, 2H), 3,04 (d, J = 6,0, 1H), 2,65 (m, 1H), 2,43 (d, J = 9,8, 1H), 2,29 (m, 3H), 1,98 (d, J = 14,1, 1H), 1,83 (d, J = 5,4, 2H), 1,67 (m, 1H), 1,48 (m, 4H), 1,16 (m, 1H), 0,75 (d, J = 13,2, 1H).
- 166
- [(3,5-dimetiltiofen-2-il)metil]((2-[(9R)-9-(4-fl uorofenil)-6-oxaspiro[4.5]decan-9-il]etil})a mina 402,1 δ 7,19 (dd, J = 8,9, 5,1, 2H), 7,01 (dd, J = 13,7, 5,0, 2H), 6,43 (s, 1H), 3,87 (m, 2H), 3,72 (m, 2H), 3,02 (s, 1H), 2,72 (dd, J = 14,6, 8,9, 1H), 2,31 (dd, J = 31,1, 10,4, 4H), 2,15 (d, J = 13,8, 1H), 2,05 (d, J = 14,0, 1H), 1,98 (m, 4H), 1,87 (m, 2H), 1,77 (d, J = 9,7, 1H), 1,67 (ddd, J = 15,6, 10,3, 5,4, 2H), 1,46 (m, 4H), 1,25 (t, J = 7,1, 1H), 0,79 (dt, J = 13,7, 8,9, 1H).
- 167
- [(5-etiltiofen-2-il)metil]({2-[(9R)-9-(4-fluorof enil)-6-oxaspiro[4.5]decan-9-il]etil})amina 402,1 δ 7,21 (dd, J = 8,9, 5,2, 2H), 7,04 (t, J = 8,6, 2H), 6,79 (d, J = 3,5, 1H), 6,62 (d, J = 3,5, 1H), 3,92 (s, 2H), 3,80 -3,67 (m, 3H), 2,82 2,67 (m, 2H), 2,32 (s, 1H), 2,16 (d, J = 14,3, 1H), 2,06 (s, 1H), 2,00 (td, J = 12,8, 4,9, 1H), 1,91 (d, J = 13,9, 2H), 1,84 -1,75 (m, 1H), 1,69 (s, 2H), 1,50 (d, J = 3,7, 4H), 1,25 (t, J = 7,5, 4H), 0,81 (dt, J = 13,4, 8,7, 1H).
- 168
- {2-[4-(4-fluorofenil)-1-oxaspiro[5,5]undecan -4-il]etil}[(5-metiltiofen-2-il)metil]amina 402,3 δ 7,12 (m, 2H), 6,93 (s, 2H), 6,66 (d, J = 3,4, 1H), 6,49 (d, J = 2,5, 1H), 3,80 (s, 2H), 3,63 (s, 2H), 2,65 (m, 1H), 2,31 (s, 3H), 2,12 (m, 2H), 1,85 (m, 1H), 1,61 (s, 3H), 1,43 (d, J = 14,0, 2H), 1,33 (m, 3H), 1,03 (s, 4H), 0,59 (m, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 169
- [(4,5-dimetiltiofen-2-il)metil]({2-[(9R)-9-(4-fl uorofenil)-6-oxaspiro[4.5]decan-9-il]etil})a mina 402,3 δ 8,92 (d, J = 108,6, 2H), 7,15 -7,05 (m, 2H), 6,93 (t, J = 8,6, 2H), 6,51 (s, 1H), 5,31 (s, 1H), 3,75 (s, 2H), 3,69 -3,54 (m, 2H), 2,63 (s, 1H), 2,27 -2,10 (m, 4H), 2,06 (d, J = 14,0, 1H), 1,98 (d, J = 13,9, 1H), 1,93-1,84 (m, 4H), 1,84 -1,65 (m, 3H), 1,58 (ddd, J = 17,0, 8,4, 3,8, 2H), 1,51 -1,27 (m, 4H), 1,17 (dd, J = 13,9, 6,2, 1H), 0,71 (dt, J = 13,6, 8,8, 1H).
- 170
- {[5-(metilsulfanil)tiofen-2-il]metil}({2-[(9R)-9 -(piridin-2-il)-6-oxaspiro[4.5]decan-9-il]etil}) amina 403 δ 9,54 (s, 1H), 8,71 (d, J = 4,5, 1H), 8,26 (t, J = 7,2, 2H), 7,80 -7,67 (m, 2H), 6,92 (dd, J = 21,5, 3,6, 2H), 4,15 (s, 2H), 3,76 (d, J = 40,3, 2H), 3,02 (td, J = 11,4, 5,3, 1H), 2,62 -2,51 (m, 1H), 2,48 (s, 3H), 2,42 (s, 1H), 2,31 (t, J = 13,3, 3H), 2,03 (d, J = 14,2, 1H), 1,92 1,78 (m, 2H), 1,78 -1,63 (m, 1H), 1,64 -1,36 (m, 4H), 1,25 -1,12 (m, 1H), 0,79 (s, 1H).
- 171
- 6-[9-(2-{[(3-metoxitiofen-2-il)metil]amino}eti l)-6-oxaspiro[4.5]decan-9-il]piridin-3-ol 403 1H NMR (400 MHz, CD3CN) δ 8,15 (d, J = 1,5, 1H), 7,60 (s, 1H), 7,43 (d, J = 5,6, 1H), 7,31 (m, 2H), 6,97 (d, J = 5,6, 1H), 4,11 (s, 2H), 3,86 (s, 3H), 3,66 (dd, J = 7,8, 2,9, 2H), 2,97 (m, 1H), 2,51 (m, 1H), 2,28 (m, 2H), 2,02 (m, 1H), 1,87 (m, 2H), 1,80 (d, J = 13,5, 2H), 1,70 (d, J = 9,8, 1H), 1,61 (dd, J = 13,8, 7,1, 2H), 1,49 (m, 4H), 1,12 (m, 1H), 0,71 (d, J = 13,5, 1H).
- 172
- 6-[9-(2-{[(3-metoxitiofen-2-il)metil]amino}eti l)-6-oxaspiro[4.5]decan-9-il]piridin-2-ol 403 δ 9,47 (brs, 1H), 7,51 (dd, J = 9,0, 7,2, 1H), 7,23 (d, J = 5,6, 1H), 6,80 (d, J = 5,5, 1H), 6,52 (d, J = 8,9, 1H), 6,27 (d, J = 7,1, 1H), 4,10 (s, 2H), 3,82 (s, 3H), 3,73 (dd, J = 6,8, 3,4, 2H), 2,83 (dd, J = 11,9, 5,7, 1H), 2,60 (t, J = 10,0, 1H), 2,27 (t, J = 15,0, 2H), 2,00 (t, J = 12,3, 2H), 1,65 (m, 10H), 0,97 (d, J = 13,4, 1H).
- 173
- 2-[(9R)-9-(2-{[(3-metoxitiofen-2-il)metil]ami no}etil)-6-oxaspiro[4.5]decan-9-il]-1-oxidopi ridin-1-io 403,2 δ 9,84 (s, 1H), 8,76 (s, 1H), 8,32 (d, J = 5,3, 1H), 7,60 (t, J = 7,7, 1H), 7,52 (m, 1H), 7,41 (m, 1H), 7,25 (d, J = 5,5, 1H), 6,81 (d, J = 5,5, 1H), 4,16 (m, 2H), 3,82 (m, 4H), 3,71 (m, 1H), 3,05 (d, J = 13,4, 2H), 2,85 (d, J = 9,1, 1H), 2,53 (s, 1H), 2,27 (d, J = 14,3, 1H), 2,14 (m, 1H), 1,99 (t, J = 11,3, 1H), 1,85 (m, 2H), 1,66 (ddd, J = 18,0, 10,0, 5,8, 1H), 1,51 (m, 4H), 1,22 (dd, J = 12,3, 6,0, 1H), 0,90 (dt, J = 13,0, 8,7, 1H).
- 174
- 2-[9-(2-{[(3-metoxitiofen-2-il)metil]amino}eti l)-6-oxaspiro[4.5]decan-9-il]piridin-4-ol 403,2 δ 9,17 (d, J = 50,2, 2H), 8,00 (d, J = 6,5, 1H), 7,16 (d, J = 5,6, 3H), 6,72 (d, J = 5,6, 1H), 4,00 (s, 2H), 3,73 (s, 5H), 2,82 (s, 1H), 2,34 (d, J = 39,9, 2H), 2,11 (dd, J = 51,0, 13,1, 3H), 1,84 (d, J = 13,9, 1H), 1,43 (m, 9H), 0,75 (s, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 175
- {2-[(9R)-9-(4-fluorofenil)-6-oxaspiro[4.5]de can-9-il]etil}[(3-metoxitiofen-2-il)metil]amin a 404 δ 7,24 (s, 3H), 7,03 (dd, J = 11,7, 5,6, 2H), 6,80 (d, J = 5,5, 1H), 4,00 (s, 2H), 3,81 (m, 5H), 2,78 (m, 1H), 2,39 (m, 1H), 2,17 (m, 1H), 2,06 (s, 2H), 1,86 (m, 2H), 1,66 (m, 3H), 1,51 (m, 3H), 1,26 (m, 2H), 0,80 (m, 1H).
- 176
- {2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]etil}( {[3-(trifluorometil)fenil]metil})amina 406,3 δ 9,43 (d, J = 141,7, 2H), 7,47 (d, J = 7,2, 1H), 7,39 (s, 1H), 7,31 (m, 2H), 6,99 (q, J = 8,3, 4H), 3,67 (m, 4H), 2,54 (d, J = 8,4,1H), 2,20 (d, J = 7,1, 3H), 2,06 (m, 3H), 1,92 (s, 2H), 1,60 (td, J = 12,5, 4,7, 1H), 1,46 (m, 2H), 1,08 (s, 3H), 0,55 (s, 3H).
- 177
- (1-benzotiofen-2-ilmetil)({2-[(9R)-9-(piridin2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 407,1 δ 8,51 (dd, J = 5,5,1,3, 1H), 8,02 (d, J = 1,4, 1H), 7,73 -7,52 (m, 3H), 7,43 (d, J = 1,0, 1H), 7,35 -7,23 (m, 3H), 3,67 (s, 3H), 2,96 (td, J = 11,5, 5,7, 1H), 2,56-2,43 (m, 1H), 2,43 -2,28 (m, 1H), 2,16 (d, J = 13,6, 3H), 1,89 (d, J = 14,2, 1H), 1,73 (ddd, J = 19,7, 11,9, 7,2, 2H), 1,55 (dt, J = 15,0, 5,7, 1H), 1,48 -1,22 (m, 4H), 1,06 (s, 1H), 0,66 (dt, J = 13,2, 8,9, 1H).
- 178
- (1-benzotiofen-3-ilmetil)({2-[(9R)-9-(piridin2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 407,1 δ 11,71 (s, 2H), 9,34 (d, J = 85,8, 1H), 8,48 (d, J = 5,0, 1H), 8,10 (s, 1H), 7,71 (dd, J = 6,2, 2,8, 1H), 7,58 (ddd, J = 22,1, 9,6, 4,3, 3H), 7,47 (s, 1H), 7,36 -7,24 (m, 2H), 4,12 (s, 2H), 3,64 (s, 2H), 2,93 (s, 1H), 2,51 -2,23 (m, 2H), 2,13 (t, J = 14,3, 3H), 1,94 -1,83 (m, 1H), 1,80 -1,64 (m, 2H), 1,62 -1,49 (m, 1H), 1,37 (dd, J = 39,4, 7,2, 4H), 1,06 (d, J = 13,0, 1H), 0,64 (dt, J =13,1, 9,0, 1H).
- 179
- [(5-clorotiofen-2-il)metil]({2-[(9R)-9-(4-fluor ofenil)-6-oxaspiro[4.5]decan-9-il]etil})amina 408,2 δ 7,11 (dd, J = 8,9, 5,2, 2H), 6,94 (dd, J = 15,9, 7,2, 2H), 6,75 -6,56 (m, 2H), 3,79 (s, 2H), 3,71 -3,52 (m, 2H), 2,61 (s, 1H), 2,18 (s, 1H), 1,84 (dddd, J = 31,4, 25,9, 23,7, 13,1, 12H), 1,58 (td, J = 9,4, 4,6, 2H), 1,39 (ddd, J = 23,7, 14,8, 9,2, 5H), 1,17 (s, 2H), 0,69 (dd, J = 8,7, 5,1, 1H).
- 180
- 2-{[(2-{2,2-dimetil-4-[4-(trifluorometil)fenil]o xan-4-il}etil)amino]metil}fenol 408,3 δ 8,34 (d, J = 45,4, 2H), 7,50 (d, J = 8,3, 2H), 7,24 (d, J = 8,2, 2H), 7,10 (s, 1H), 6,77 (m, 3H), 3,80 (s, 2H), 3,66 (d, J = 12,3, 2H), 3,31 (s, 3H), 2,63 (s, 1H), 2,09 (dd, J = 26,1, 13,9, 3H), 1,87 (t, J = 10,4, 1H), 1,71 (t, J = 10,4, 1H), 1,58 (d, J = 14,0, 2H), 1,10 (s, 3H), 0,53 (s, 3H).
- 181
- [(5-clorotiofen-2-il)metil]({2-[2,2-dietil-4-(4-fl uorofenil)oxan-4-il]etil})amina 410,1 δ 7,12 (dd, J = 8,9, 5,2, 2H), 6,96 (t, J = 8,6, 2H), 6,69 (q, J = 3,8, 2H), 3,79 (s, 2H), 3,63 (dd, J = 12,2, 7,1, 2H), 2,63 (dd, J = 12,2, 7,5, 1H), 2,29 -1,77 (m, 8H), 1,67 (td, J = 12,5, 4,7, 1H), 1,44 (dd, J = 24,5, 10,8, 3H), 1,31 (d, J = 7,5, 1H), 0,95 (s, 1H), 0,74 (t, J = 7,5, 4H), 0,44 (t, J = 7,4, 3H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- δ 9,56 (brs, 1H), 8,66 (d, J = 4,7, 1H), 8,09 (t,
- J = 7,5, 1H), 7,62 (d, J = 8,1, 1H), 7,55 (m,
- 1H), 6,87 (d, J = 3,4, 1H), 6,59 (d, J = 3,4,
- 182
- {[5-(2-metilpropil)tiofen-2-il]metil}({2-[(9R)9-(piridin-2-il)-6-oxaspiro[4.5]decan-9-il]etil })amina 413,1 1H), 4,08 (m, 2H), 3,75 (m, 2H), 2,96 (d, J = 4,8, 1H), 2,57 (d, J = 7,0, 2H), 2,50 (t, J = 9,6, 1H), 2,31 (m, 3H), 2,14 (td, J = 13,5, 5,4, 1H), 1,96 (d, J = 14,1, 1H), 1,80 (m, 3H),
- 1,66 (m, 1H), 1,47 (m, 4H), 1,14 (d, J = 13,0,
- 1H), 0,89 (d, J = 6,6, 6H), 0,73 (dt, J = 13,6,
- 9,0, 1H).
- δ 10,87 (brs, 1H), 9,42 (brs, 1H), 8,70 (d, J =
- 4,8, 1H), 8,17 (t, J = 7,7, 1H), 7,68 (d, J =
- 8,1, 1H), 7,62 (m, 1H), 6,85 (d, J = 3,5, 1H),
- 6,60 (d, J = 3,4, 1H), 4,08 (s, 2H), 3,79 (m,
- 183
- [(5-butiltiofen-2-il)metil]({2-[(9R)-9-(piridin-2 -il)-6-oxaspiro[4.5]decan-9-il]etil})amina 413,1 1H), 3,67 (t, J = 10,0, 1H), 2,97 (d, J = 4,3, 1H), 2,70 (t, J = 7,6, 2H), 2,50 (t, J = 9,9, 1H), 2,33 (m, 3H), 2,16 (td, J = 13,1, 5,0, 1H),
- 1,98 (t, J = 9,4, 1H), 1,80 (t, J = 9,6, 2H),
- 1,54 (m, 7H), 1,33 (dq, J = 14,5, 7,3, 2H),
- 1,14 (m, 1H), 0,90 (t, J = 7,3, 3H), 0,73 (dt, J
- = 13,0, 8,9, 1H).
- δ 7,20 (m, 2H), 7,01 (dd, J = 13,5, 4,7, 2H),
- 6,65 (s, 1H), 3,88 (s, 2H), 3,72 (m, 3H), 2,78
- 184
- {4H,5H,6H-ciclopenta[b]tiofen -2-ilmetil}({2-[(9R)-9-(4-fluorofenil)-6-oxasp iro[4.5]decan-9-il]etil})amina 414 (t, J = 7,2, 3H), 2,61 (t, J = 7,2, 2H), 2,34 (dt, J = 14,5, 7,3, 3H), 2,15 (d, J = 14,1, 1H), 2,06 (d, J = 13,9, 1H), 1,99 (m, 1H), 1,89 (m, 2H), 1,78 (m, 1H), 1,67 (ddd, J = 18,6, 11,9,
- 7,0, 2H), 1,46 (m, 4H), 1,25 (m, 1H), 0,79 (dt,
- J = 13,4, 8,7, 1H).
- δ 9,37 (s, 1H), 8,65 (dd, J = 5,3, 1,3, 1H),
- 8,12 (td, J = 7,9, 1,6, 1H), 7,65 (d, J = 8,2,
- 1H), 7,56 (dd, J = 7,1, 5,7, 1H), 6,34 (s, 1H),
- 185
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]deca n-9-il]etil}({2H,3H-tieno[3,4-b][1,4]dioxin-5-i lmetil})amina 415 5,94 (s, 1H), 4,16 (dt, J = 8,2, 6,0, 4H), 4,05 (m, 2H), 3,77 (m, 2H), 3,06 (dd, J = 17,1, 11,1, 1H), 2,61 (t, J = 8,9, 1H), 2,29 (m, 4H), 1,99 (t, J = 8,8, 1H), 1,82 (ddd, J = 13,6, 9,4,
- 4,3, 2H), 1,67 (m, 1H), 1,48 (ddd, J = 14,5,
- 12,7, 6,9, 4H), 1,19 (m, 1H), 0,74 (dt, J =
- 13,3, 9,0, 1H).
- δ 8,66 (d, J = 167,7, 2H), 7,92 (m, 1H), 7,52
- (m, 3H), 7,05 (s, 4H), 4,21 (s, 2H), 3,71 (m,
- 186
- {2-[2,2-dimetil-4-(4-metilfenil)oxan-4-il]etil}[ (2-metanosulfonilfenil)metil]amina 416,3 2H), 3,49 (s, 1H), 3,06 (s, 3H), 2,85 (s, 1H), 2,47 (d, J = 4,8,1H), 2,20 (m, 4H), 2,09 (dd, J = 13,9, 2,1, 1H), 1,94 (d, J = 4,6, 1H), 1,72
- (s, 1H), 1,55 (m, 2H), 1,10 (s, 3H), 0,57 (s,
- 3H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 187
- [(4-bromofuran-2-il)metil]({2-[(9R)-9-(piridin -2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 419 δ 9,52 (s, 1H), 8,77 (s, 1H), 8,38 (s, 1H), 7,83 (d, J = 7,6, 2H), 7,40 (s, 1H), 6,51 (s, 1H), 4,09 (s, 2H), 3,78 (d, J = 48,0, 2H), 3,03 (s, 1H), 2,63 -2,41 (m, 2H), 2,33 (dd, J = 28,3, 13,9, 3H), 2,09 (d, J = 14,2, 1H), 1,90 (s, 2H), 1,82 -1,63 (m, 1H), 1,53 (ddd, J = 12,9, 10,9, 4,5, 4H), 1,19 (s, 1H), 0,79 (dt, J =13,0, 8,9, 1H).
- 188
- {2-[(9R)-9-(4-fluorofenil)-6-oxaspiro[4.5]de can-9-il]etil}({[5-(metilsulfanil)tiofen-2-il]met il})amina 420 δ 7,22 (dd, J = 8,9, 5,2, 2H), 7,05 (t, J = 8,6, 2H), 6,85 (dd, J = 10,8, 3,7, 2H), 3,95 (s, 2H), 3,75 (d, J = 4,6, 2H), 2,75 (s, 1H), 2,47 (s, 3H), 2,32 (s, 1H), 2,17 (d, J = 14,4, 1H), 2,09 (d, J = 13,8,1H), 1,99 (dt, J = 12,3, 6,4, 1H), 1,91 (d, J = 13,9, 2H), 1,80 (d, J = 10,5, 1H), 1,74 -1,61 (m, 2H), 1,49 (dt, J = 18,7, 11,7, 4H), 1,26 (s, 1H), 0,89 -0,75 (m, 1H).
- 189
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]deca n-9-il]etil}({[6-(trifluorometil)piridin-3-il]metil })amina 420,3 δ 8,83 -8,56 (m, 2H), 8,35 (t, J = 7,6, 1H), 7,96 (dd, J = 19,3, 8,7, 1H), 7,87 -7,75 (m, 2H), 7,71 (t, J = 9,2, 1H), 4,16 (s, 2H), 3,84 (dd, J = 8,5, 4,4, 1H), 3,71 (t, J = 10,0, 1H), 3,07 (dd, J = 11,7, 6,8, 1H), 2,55 (dt, J = 25,6, 11,9, 2H), 2,43 -2,21 (m, 3H), 2,10 (d, J = 14,2, 1H), 1,90 (ddd, J = 26,1, 14,9, 6,7, 2H), 1,76 -1,62 (m, 1H), 1,60 -1,34 (m, 4H), 1,33 -1,09 (m, 1H), 0,76 (dt, J = 12,8, 8,8, 1H).
- 190
- [(5-bromofuran-2-il)metil]({2-[(9R)-9-(piridin -2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 421 δ 8,75 (d, J = 4,8, 1H), 8,24 (t, J = 7,7, 1H), 7,86-7,58 (m, 2H), 6,44 (d, J = 3,3,1H), 6,28 (d, J = 3,3, 1H), 4,07 (s, 2H), 3,94 -3,79 (m, 1H), 3,72 (t, J = 10,1, 1H), 3,01 (dd, J = 11,1, 6,0, 1H), 2,56 (t, J = 9,9, 1H), 2,49 -2,11 (m, 4H), 2,05 (d, J = 14,1, 1H), 1,88 (ddd, J = 18,8, 11,0, 6,5, 2H), 1,78 -1,31 (m, 5H), 1,31-1,07 (m, 1H), 0,77 (dt, J = 13,1, 8,9, 1H)
- 191
- (2-{2,2-dimetil-4-[4-(trifluorometil)fenil]oxan -4-il}etil)[(2-metoxifenil)metil]amina 422,3 δ 8,49 (d, J = 118,7, 2H), 7,50 (d, J = 8,3, 2H), 7,25 (dd, J = 10,3, 4,6, 3H), 6,96 (dd, J = 7,5, 1,5, 1H), 6,79 (ddd, J = 22,1, 14,4, 4,4, 2H), 6,08 (s, 1H), 3,84 (d, J = 9,2, 2H), 3,68 (m, 5H), 2,64 (s, 1H), 2,09 (m, 3H), 1,90 (m, 1H), 1,77 (dd, J = 12,7, 4,5, 1H), 1,58 (ddd, J = 14,0, 10,8, 10,1, 2H), 1,12 (s, 3H), 0,55 (s, 3H).
- 192
- {2-[2,2,6,6-tetrametil-4-(piridin-2-il)oxan-4-il ]etil}({[6-(trifluorometil)piridin-3-il]metil})ami na 422,3 δ 8,79 -8,63 (m, 2H), 8,31 (t, J = 7,9, 1H), 8,05 -7,90 (m, 2H), 7,87 -7,61 (m, 2H), 4,16 (s, 2H), 2,82 (dd, J = 10,0, 6,6, 2H), 2,54 (d, J = 14,7, 2H), 2,46 -2,30 (m, 2H), 1,95 (d, J = 14,8, 2H), 1,32 (s, 5H), 0,98 (s, 5H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 193
- {[5-(furan-2-il)tiofen-2-il]metil}({2-[(9R)-9-(pi ridin-2-il)-6-oxaspiro[4.5]decan-9-il]etil})ami na 423,1 δ 9,59 (s, 1H), 8,56 (d, J = 4,7, 1H), 8,05 (t, J = 7,4, 1H), 7,57 (d, J = 8,1, 1H), 7,46 (dd, J = 12,2, 6,3, 1H), 7,35 -7,26 (m, 1H), 6,93 (dd, J = 19,9, 3,7, 2H), 6,46 -6,30 (m, 2H), 4,08 (s, 2H), 3,78 -3,54 (m, 2H), 3,00 -2,81 (m, 1H), 2,46 (t, J = 9,7, 1H), 2,30 (t, J = 10,6, 1H), 2,13 (ddd, J = 17,3, 16,1, 9,3, 3H), 1,89 (d, J = 14,2, 1H), 1,72 (ddd, J = 13,9, 9,5, 4,3, 2H), 1,54 (dd, J = 21,6, 14,5, 1H), 1,48 1,23 (m, 4H), 1,06 (d, J = 13,2, 1H), 0,65 (dt, J = 13,3, 8,9, 1H).
- 194
- [(5-clorotiofen-2-il)metil]({2-[4-(4-fluorofenil )-1-oxaspiro[5,5]undecan-4-il]etil))amina 423,2 δ 7,13 (dd, J = 8,9, 5,1, 2H), 6,95 (dd, J = 15,5, 6,8, 2H), 6,69 (q, J = 3,9, 2H), 3,81 (s, 2H), 3,62 (d, J = 13,8, 2H), 2,68 (m, 1H), 2,11 (dd, J = 22,2, 13,8, 3H), 1,84 (m, 1H), 1,54 (m, 4H), 1,30 (m, 4H), 1,05 (d, J = 11,4, 4H), 0,63 (m, 1H).
- 195
- (1-benzotiofen-2-ilmetil)({2-[(9R)-9-(4-fluor ofenil)-6-oxaspiro[4.5]decan-9-il]etil})amina 424 δ 9,53 (d, J = 105,8, 2H), 7,77 -7,66 (m, 2H), 7,36 -7,32 (m, 2H), 7,15 (dd, J = 8,8, 5,2, 3H), 6,96 (t, J = 8,6, 2H), 3,96 (s, 2H), 3,75 3,63 (m, 2H), 2,75 (s, 1H), 2,33 (s, 1H), 2,19 -2,16 (m, 0H), 2,15 -1,71 (m, 6H), 1,71 1,29 (m, 6H), 1,22 (s, 1H), 0,77 (dt, J = 13,5, 9,0, 1H).
- 196
- (1-benzotiofen-3-ilmetil)({2-[(9R)-9-(4-fluor ofenil)-6-oxaspiro[4.5]decan-9-il]etil})amina 424 δ 8,67 (d, J = 139,8, 2H), 7,76 -7,61 (m, 1H), 7,56 -7,39 (m, 1H), 7,34 -7,25 (m, 3H), 6,98 (dd, J = 8,8, 5,1, 2H), 6,84 (t, J = 8,6, 2H), 3,89 (s, 2H), 3,71 -3,54 (m, 2H), 2,66 (s, 1H), 2,21 (s, 1H), 2,07 -1,89 (m, 2H), 1,89 1,60 (m, 4H), 1,60 -1,45 (m, 2H), 1,44 -1,24 (m, 4H), 1,19 -1,07 (m, 1H), 0,67 (dt, J = 13,8, 8,9, 1H).
- 197
- [(5-fluoro-1-benzotiofen-2-il)metil]({2-[(9R)9-(piridin-2-il)-6-oxaspiro[4.5]decan-9-il]etil })amina 425 δ 8,47 (s, 1H), 7,69 (s, 2H), 7,42 (d, J = 9,2, 1H), 7,30 (dd, J = 10,5, 9,5, 3H), 7,13 (s, 2H), 4,21 (d, J = 13,3, 2H), 3,73 (s, 2H), 3,16 -2,91 (m, 1H), 2,82 -2,52 (m, 1H), 2,27 (d, J = 14,8, 2H), 2,21 -2,09 (m, 1H), 2,08 -1,94 (m, 1H), 1,85 (d, J = 13,6, 1H), 1,65 (s, 4H), 1,43 (d, J = 38,4, 3H), 1,18 -1,02 (m, 1H), 0,75 -0,60 (m, 1H).
- 198
- [(5-ciclopentiltiofen-2-il)metil]({2-[(9R)-9-(pi ridin-2-il)-6-oxaspiro[4.5]decan-9-il]etil})ami na 425,1 δ 12,19 -12,13 (m, 0H), 8,69 (d, J = 4,7, 1H), 8,18 (s, 1H), 7,80 -7,59 (m, 2H), 6,90 (d, J = 3,5, 1H), 6,67 (d, J = 2,9, 1H), 4,14 (s, 2H), 3,82 (d, J = 12,7, 2H), 3,73 (d, J = 9,7, 1H), 3,17 (t, J = 8,3, 1H), 3,02 (s, 1H), 2,58 (s, 1H), 2,31 (d, J = 14,1, 4H), 2,05 (dd, J = 33,0, 10,0, 3H), 1,90 -1,74 (m, 4H), 1,68 (dt, J = 12,1, 9,1, 3H), 1,51 (ddd, J = 13,4, 10,8, 5,9, 6H), 1,18 (s, 1H), 0,79 (s, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 199
- [(4-fenilfenil)metil]({2-[(9R)-9-(piridin-2-il)-6 -oxaspiro[4.5]decan-9-il]etil})amina 427,3 δ 8,59 (d, J = 4,9, 1H), 8,18 (t, J = 7,4, 1H), 7,75 -7,52 (m, 2H), 7,47 -7,38 (m, 4H), 7,35 -7,29 (m, 2H), 7,29 -7,21 (m, 3H), 3,91 (s, 2H), 3,70 (dt, J = 12,3, 4,2, 1H), 3,57 (t, J = 9,7, 1H), 2,92 (s, 1H), 2,40 (dd, J = 26,0, 12,7, 2H), 2,30-2,04 (m, 3H), 2,04-1,84 (m, 1H), 1,76 (ddd, J = 27,2, 15,3, 6,8, 2H), 1,65 -1,21 (m, 5H), 1,07 (dd, J = 14,4, 5,6, 1H), 0,67 (dt, J = 13,0, 9,0, 1H).
- 200
- [(3-fenilfenil)metil]({2-[(9R)-9-(piridin-2-il)-6 -oxaspiro[4.5]decan-9-il]etil})amina 427,3 δ 8,44 (d, J = 4,1, 1H), 7,96 (t, J = 7,1, 1H), 7,53 -7,43 (m, 5H), 7,42 -7,26 (m, 3H), 7,19 (s, 3H), 3,94 (s, 1H), 3,82 -3,45 (m, 2H), 2,73 (s, 2H), 2,44 (s, 1H), 2,31 (d, J = 10,6, 1H), 2,15 (d, J = 13,2, 3H), 1,86 (d, J = 14,1, 1H), 1,70 (t, J = 9,7, 2H), 1,56 (s, 1H), 1,50-1,22 (m, 5H), 1,06 (s, 1H), 0,66 (dd, J = 13,3, 9,0, 1H).
- 201
- bencil({2-[9-(4-bromofenil)-6-oxaspiro[4.5]d ecan-9-il]etil})amina 428,2 δ 9,51 (s, 1H), 9,15 (s, 1H), 7,42 (d, J = 8,6, 2H), 7,30 (m, 3H), 7,16 (dd, J = 7,3, 2,1, 2H), 7,06 (d, J = 8,7, 2H), 3,68 (m, 4H), 2,62 (m, 1H), 2,19 (m, 1H), 2,04 (dd, J = 22,4, 13,9, 2H), 1,93 (m, 1H), 1,85 (m, 3H), 1,60 (m, 2H), 1,45 (ddd, J = 21,1, 16,1, 8,8, 5H), 1,25 (m, 2H), 0,77 (dt, J = 13,2, 8,7, 1H).
- 202
- 2-amino-4-cloro-5-[({2-[(9R)-9-(piridin-2-il)6-oxaspiro[4.5]decan-9-il]etil}amino)metil]ti ofeno-3-carbonitrilo 431 1H NMR (400 MHz, CD3CN) δ 8,57 (dd, J = 4,9, 1,0, 1H), 7,83 (m, 1H), 7,48 (d, J = 8,1, 1H), 7,31 (ddd, J = 7,5, 4,9, 0,9, 1H), 6,13 (s, 2H), 4,06 (s, 2H), 3,69 (m, 2H), 2,96 (m, 1H), 2,42 (m, 2H), 2,08 (m, 2H), 1,92 (m, 1H), 1,87 (d, J = 13,5, 1H), 1,57 (m, 8H), 1,10 (m, 1H), 0,71 (m, 1H).
- 203
- {2-[(9R)-9-(4-fluorofenil)-6-oxaspiro[4.5]de can-9-il]etil}({2H,3H-tieno[3,4-b][1,4]dioxin5-ilmetil})amina 432 δ 7,21 (dd, J = 9,0, 5,1, 2H), 7,03 (t, J = 8,6, 2H), 6,33 (s, 1H), 4,13 (s, 4H), 3,90 (s, 2H), 3,74 (m, 2H), 3,01 (brs, 1H), 2,77 (t, J = 13,7, 1H), 2,35 (m, 1H), 2,17 (d, J = 14,0, 1H), 2,02 (dt, J = 14,7, 9,5, 2H), 1,89 (m, 2H), 1,78 (d, J = 10,1, 1H), 1,68 (ddd, J = 16,9, 10,6, 5,8, 2H), 1,46 (ddd, J = 17,8, 10,0, 5,9, 4H), 1,25 (m, 1H), 0,79 (dt, J = 13,5, 8,8, 1H).
- 204
- [(4-feniltiofen-2-il)metil]({2-[(9R)-9-(piridin-2 -il)-6-oxaspiro[4.5]decan-9-il]etil})amina 433,1 δ 9,71 (s, 4H), 8,53 (d, J = 5,0, 1H), 8,09 (t, J = 7,6, 1H), 7,62 (d, J = 8,1, 1H), 7,54 -7,44 (m, 1H), 7,43 -7,35 (m, 2H), 7,32 -7,19 (m, 5H), 4,12 (s, 2H), 3,77 -3,52 (m, 2H), 3,00 2,76 (m, 1H), 2,41 (dt, J = 25,0, 11,5, 2H), 2,18 (t, J = 17,1, 3H), 1,90 (d, J = 14,1, 1H), 1,73 (ddd, J = 19,6, 11,4, 6,9, 2H), 1,55 (dd, J = 10,0, 4,9, 1H), 1,48 -1,26 (m, 4H), 1,04 (s, 1H), 0,72 -0,56 (m, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 205
- [(5-feniltiofen-2-il)metil]({2-[(9R)-9-(piridin-2 -il)-6-oxaspiro[4.5]decan-9-il]etil})amina 433,1 δ 9,74 (brs, 1H), 7,62 (d, J = 8,1, 1H), 7,50 (m, 3H), 7,37 (m, 2H), 7,31 (m, 1H), 7,12 (d, J = 3,7, 1H), 7,04 (d, J = 3,7, 1H), 5,23 (brs, 1H), 4,19 (mz, 2H), 3,72 (m, 2H), 3,02 (d, J = 6,5, 1H), 2,59 (t, J = 9,1, 1H), 2,39 (t, J = 10,1, 1H), 2,22 (dd, J = 29,2, 10,0, 3H), 1,96 (d, J = 14,1, 1H), 1,80 (t, J = 11,0, 2H), 1,62 (dd, J = 14,1, 7,4,1H), 1,44 (ddd, J = 16,8, 16,4, 7,5, 4H), 1,13 (m, 1H), 0,73 (dt, J = 12,7, 8,8, 1H).
- 206
- [(5-metanosulfoniltiofen-2-il)metil]({2-[(9R)9-(piridin-2-il)-6-oxaspiro[4.5]decan-9il]etil})amina 435 δ 8,67 (d, J = 5,0,1H), 8,32 (t, J = 8,0, 1H), 7,79 (d, J = 7,9, 2H), 7,59 (d, J = 3,8, 1H), 7,22 (d, J = 3,8, 1H), 4,31 (d, J = 6,2, 2H), 3,84 (s, 1H), 3,74 (s, 1H), 3,18 (s, 1H), 3,05 (s, 2H), 2,54 (t, J = 10,3, 2H), 2,31 (d, J = 13,3, 2H), 2,14 -2,00 (m, 2H), 1,89 (d, J = 13,8, 3H), 1,81 -1,64 (m, 1H), 1,64 -1,37 (m, 3H), 1,28 (s, 2H), 0,81 (d, J = 13,2, 1H).
- 207
- [(4-bromotiofen-3-il)metil]({2-[(9R)-9-(piridi n-2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 435 δ 11,51 (s, 1H), 9,44 (s, 1H), 8,69 -8,58 (m, 1H), 8,14 (td, J = 8,0, 1,6, 1H), 7,68 -7,56 (m, 2H), 7,52 (d, J = 3,4, 1H), 7,21 (d, J = 3,3, 1H), 4,01 (s, 2H), 3,82 -3,54 (m, 2H), 2,97 (td, J = 11,5, 5,7, 1H), 2,62 -2,43 (m, 1H), 2,41 -2,12 (m, 4H), 2,02 -1,89 (m, 1H), 1,78 (ddd, J = 18,6, 11,9, 6,5, 2H), 1,60 (dt, J = 13,5, 7,7, 1H), 1,55 -1,30 (m, 4H), 1,10 (d, J = 4,1, 0H), 0,67 (dt, J = 13,1, 8,9, 1H).
- 208
- [(4-bromotiofen-2-il)metil]({2-[(9R)-9-(piridi n-2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 435,1 δ 8,59 (d, J = 4,0, 1H), 8,13 (t, J = 7,1, 1H), 7,65 (d, J = 8,2, 1H), 7,59 (m, 1H), 7,23 (d, J = 1,4, 1H), 7,04 (d, J = 1,2, 1H), 4,19 (s, 2H), 3,75 (m, 2H), 3,01 (m, 1H), 2,84 (s, 1H), 2,60 (m, 1H), 2,40 (m, 1H), 2,25 (d, J = 13,0, 3H), 1,97 (d, J = 14,0, 1H), 1,83 (d, J = 9,4, 2H), 1,67 (m, 1H), 1,48 (dd, J = 24,0, 15,8, 4H), 1,17 (brs, 1H), 0,77 (m, 1H).
- 209
- [(5-bromotiofen-2-il)metil]({2-[(9R)-9-(piridi n-2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 435,1 δ 8,61 (d, J = 4,3, 1H), 8,14 (t, J = 7,9, 1H), 7,65 (d, J = 8,1,1H), 7,60 (m, 1H), 6,94 (d, J = 3,8, 1H), 6,89 (d, J = 3,8, 1H), 4,14 (s, 2H), 3,76 (m, 3H), 2,99 (m, 1H), 2,58 (m, 1H), 2,38 (d, J = 9,8, 1H), 2,26 (d, J = 13,9, 3H), 1,97 (d, J = 14,1, 1H), 1,82 (t, J = 9,7, 2H), 1,67 (s, 1H), 1,47 (m, 4H), 1,16 (s, 1H), 0,75 (dt, J = 13,4, 9,2, 1H).
- 210
- [(2-bromotiofen-3-il)metil]({2-[(9R)-9-(piridi n-2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 436 δ 8,66 (d, J = 5,3, 1H), 8,21 (d, J 7,2, 1H), 7,85 -7,58 (m, 2H), 7,33 (d, J = 5,7,1H), 7,09 (d, J = 5,7, 1H), 4,02 -3,63 (m, 3H), 3,10 2,97 (m, 2H), 2,61 (t, J = 9,1, 1H), 2,43 (d, J = 11,0, 1H), 2,30 (d, J = 13,6, 3H), 2,04 (s, 1H), 1,94 -1,80 (m, 2H), 1,69 (s, 1H), 1,64 1,40 (m, 4H), 1,20 (s, 1H), 0,86 -0,68 (m, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 211
- [(5-bromofuran-2-il)metil]({2-[(9R)-9-(4-fluo rofenil)-6-oxaspiro[4.5]decan-9-il]etil})amin a 436 δ 9,07 (d, J = 116,7, 2H), 7,16 -7,06 (m, 2H), 7,01 -6,89 (m, 2H), 6,25 (d, J = 3,4, 1H), 6,17 (s, 1H), 3,83 (s, 2H), 3,76 -3,58 (m, 2H), 2,66 (s, 1H), 2,23 (s, 1H), 2,09 (d, J = 14,0, 1H), 2,04 -1,96 (m, 1H), 1,95 -1,66 (m, 4H), 1,66 -1,50 (m, 2H), 1,50 -1,28 (m, 4H), 1,28 -1,13 (m, 1H), 0,71 (dt, J = 13,6, 8,8, 1H).
- 212
- (2-[(9R)-9-(4-fluorofenil)-6-oxaspiro[4.5]de can-9-il]etil}({[6-(trifluorometil)piridin-3-il]m etil})amina 437,2 δ 8,63 (s, 1H), 7,83 (d, J = 8,3, 1H), 7,68 (d, J = 8,0, 1H), 7,29 (s, 1H), 7,21 (dd, J = 8,9, 5,1, 3H), 7,05 (s, 2H), 3,93 (s, 2H), 3,75 (dd, J = 11,3, 7,3, 2H), 2,84 -2,58 (m, 1H), 2,44 2,04 (m, 10H), 2,02 -1,75 (m, 5H), 1,74 -1,56 (m, 3H), 1,59 -1,33 (m, 5H), 1,33 -1,19 (m, 1H), 0,78 (d, J = 13,6, 1H).
- 213
- [(4-bromofuran-2-il)metil]({2-[(9R)-9-(4-fluo rofenil)-6-oxaspiro[4.5]decan-9-il]etil})amin a 437,9 δ 7,38 (d, J = 0,6, 1H), 7,28 (s, 1H), 7,22 (d, J = 5,2, 2H), 7,08 (d, J = 8,5, 2H), 3,75 (dd, J = 11,7, 7,1, 2H), 2,73 (s, 1H), 2,30 (d, J = 4,5, 2H), 2,17 (d, J = 13,5, 1H), 2,10 (d, J = 13,9, 1H), 2,05 -1,95 (m, 1H), 1,94 (s, 2H), 1,79 (d, J = 9,8, 1H), 1,74 -1,62 (m, 2H), 1,49 (dt, J = 16,4, 10,6, 4H), 1,28 (s, 2H), 0,80 (d, J = 13,7, 1H).
- 214
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]deca n-9-il]etil}({[5-(tiofen-2-il)tiofen-2-il]metil})a mina 439 δ 8,52 (d, J = 5,3, 1H), 7,96 (t, J = 7,9, 1H), 7,50 (d, J = 8,1, 1H), 7,40 (dd, J = 16,2, 10,4, 1H), 7,24 -7,10 (m, 1H), 7,03 (dd, J = 3,6, 1,0, 1H), 6,98 -6,81 (m, 3H), 4,07 (s, 2H), 3,80 -3,49 (m, 2H), 2,90 (d, J = 11,1, 2H), 2,16 (s, 5H), 1,87 (d, J = 14,0, 1H), 1,71 (dd, J = 11,5, 7,2, 2H), 1,54 (d, J = 6,1, 1H), 1,36 (ddd, J = 16,8, 12,9, 6,1, 5H), 1,05 (s, 1H), 0,82 -0,54 (m, 1H).
- 215
- {2-[2,2-dietil-4-(4-fluorofenil)oxan-4-il]etil}({[ 6-(trifluorometil)piridin-3-il]metil})amina 439,3 δ 8,62 (s, 1H), 7,84 (d, J = 8,2, 1H), 7,66 (d, J = 8,2, 1H), 7,20 (m, 1H), 7,04 (s, 2H), 3,90 (s, 2H), 3,71 (d, J = 12,1, 2H), 2,77 (m, 1H), 2,19 (m, 3H), 1,98 (m, 1H), 1,68 (M, 3H), 1,40 (d, J = 7,6, 2H), 1,04 (s, 1H), 0,83 (t, J = 7,5, 4H), 0,54 (d, J = 7,3, 3H).
- 216
- [(5-cloro-1-benzotiofen-3-il)metil]({2-[(9R)9-(piridin-2-il)-6-oxaspiro[4.5]decan-9-il]etil })amina 442 δ 8,61 (d, J = 4,9, 1H), 8,44 (s, 1H), 8,17 (s, 1H), 7,93 (d, J = 5,5,1H), 7,69 (d, J = 8,1, 1H), 7,60 (s, 1H), 7,50 (d, J = 5,5, 1H), 7,28 (s, 1H), 3,82 (s, 3H), 3,17 (dd, J = 16,8, 10,9, 1H), 2,75 (t, J = 8,9, 1H), 2,47 (t, J = 9,7, 1H), 2,32 (d, J = 13,9, 3H), 2,10 -1,98 (m, 1H), 1,87 (dd, J = 12,1, 7,1, 2H), 1,78 -1,62 (m, 1H), 1,48 (dd, J = 23,5, 18,9, 5H), 1,18 (s, 1H), 0,77 (dt, J = 13,2, 9,0, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 217
- [(5-bromo-4-metiltiofen-2-il)metil]({2-[(9R)9-(piridin-2-il)-6-oxaspiro[4.5]decan-9-il]etil })amina 449 δ 10,10 -9,21 (m, 1H), 8,53 (d, J = 3,9, 1H), 7,90 (td, J = 7,9, 1,6, 1H), 7,45 (d, J = 8,1, 1H), 7,38 (dd, J = 7,0, 5,4, 1H), 6,69 (s, 1H), 4,02 -3,86 (m, 2H), 3,74 -3,55 (m, 2H), 2,85 (dd, J = 11,4, 5,9, 1H), 2,47 -2,33 (m, 1H), 2,31 -2,09 (m, 3H), 2,09 -1,93 (m, 4H), 1,87 (d, J = 14,0, 1H), 1,69 (dt, J = 14,4, 6,1, 2H), 1,57 (d, J = 5,4, 1H), 1,38 (ddd, J = 26,7, 14,6, 8,4, 4H), 1,04 (s, 1H), 0,73 -0,56 (m, 1H).
- 218
- [(4-bromo-5-metiltiofen-2-il)metil]({2-[(9R)9-(piridin-2-il)-6-oxaspiro[4.5]decan-9-il]etil })amina 449 δ 8,72 (d, J = 4,9, 1H), 8,26 (d, J = 7,7, 1H), 7,74 (dd, J = 16,7, 7,1, 2H), 6,92 (s, 1H), 4,21 (d, 1H), 3,90 -3,78 (m, 2H), 3,74 (d, J = 9,6, 1H), 3,02 (s, 1H), 2,51 (dd, J = 52,4, 11,0, 2H), 2,39 -2,16 (m, 6H), 2,05 (d, J = 13,8, 1H), 1,87 (d, J = 9,5, 2H), 1,69 (s, 1H), 1,63 -1,41 (m, 4H), 1,24 (d, J = 30,9, 1H), 0,81 (s, 1H).
- 219
- [(3-bromo-5-metiltiofen-2-il)metil]({2-[(9R)9-(piridin-2-il)-6-oxaspiro[4.5]decan-9-il]etil })amina 449 δ 8,61 (d, J = 4,9, 1H), 8,02 (d, J = 7,9, 1H), 7,69 -7,41 (m, 2H), 6,68 (d, J = 1,0, 1H), 4,23 (q, J = 14,2, 2H), 3,90 -3,59 (m, 2H), 3,10 (s, 1H), 2,75 (m, 2H), 2,36 -2,13 (m, 5H), 1,96 (d, J = 13,9, 1H), 1,82 (d, J = 9,9, 2H), 1,75 -1,62 (m; 1H), 1,62 -1,38 (m, 4H), 1,24 -1,05 (m, 1H), 0,74 (d, J = 13,2, 1H).
- 220
- [(4-bromo-3-metiltiofen-2-il)metil]({2-[(9R)9-(piridin-2-il)-6-oxaspiro[4.5]decan-9-il]etil })amina 449 δ 8,61 (d, J = 5,2, 1H), 8,09 (t, J = 7,7, 1H), 7,71 -7,49 (m, 2H), 7,30 (s, 1H), 4,21 (d, J = 4,3, 2H), 4,00 -3,59 (m, 2H), 3,05 (s, 1H), 2,64 (s, 1H), 2,31 (d, J = 14,5, 2H), 2,25 (d, J = 13,7, 2H), 2,18 (s, 3H), 1,96 (d, J = 13,9, 1H), 1,82 (dd, J = 12,0, 7,2, 2H), 1,68 (s, 1H), 1,61 -1,40 (m, 4H), 1,17 (s, 1H), 0,92 0,64 (m, 1H).
- 221
- {2-[4-(4-fluorofenil)-1-oxaspiro[5,5]undecan -4-il]etil}({[6-(trifluorometil)piridin-3-il]metil}) amina 451,2 δ 8,52 (s, 1H), 7,73 (d, J = 9,6, 1H), 7,57 (d, J = 8,0, 1H), 7,11 (dd, J = 9,0, 5,2, 2H), 6,94 (t, J = 8,4, 2H), 3,83 (s, 2H), 3,63 (d, J = 18,0, 2H), 2,69 (m, 1H), 2,12 (t, J = 13,9, 3H), 1,70 (m, 5H), 1,31 (d, J = 18,3, 4H), 1,03 (s, 4H), 0,57 (m, 1H).
- 222
- [(4-bromotiofen-3-il)metil]({2-[(9R)-9-(4-fluo rofenil)-6-oxaspiro[4.5]decan-9-il]etil})amin a 451,9 δ 9,26 (d, J = 136,7, 2H), 7,39 (dd, J = 22,6, 19,3, 2H), 7,10 (dd, J = 8,8, 5,2, 2H), 6,92 (dd, J = 10,6, 6,6, 2H), 3,82 (s, 2H), 3,71 3,53 (m, 2H), 2,64 (s, 1H), 2,20 (s, 1H), 2,05 (d, J = 14,1, 1H), 1,97 (d, J = 13,9, 1H), 1,89 (td, J = 12,6, 4,6, 1H), 1,83 -1,64 (m, 3H), 1,57 (ddd, J = 14,0, 9,6, 4,7, 2H), 1,49 -1,25 (m, 4H), 1,17 (d, J = 13,2, 1H), 0,69 (dt, J = 13,8, 8,8, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 223
- [(4-bromotiofen-2-il)metil]({2-[(9R)-9-(4-fluo rofenil)-6-oxaspiro[4.5]decan-9-il]etil})amin a 452,1 δ 9,38 (d, J = 89,0, 2H), 7,16 -7,03 (m, 3H), 6,96 (t, J = 8,6, 2H), 6,84 (d, J = 1,3, 1H), 3,86 (s, 2H), 3,70 -3,55 (m, 2H), 2,62 (dd, J = 12,1, 7,7, 1H), 2,18 (dd, J = 11,9, 7,8, 1H), 2,02 (dd, J = 32,5, 14,0, 2H), 1,91 -1,63 (m, 4H), 1,64 -1,50 (m, 2H), 1,49 -1,25 (m, 4H), 1,16 (dd, J = 14,0, 6,1, 1H), 0,69 (dt, J = 13,5, 8,8, 1H).
- 224
- [(5-bromotiofen-2-il)metil]({2-[(9R)-9-(4-fluo rofenil)-6-oxaspiro[4.5]decan-9-il]etil})amin a 452,1 δ 9,31 (d, J = 92,6, 2H), 7,15 -7,04 (m, 2H), 6,95 (t, J = 8,6, 2H), 6,82 (d, J = 3,8, 1H), 6,67 (d, J = 3,8, 1H), 3,82 (s, 2H), 3,70 -3,53 (m, 2H), 3,44 (s, 1H), 2,62 (dd, J = 12,0, 7,6, 1H), 2,18 (dd, J = 11,8, 7,9, 1H), 2,02 (dd, J = 31,6, 14,0, 2H), 1,93 -1,64 (m, 4H), 1,57 (ddd, J = 12,1, 8,5, 3,8, 2H), 1,52 -1,25 (m, 4H), 1,16 (dd, J = 14,9, 5,1, 1H), 0,69 (dt, J = 13,6, 8,8, 1H).
- 225
- dibencil({2-[(9R)-9-(4-fluorofenil)-6-oxaspir o[4.5]decan-9-il]etil})amina 458,3 δ 7,27 (m, 17H), 7,00 (dd, J = 8,9, 5,2, 2H), 6,86 (t, J = 8,6, 2H), 4,24 (s, 2H), 3,90 (m, 2H), 3,55 (d, J = 3,4, 2H), 2,59 (m, 1H), 2,22 (m, 12H), 1,86 (dd, J = 75,2, 14,8, 7H), 1,59 (dd, J = 44,5, 9,1, 2H), 1,38 (m, 6H), 1,18 (s, 1H), 1,11 (s, 1H), 0,68 (m, 1H).
- 226
- dibencil({2-[2,2-dietil-4-(4-fluorofenil)oxan4-il]etil})amina 460,3 δ 7,27 (d, J = 34,4, 7H), 7,18 (s, 4H), 6,98 (dd, J = 8,9, 5,2, 2H), 6,84 (t, J = 8,6, 2H), 4,25 (s, 2H), 3,85 (d, J = 46,4, 2H), 3,53 (m, 2H), 2,57 (d, J = 4,7, 2H), 2,12 (d, J = 4,0, 2H), 1,97 (m, 3H), 1,73 (d, J = 4,8, 1H), 1,44 (s, 1H), 1,38 (dd, J = 13,8, 7,5, 3H), 1,23 (m, 1H), 0,90 (m, 1H), 0,70 (dt, J = 10,8, 7,4, 4H), 0,40 (t, J = 7,4, 3H).
- 227
- [(4-bromo-3-metiltiofen-2il)metil]({2-[(9R)-9-(4-fluorofenil)-6-oxaspiro [4.5]decan-9-il]etil})amina 465,9 δ 7,19 (dd, J = 8,9, 5,1, 2H), 7,04 (t, J = 8,6, 2H), 3,94 (d, J = 16,3, 2H), 3,72 (m, 2H), 2,72 (dd, J = 13,8, 6,5, 1H), 2,31 (m, 1H), 2,15 (d, J = 12,1, 2H), 2,07 (s, 3H), 1,90 (m, 5H), 1,65 (m, 2H), 1,47 (m, 4H), 1,25 (s, 1H), 0,78 (m, 1H).
- 228
- [(4-bromo-5-metiltiofen-2-il)metil]({2-[(9R)9-(4-fluorofenil)-6-oxaspiro[4.5]decan-9-il]e til})amina 465,9 δ 9,06 (d, J = 100,4, 2H), 7,15 -7,04 (m, 2H), 6,95 (s, 2H), 6,68 (s, 1H), 3,80 (s, 2H), 3,73 3,57 (m, 2H), 2,64 (s, 1H), 2,21 (s, 4H), 2,07 (d, J = 14,1, 1H), 1,99 (d, J = 13,9, 1H), 1,94 -1,64 (m, 4H), 1,64 -1,51 (m, 2H), 1,51 1,26 (m, 4H), 1,17 (dd, J = 13,9, 6,3, 1H), 0,70 (dt, J = 13,7, 8,8, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 229
- [(3-bromo-5-metiltiofen-2-il)metil]({2-[(9R)9-(4-fluorofenil)-6-oxaspiro[4.5]decan-9-il]e til})amina 466 δ 7,20 (m, 2H), 7,01 (dd, J = 11,1, 6,1, 2H), 6,61 (d, J = 1,1, 1H), 4,01 (s, 2H), 3,72 (m, 2H), 2,75 (m, 1H), 2,61 (brs, 1H), 2,41 (d, J = 0,9, 3H), 2,32 (m, 1H), 2,15 (d, J = 14,2, 1H), 2,07 (d, J = 13,9, 1H), 1,99 (m, 1H), 1,89 (m, 2H), 1,77 (m, 1H), 1,67 (ddd, J = 17,0, 10,6, 5,6, 2H), 1,46 (m, 4H), 1,25 (m, 1H), 0,78 (dt, J = 13,9, 8,9, 1H).
- 230
- [(5-bromo-4-metiltiofen-2-il)metil]({2-[(9R)9-(4-fluorofenil)-6-oxaspiro[4.5]decan-9-il]e til})amina 466,9 δ 7,20 (d, J = 5,2, 2H), 7,06 (d, J = 8,5, 2H), 6,85 (t, J = 3,6, 1H), 3,91 (s, 2H), 3,81 -3,62 (m, 2H), 2,71 (s, 1H), 2,28 (s, 1H), 2,07 (s, 6H), 1,91 (d, J = 13,8, 2H), 1,79 (d, J = 10,3, 1H), 1,69 (ddd, J = 14,1, 9,4, 4,7, 2H), 1,59 1,37 (m, 4H), 1,28 (s, 1H), 0,80 (dd, J = 8,8, 4,9, 1H).
- 231
- {2-[2,2-dietil-4-(4-fluorofenil)oxan-4-il]etil}bi s(tiofen-2-ilmetil)amina 472,2 δ 7,31 (d, J = 4,9, 2H), 7,07 (dd, J = 8,9, 5,2, 2H), 6,99 (s, 2H), 6,95 (d, J = 4,5, 2H), 6,89 (t, J = 8,6, 2H), 4,24 (s, 2H), 3,58 (dt, J = 23,8, 6,6, 2H), 2,66 (m, 1H), 2,06 (d, J = 14,0, 4H), 1,82 (m, 2H), 1,51 (d, J = 14,3, 3H), 1,25 (m, 2H), 0,94 (dd, J = 14,6, 7,4, 1H), 0,74 (t, J = 7,5, 4H), 0,42 (t, J = 7,4, 3H).
- 232
- [(4,5-dibromotiofen-2-il)metil]({2-[(9R)-9-(pi ridin-2-il)-6-oxaspiro[4.5]decan-9-il]etil})ami na 514,8 δ 8,61 (dd, J = 5,3, 1,3, 1H), 8,13 (td, J = 8,0, 1,7, 1H), 7,64 (d, J = 8,2, 1H), 7,60 (m, 1H), 6,94 (s, 1H), 4,40 (brs, 1H), 4,11 (s, 2H), 3,77 (ddd, J = 36,9, 13,7, 7,2, 2H), 2,98 (td, J = 11,3, 6,0, 1H), 2,54 (td, J = 11,2, 4,3, 1H), 2,38 (m, 1H), 2,22 (m, 3H), 1,98 (d, J = 14,0, 1H), 1,83 (dt, J = 18,5, 9,2, 2H), 1,68 (m, 1H), 1,48 (m, 4H), 1,21 (d, J = 37,1, 1H), 0,75 (dt, J = 13,1, 9,0, 1H).
- 233
- [(3,4-dibromotiofen-2-il)metil]({2-[(9R)-9-(pi ridin-2-il)-6-oxaspiro[4.5]decan-9-il]etil})ami na 514,8 δ 8,39 (d, J = 4,0, 1H), 7,67 (t, J = 7,0, 1H), 7,38 (s, 1H), 7,28 (d, J = 8,1, 1H), 7,18 (s, 1H), 4,22 (d, J = 18,2, 2H), 3,65 (dd, J = 11,2, 7,1, 2H), 3,09 -2,85 (m, 1H), 2,60 (s, 1H), 2,22 (dd, J = 25,9, 13,8, 2H), 2,10 -1,83 (m, 2H), 1,87 -1,50 (m, 4H), 1,36 (dd, J = 18,7, 10,7, 3H), 1,02 (s, 2H), 0,68 -0,50 (m, 1H).
- 234
- [(4,5-dibromotiofen-2-il)metil]({2-[(9R)-9-(4fluorofenil)-6-oxaspiro[4.5]decan-9-il]etil})a mina 531,8 δ 7,20 (m, 2H), 7,05 (t, J = 8,6, 2H), 6,81 (s, 1H), 3,91 (s, 2H), 3,74 (m, 2H), 3,60 (brs, 1H), 2,74 (m, 1H), 2,31 (td, J = 12,1, 4,7, 1H), 2,15 (d, J = 14,1, 1H), 2,08 (d, J = 13,9, 1H), 1,88 (m, 4H), 1,67 (ddd, J = 15,1, 10,2, 5,0, 2H), 1,46 (ddd, J = 27,4, 14,5, 7,2, 4H), 1,24 (dd, J = 10,5, 5,6,1H), 0,78 (dt, J = 13,5, 8,8, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 235
- [(3,4-dibromotiofen-2-il)metil]({2-[(9R)-9-(4fluorofenil)-6-oxaspiro[4.5]decan-9-il]etil})a mina 531,8 δ 7,35 (s, 1H), 7,11 -7,06 (m, 2H), 6,94 (dd, J = 14,3, 5,7, 2H), 4,05 (s, 2H), 3,75 -3,56 (m, 2H), 2,70 (dd, J = 11,9, 7,4, 1H), 2,25 (dd, J = 11,7, 7,3, 1H), 2,08 (d, J = 14,7, 1H), 1,99 (d, J = 13,9, 1H), 1,95-1,65 (m, 4H), 1,65 -1,50 (m, 2H), 1,50 -1,29 (m, 4H), 1,16 (dd, J = 14,8, 7,3, 1H), 0,70 (dt, J = 13,6, 8,8, 1H).
- 236
- [(2-fluorofenil)metil] ({2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]dec an-9-il]etil})amina 369 δ 8,82 (s, 2H), 8,61 (dd, J = 4,8, 1,2, 1H), 7,85 (td, J = 7,8, 1,8, 1H), 7,51 (m, 3H), 7,30 (m, 3H), 5,22 (s, 2H), 4,12 (d, J = 5,3, 2H), 3,66 (m, 2H), 2,90 (d, J = 4,5, 1H), 2,39 (m, 3H), 2,08 (td, J = 12,8, 4,4, 1H), 1,54 (m, 7H), 1,02 (dd, J = 12,3, 5,8, 1H), 0,68 (dt, J = 13,3, 8,9, 1H).
- 237
- [(2-bromofenil)metil]({2-[(9R)-9-(piridin-2-il) -6-oxaspiro[4.5]decan-9-il]etil})amina 429 δ 8,93 (s, 2H), 8,60 (dd, J = 4,8, 1,2, 1H), 7,83 (td, J = 7,8, 1,9, 1H), 7,71 (dd, J = 8,0, 1,1, 1H), 7,50 (m, 3H), 7,33 (m, 2H), 4,18 (s, 2H), 3,65 (m, 2H), 2,94 (s, 1H), 2,43 (t, J = 12,2, 3H), 2,11 (td, J = 12,8, 4,4, 1H), 1,89 (m, 2H), 1,55 (m, 7H), 1,01 (m, 1H), 0,67 (dt, J = 13,3, 8,9, 1H).
- 238
- [(2-clorofenil)metil]({2-[(9R)-9-(piridin-2-il)6-oxaspiro[4.5]decan-9-il]etil})amina 385 δ 8,75 (dd, J = 5,4, 1,2, 1H), 8,52 (s, 3H), 8,22 (td, J = 8,0, 1,7, 1H), 7,77 (d, J = 8,2, 1H), 7,67 (ddd, J = 7,5, 5,4, 0,9, 1H), 7,42 (m, 4H), 4,20 (d, J = 14,0, 2H), 3,72 (m, 2H), 3,05 (td, J = 12,0, 5,1, 1H), 2,53 (td, J = 12,0, 4,4, 1H), 2,36 (m, 3H), 2,17 (m, 1H), 2,01 (d, J = 14,2, 1H), 1,79 (ddd, J = 9,3, 6,7, 3,4, 2H), 1,52 (m, 5H), 1,17 (m, 1H), 0,78 (dt, J = 12,9, 8,8, 1H).
- 239
- [(2-metilfenil)metil]({2-[(9R)-9-(piridin-2-il)-6 -oxaspiro[4.5]decan-9-il]etil})amina 365,1 δ 8,81 (dd, J = 5,7, 1,3, 1H), 8,43 (td, J = 8,0,1,7, 1H), 7,98 (s, 1H), 7,92 (d, J = 8,2, 1H), 7,86 (ddd, J = 7,6, 5,7, 1,0, 1H), 7,27 (m, 2H), 7,18 (m, 2H), 3,98 (s, 2H), 3,75 (m, 2H), 2,98 (d, J = 4,4, 1H), 2,44 (m, 2H), 2,36 (m, 5H), 2,25 (dd, J = 13,5, 5,4, 1H), 2,07 (d, J = 14,3, 1H), 1,84 (m, 2H), 1,55 (m, 5H), 1,23 (m, 1H), 0,83 (dt, J = 13,0, 8,8, 1H).
- 240
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]deca n-9-il]etil}({[2-(trifluorometil)fenil]metil})ami na 419,1 δ 8,71 (dd, J = 5,3, 1,2, 1H), 8,18 (td, J = 8,0, 1,7, 1H), 7,79 (d, J = 7,8, 1H), 7,75 (d, J = 8,2, 1H), 7,70 (m, 2H), 7,62 (ddd, J = 13,7, 6,8, 1,2, 2H), 6,71 (s, 3H), 4,23 (s, 2H), 3,75 (ddd, J = 17,6, 8,8, 3,7, 2H), 3,08 (m, 1H), 2,56 (m, 1H), 2,36 (m, 3H), 2,19 (m, 1H), 1,79 (dq, J = 7,2, 4,7, 2H), 1,53 (m, 5H), 1,19 (m, 1H), 0,79 (m, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 241
- 2-[({2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]d ecan-9-il]etil}amino)metil]fenol 367 δ 8,74 (m, 1H), 8,21 (td, J = 8,0, 1,8, 1H), 7,75 (d, J = 8,2, 1H), 7,66 (ddd, J = 7,6, 5,4, 1,0, 1H), 7,27 (m, 1H), 7,20 (dd, J = 7,6, 1,6, 1H), 6,90 (m, 4H), 4,05 (s, 2H), 3,72 (ddd, J = 12,4, 11,1, 5,4, 2H), 2,96 (d, J = 5,2, 1H), 2,35 (m, 4H), 2,13 (m, 1H), 1,78 (m, 2H), 1,51 (m, 5H), 1,15 (dd, J = 4,0, 2,0, 1H), 0,78 (m, 1H).
- 242
- [(2-metoxifenil)metil]({2-[(9R)-9-(piridin-2-il) -6-oxaspiro[4.5]decan-9-il]etil})amina 381,1 δ 9,66 (s, 3H), 8,80 (dd, J = 5,5, 1,2, 1H), 8,31 (td, J = 8,0, 1,7, 1H), 7,77 (m, 3H), 7,42 (ddd, J = 15,9, 8,0, 1,6, 1H), 7,25 (dd, J = 7,5, 1,6, 1H), 7,04 (m, 1H), 6,96 (td, J = 7,5, 1,0, 1H), 4,04 (s, 2H), 3,85 (m, 4H), 3,73 (m, 2H), 2,97 (d, J = 4,9, 1H), 2,37 (m, 4H), 2,19 (dd, J = 13,2, 5,2, 1H), 2,04 (d, J = 14,1, 1H), 1,81 (ddd, J = 14,0, 9,5, 4,5, 2H), 1,81 (ddd, J = 14,0, 9,5, 4,5, 2H), 1,54 (m, 5H), 1,18 (m, 1H), 0,80 (m, 1H).
- 243
- [(3-fluorofenil)metil]({2-[(9R)-9-(piridin-2-il)6-oxaspiro[4.5]decan-9-il]etil})amina 369 δ 8,77 (dd, J = 5,4, 1,5, 1H), 8,38 (s, 1H), 8,29 (td, J = 8,0, 1,7, 1H), 7,82 (d, J = 8,2, 1H), 7,74 (dd, J = 7,1, 6,1, 1H), 7,43 (ddd, J = 13,8, 7,5, 1,4, 1H), 7,19 (m, 3H), 6,90 (s, 3H), 4,03 (d, J = 2,0, 2H), 3,74 (m, 2H), 2,98 (dt, J = 11,4, 5,6, 1H), 2,42 (ddd, J = 29,2, 13,0, 3,8, 4H), 2,18 (m, 1H), 2,03 (d, J = 14,1, 1H), 1,81 (ddd, J = 13,9, 9,4, 4,5, 2H), 1,55 (m, 5H), 1,20 (ddd, J = 9,9, 6,9, 2,4, 1H), 0,80 (dt, J = 12,9, 8,8, 1H).
- 244
- [(3-bromofenil)metil]({2-[(9R)-9-(piridin-2-il) -6-oxaspiro[4.5]decan-9-il]etil})amina 431 δ 8,75 (dd, J = 5,4, 1,2, 1H), 8,41 (s, 1H), 8,25 (td, J = 8,0, 1,8, 1H), 7,79 (d, J = 8,2, 1H), 7,70 (ddd, J = 7,6, 5,5, 0,9, 1H), 7,59 (m, 2H), 7,36 (ddd, J = 22,8, 10,9, 4,6, 2H), 6,76 (s, 3H), 4,01 (d, J = 2,3, 2H), 3,74 (ddd, J = 12,3,11,0, 5,4, 2H), 2,97 (d, J = 5,0, 1H), 2,38 (m, 4H), 2,16 (m, 1H), 2,00 (m, 1H), 1,79 (ddd, J = 8,6, 7,8, 4,7, 2H), 1,53 (m, 5H), 1,20 (m, 1H), 0,80 (m, 1H).
- 245
- [(3-clorofenil)metil]({2-[(9R)-9-(piridin-2-il)6-oxaspiro[4.5]decan-9-il]etil})amina 385 δ 8,72 (dd, J = 5,4, 1,1, 1H), 8,57 (s, 1H), 8,19 (td, J = 8,0, 1,8, 1H), 7,74 (d, J = 8,2, 1H), 7,64 (ddd, J = 7,6, 5,4, 0,9, 1H), 7,37 (m, 5H), 3,99 (d, J = 2,3, 2H), 3,70 (m, 2H), 2,95 (m, 1H), 2,36 (m, 4H), 2,12 (td, J = 12,9, 5,1, 1H), 1,76 (ddd, J = 14,2, 9,3, 5,1, 2H), 1,50 (m, 5H), 0,77 (dt, J = 13,0, 8,9, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 246
- [(3-metilfenil)metil]({2-[(9R)-9-(piridin-2-il)-6 -oxaspiro[4.5]decan-9-il]etil})amina 365 δ 8,81 (dd, J = 5,7, 1,3, 1H), 8,43 (td, J = 8,0, 1,7, 1H), 7,98 (s, 1H), 7,92 (d, J = 8,2, 1H), 7,86 (ddd, J = 7,6, 5,7, 1,0, 1H), 7,24 (dq, J = 19,8, 7,4, 4H), 3,98 (s, 2H), 3,75 (m, 2H), 2,98 (d, J = 4,4, 1H), 2,44 (m, 2H), 2,36 (m, 5H), 2,25 (dd, J = 13,5, 5,4, 1H), 2,07 (d, J = 14,3, 1H), 1,84 (m, 2H), 1,55 (m, 5H), 1,23 (m, 1H), 0,83 (dt, J = 13,0, 8,8, 1H).
- 247
- 3-[({2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]d ecan-9-il]etil}amino)metil]benzoato de metilo 409,1 δ 8,78 (dd, J = 5,5, 1,3, 1H), 8,33 (td, J = 8,0,1,7, 1H), 8,24 (s, 1H), 8,04 (m, 2H), 7,85 (d, J = 8,2, 1H), 7,78 (m, 1H), 7,63 (m, 2H), 7,55 (d, J = 7,7, 1H), 4,10 (d, J = 2,0, 2H), 3,90 (s, 3H), 3,75 (ddd, J = 12,2, 11,0, 5,4, 2H), 3,00 (dd, J = 11,5, 7,1, 1H), 2,40 (m, 4H), 2,21 (m, 1H), 2,04 (d, J = 14,2, 1H), 1,83 (ddd, J = 13,9, 9,2, 4,3, 2H), 1,51 (dddd, J = 17,6, 10,1, 8,1, 3,0, 5H), 1,21 (s, 1H), 0,82 (dd, J = 15,6, 6,6, 1H).
- 248
- 3-[({2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]d ecan-9-il]etil}amino)metil]fenol 367 δ 8,77 (dd, J = 5,5, 1,2, 1H), 8,30 (td, J = 8,0, 1,7, 1H), 7,81 (s, 1H), 7,75 (ddd, J = 7,6, 5,5, 1,0, 1H), 7,23 (t, J = 8,1, 1H), 6,85 (dt, J = 3,2, 2,1, 3H), 6,65 (s, 3H), 3,96 (s, 2H), 3,73 (dd, J = 13,8, 7,3, 2H), 2,96 (s, 1H), 2,36 (m, 4H), 2,15 (ddd, J = 9,9, 8,5, 4,7, 1H), 2,03 (d, J = 14,2, 1H), 1,80 (dt, J = 11,2, 4,8, 2H), 1,52 (ddd, J = 21,7, 12,8, 7,4, 5H), 1,20 (m, 1H), 0,80 (d, J = 13,3, 1H).
- 249
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]deca n-9-il]etil}({[3-(trifluorometil)fenil]metil})ami na 419,1 δ 8,66 (m, 1H), 8,07 (td, J = 7,9, 1,8, 1H), 7,72 (m, 2H), 7,65 (m, 2H), 7,54 (m, 2H), 6,22 (s, 2H), 4,08 (d, J = 3,1, 2H), 3,71 (m, 2H), 2,97 (d, J = 5,0, 1H), 2,34 (dddd, J = 25,4, 19,6, 16,7, 4,4, 4H), 2,09 (m, 1H), 1,74 (m, 2H), 1,49 (m, 5H), 0,76 (m, 1H).
- 250
- N-metil-5-[({2-[(9R)-9-(piridin-2-il)-6-oxaspi ro[4.5]decan-9-il]etil}amino)metil]tiofeno-2carboxamida 414,1 δ 8,78 (dd, J = 5,6, 1,3, 1H), 8,36 (td, J = 8,0, 1,7, 1H), 7,86 (d, J = 8,2, 1H), 7,79 (ddd, J = 7,6, 5,6, 1,0, 1H), 7,38 (d, J = 3,8, 1H), 7,14 (d, J = 3,8, 1H), 7,06 (d, J = 3,9, 1H), 4,21 (s, 2H), 3,72 (m, 2H), 2,97 (td, J = 12,0, 5,1, 1H), 2,84 (d, J = 4,7, 3H), 2,34 (m, 4H), 2,16 (m, 1H), 2,03 (d, J = 14,2, 1H), 1,80 (dd, J = 12,2, 3,0, 2H), 1,50 (m, 5H), 1,20 (m, 1H), 0,82 (s, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 251
- N-etil-5-[({2-[(9R)-9-(piridin-2-il)-6-oxaspiro [4.5]decan-9-il]etil}amino)metil]tiofeno-2-ca rboxamida 428,1 δ 8,78 (dd, J = 5,6, 1,2, 1H), 8,35 (td, J = 8,0, 1,7, 1H), 7,86 (d, J = 8,2, 1H), 7,79 (ddd, J = 7,6, 5,6, 0,9, 1H), 7,40 (d, J = 3,8, 1H), 7,14 (t, J = 10,7, 2H), 6,20 (s, 4H), 4,21 (d, J = 1,2, 2H), 3,72 (m, 2H), 3,34 (m, 2H), 2,97 (m, 1H), 2,39 (m, 4H), 2,18 (m, 1H), 2,03 (d, J = 14,2, 1H), 1,81 (m, 2H), 1,52 (m, 5H), 1,19 (m, 4H), 0,80 (m, 1H).
- 252
- N-metil-3-[({2-[(9R)-9-(piridin-2-il)-6-oxaspi ro[4.5]decan-9-il]etil}amino)metil]benzamid a 408,1 δ 8,75 (dd, J = 5,4, 1,2, 1H), 8,24 (td, J = 8,0, 1,7, 1H), 7,89 (s, 1H), 7,77 (m, 2H), 7,69 (ddd, J = 7,6, 5,5, 0,9, 1H), 7,49 (ddd, J = 18,3, 10,6, 4,6, 2H), 7,33 (s, 1H), 4,07 (s, 2H), 3,73 (m, 2H), 2,98 (m, 1H), 2,88 (d, J = 4,6, 3H), 2,47 (t, J = 10,7, 1H), 2,36 (dd, J = 12,8, 7,5, 3H), 2,16 (d, J = 4,8, 1H), 1,79 (m, 2H), 1,50 (ddd, J = 18,7, 13,3, 6,9, 5H), 1,19 (ddd, J = 8,3, 7,0, 1,8, 1H), 0,80 (d, J = 13,3, 1H).
- 253
- N-etil-3-[({2-[(9R)-9-(piridin-2-il)-6-oxaspiro [4.5]decan-9-il]etil}amino)metil]benzamida 422,1 δ 8,70 (dd, J = 5,3, 1,2, 1H), 8,43 (s, 1H), 8,14 (td, J = 7,9, 1,8, 1H), 7,89 (d, J = 1,4, 1H), 7,76 (dt, J = 7,3, 1,6, 1H), 7,71 (d, J = 8,2, 1H), 7,59 (ddd, J = 7,6, 5,3, 0,9, 1H), 7,46 (m, 2H), 7,37 (s, 1H), 6,55 (s, 3H), 4,05 (s, 2H), 3,70 (m, 2H), 3,36 (qd, J = 7,2, 5,7, 2H), 2,96 (d, J = 7,9, 1H), 2,45 (t, J = 10,2, 1H), 2,32 (dd, J = 21,2, 8,7, 3H), 2,11 (d, J = 5,2, 1H), 1,77 (m, 2H), 1,47 (m, 5H), 1,19 (m, 4H), 0,76 (d, J = 13,3, 1H).
- 254
- [(4-metoxifenil)metil]({2-[(9R)-9-(piridin-2-il) -6-oxaspiro[4.5]decan-9-il]etil})amina 381,1 δ 9,09 (d, J = 86,1, 2H), 8,69 (d, J = 5,0, 1H), 8,29 (t, J = 7,7, 1H), 8,06 (s, 3H), 7,75 (m, 2H), 7,20 (d, J = 8,6, 2H), 6,81 (d, J = 8,6, 2H), 3,89 (s, 2H), 3,79 (m, 4H), 3,66 (m, 1H), 2,96 (s, 1H), 2,43 (dd, J = 23,4, 11,5, 2H), 2,27 (t, J = 16,0, 3H), 2,01 (d, J = 14,2, 1H), 1,83 (dd, J = 19,3, 9,5, 2H), 1,66 (m, 1H), 1,47 (m, 4H), 1,14 (d, J = 7,0, 1H), 0,75 (m, 1H).
- 255
- 4-[({2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]d ecan-9-il]etil}amino)metil]fenol 367 δ 8,76 (dd, J = 5,5, 1,2, 1H), 8,26 (m, 1H), 7,80 (d, J = 8,2, 1H), 7,72 (ddd, J = 7,6, 5,5, 0,9,1H), 7,65 (s, 1H), 7,22 (m, 2H), 6,82 (m, 2H), 3,93 (s, 2H), 3,73 (dd, J = 10,7, 7,6, 2H), 2,94 (dd, J = 11,1, 5,9, 1H), 2,36 (m, 4H), 2,13 (m, 1H), 2,01 (m, 1H), 1,80 (d, J = 3,6, 2H), 1,51 (dd, J = 9,7, 5,6, 5H), 1,19 (m, 1H), 0,81 (s, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 256
- [(2,3-difluorofenil)metil]({2-[(9R)-9-(piridin-2 -il)-6-oxaspiro[4.5]decan-9-il]etil})amina 387 δ 8,75 (dd, J = 5,4, 1,3, 1H), 8,26 (td, J = 8,0, 1,7, 1H), 7,80 (d, J = 8,2, 1H), 7,71 (ddd, J = 7,5, 5,5,. 0,9, 1H), 7,34 (dtd, J = 10,0, 7,9, 1,9, 1H), 7,21 (m, 4H), 4,11 (s, 2H), 3,72 (m, 2H), 3,02 (td, J = 12,0, 5,1, 1H), 2,49 (td, J = 12,1, 4,3, 1H), 2,35 (m, 3H), 2,16 (m, 1H), 2,01 (d, J = 14,1, 1H), 1,79 (ddd, J = 11,2, 9,4, 4,1, 2H), 1,52 (m, 5H), 1,17 (m, 1H), 0,78 (dt, J = 12,9, 8,8, 1H).
- 257
- [(2,4-difluorofenil)metil]({2-[(9R)-9-(piridin-2 -il)-6-oxaspiro[4.5]decan-9-il]etil})amina 387 δ 8,79 (dd, J = 5,5, 1,3, 1H), 8,38 (s, 1H), 8,32 (m, 1H), 7,84 (d, J = 8,2, 1H), 7,76 (ddd, J = 7,6, 5,5, 0,9, 1H), 7,50 (dd, J = 14,8, 8,3, 1H), 7,03 (m, 2H), 4,08 (s, 2H), 3,74 (m, 2H), 3,02 (td, J = 12,0, 5,0, 1H), 2,42 (m, 4H), 2,18 (m, 1H), 2,03 (d, J = 14,2, 1H), 1,82 (ddd, J = 14,2, 9,6, 4,5, 2H), 1,56 (m, 5H), 1,19 (ddd, J = 7,0, 6,2, 2,8, 1H), 0,80 (dt, J = 12,9, 8,8, 1H).
- 258
- [(2,5-difluorofenil)metil]({2-[(9R)-9-(piridin-2 -il)-6-oxaspiro[4.5]decan-9-il]etil})amina 387 δ 8,74 (dd, J = 5,4, 1,2, 1H), 8,26 (td, J = 8,0,1,7, 1H), 7,72 (m, 2H), 7,21 (dddd, J = 8,4, 7,0, 4,8, 1,8, 3H), 6,45 (s, 3H), 4,07 (s, 2H), 3,73 (ddd, J = 12,2, 11,1, 5,5, 2H), 3,02 (d, J = 5,2, 1H), 2,49 (d, J = 4,3, 1H), 2,36 (dt, J = 11,8, 4,5, 3H), 2,18 (dd, J = 12,3, 5,2, 1H), 2,00 (m, 1H), 1,79 (ddd, J = 13,9, 9,3, 4,4, 2H), 1,49 (m, 5H), 1,18 (m, 1H), 0,78 (d, J = 13,3, 1H).
- 259
- [(2,6-difluorofenil)metil]({2-[(9R)-9-(piridin-2 -il)-6-oxaspiro[4.5]decan-9-il]etil})amina 387,1 δ 8,79 (dd, J = 5,6, 1,3, 1H), 8,36 (m, 1H), 8,20 (s, 4H), 7,86 (d, J = 8,2, 1H), 7,79 (ddd, J = 7,6, 5,6, 1,0, 1H), 7,50 (tt, J = 8,5, 6,6, 1H), 7,04 (m, 2H), 4,13 (s, 2H), 3,72 (m, 2H), 3,05 (td, J = 12,0, 5,1, 1H), 2,52 (td, J = 12,1, 4,2, 1H), 2,37 (m, 3H), 2,19 (m, 1H), 2,04 (d, J = 14,2, 1H), 1,81 (m, 2H), 1,53 (m, 5H), 1,18 (m, 1H), 0,79 (dt, J = 12,8, 8,8, 1H).
- 260
- [(3,4-difluorofenil)metil]({2-[(9R)-9-(piridin-2 -il)-6-oxaspiro[4.5]decan-9-il]etil})amina 387,1 δ 8,84 (s, 1H), 8,79 (dd, J = 5,6, 1,3, 1H), 8,41 (td, J = 8,0, 1,6, 1H), 8,25 (s, 1H), 7,86 (ddd, J = 13,3, 7,6, 7,0, 2H), 7,30 (m, 3H), 3,99 (d, J = 1,7, 2H), 3,73 (m, 2H), 2,96 (dd, J = 12,1, 7,4, 1H), 2,38 (m, 4H), 2,21 (m, 1H), 2,05 (d, J = 14,2, 1H), 1,82 (ddd, J = 12,6, 9,0, 4,2, 2H), 1,53 (m, 5H), 1,21 (m, 1H), 0,81 (dt, J = 12,9, 8,8, 1H).
- 261
- [(3,5-difluorofenil)metil]({2-[(9R)-9-(piridin-2 -il)-6-oxaspiro[4.5]decan-9-il]etil})amina 387 δ 8,77 (d, J = 5,4, 1H), 8,43 (s, 1H), 8,35 (d, J = 7,7, 1H), 7,83 (m, 2H), 7,03 (m, 3H), 4,01 (s, 2H), 3,74 (ddd, J = 27,7, 13,8, 7,4, 2H), 2,96 (m, 1H), 2,39 (m, 4H), 2,23 (dd, J = 13,3, 5,1, 1H), 2,02 (m, 1H), 1,81 (m, 2H), 1,52 (m, 5H), 1,21 (dd, J = 9,4, 5,3, 1H), 0,80 (dt, J = 12,9, 8,9, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 262
- [(2,3-dimetoxifenil)metil]({2-[(9R)-9-(piridin2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 411,1 δ 8,75 (dd, J = 5,4,1,2, 1H), 8,21 (td, J = 8,0,1,8, 1H), 7,88 (s, 2H), 7,75 (d, J = 8,2, 1H), 7,66 (ddd, J = 7,6, 5,4, 0,9, 1H), 7,08 (dd, J = 9,0, 5,6, 2H), 6,87 (dd, J = 6,2, 3,0, 1H), 4,05 (s, 2H), 3,86 (d, J = 6,3, 6H), 3,73 (ddd, J = 12,5, 11,1, 5,4, 2H), 2,97 (s, 1H), 2,45 (s, 1H), 2,35 (m, 3H), 2,14 (m, 1H), 1,78 (ddd, J = 14,2, 6,0, 3,9, 2H), 1,49 (m, 5H), 1,16 (m, 1H), 0,77 (d, J = 13,3, 1H).
- 263
- [(3,4-dimetoxifenil)metil]({2-[(9R)-9-(piridin2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 411,1 δ 8,73 (dd, J = 5,5, 1,2, 1H), 8,24 (td, J = 8,0, 1,7, 1H), 8,00 (s, 1H), 7,78 (d, J = 8,2, 1H), 7,69 (ddd, J = 7,5, 5,5, 0,8, 1H), 6,96 (d, J = 1,0, 1H), 6,88 (d, J = 1,7, 2H), 6,55 (s, 3H), 3,93 (s, 2H), 3,78 (t, J = 7,5, 6H), 3,72 (m, 2H), 2,92 (s, 1H), 2,35 (m, 4H), 2,15 (m, 1H), 1,99 (d, J = 14,2, 1H), 1,79 (m, 2H), 1,49 (m, 5H), 1,18 (s, 1H), 0,79 (dd, J = 15,6, 6,6, 1H).
- 264
- 2-metoxi-4-[({2-[(9R)-9-(piridin-2-il)-6-oxas piro[4.5]decan-9-il]etil}amino)metil]fenol 397,1 δ 8,62 (dd, J = 5,0, 1,0, 1H), 7,94 (td, J = 7,9, 1,8, 1H), 7,57 (d, J = 8,1, 1H), 7,42 (m, 1H), 7,00 (s, 1H), 6,81 (d, J = 0,8, 2H), 3,93 (s, 2H), 3,84 (s, 3H), 3,70 (m, 3H), 2,93 (s, 1H), 2,36 (s, 3H), 2,17 (m, 1H), 1,90 (d, J = 13,7, 1H), 1,74 (m, 2H), 1,51 (s, 5H), 1,13 (m, 1H), 0,73 (dt, J = 13,2, 8,9, 1H).
- 265
- [(5-fluoropiridin-3-il)metil]({2-[(9R)-9-(piridin -2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 370 δ 8,82 (s, 1H), 8,50 (dd, J = 34,5, 26,7, 3H), 7,93 (m, 2H), 7,74 (t, J = 9,7, 1H), 4,12 (d, J = 10,8, 2H), 3,76 (dd, J = 25,7, 11,8, 2H), 3,03 (d, J = 7,9, 1H), 2,39 (m, 5H), 2,09 (t, J = 13,0, 1H), 1,85 (d, J = 9,0, 2H), 1,60 (d, J = 44,8, 5H), 1,24 (s, 1H), 0,86 (d, J 9,1, 1H).
- 266
- [(5-bromopiridin-3-y)metil]({2-[(9R)-9-(piridi n-2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 430 δ 8,64 (m, 5H), 8,16 (s, 1H), 8,00 (d, J = 8,2, 1H), 7,95 (m, 1H), 4,10 (m, 2H), 3,76 (m, 2H), 3,02 (td, J = 12,4, 5,0, 1H), 2,49 (m, 2H), 2,29 (m, 3H), 2,12 (t, J = 10,2, 1H), 1,88 (ddd, J = 25,8, 12,8, 8,1, 2H), 1,57 (m, 5H), 1,26 (m, 1H), 0,86 (dt, J = 12,9, 8,9, 1H).
- 267
- [(5-cloropiridin-3-il)metil]({2-[(9R)-9-(piridin2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 386 δ 8,80 (s, 1H), 8,63 (s, 1H), 8,49 (dd, J = 17,4, 10,6, 3H), 7,93 (m, 3H), 4,08 (s, 2H), 3,75 (dd, J = 29,6, 6,9, 2H), 2,99 (d, J = 11,6, 1H), 2,45 (m, 2H), 2,28 (m, 3H), 2,08 (d, J = 14,3, 1H), 1,85 (d, J = 7,5, 2H), 1,60 (m, 5H), 1,23 (s, 1H), 0,84 (d, J = 5,6,1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 268
- [(5-metoxipiridin-3-il)metil]({2-[(9R)-9-(piridi n-2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 382,1 δ 8,81 (d, J = 5,5, 1H), 8,48 (m, 3H), 7,95 (m, 3H), 4,22 (d, J = 13,4, 2H), 3,98 (s, 3H), 3,75 (ddd, J = 19,2, 12,7, 9,3, 2H), 3,04 (td, J = 11,6, 4,8, 1H), 2,42 (m, 7H), 2,09 (d, J = 14,3, 1H), 1,88 (m, 2H), 1,57 (m, 6H), 1,26 (d, J = 10,9, 1H), 0,85 (dt, J = 12,4, 8,7, 1H).
- 269
- 5-[({2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]d ecan-9-il]etil}amino)metil]piridina-3-carboni trilo 377,1 δ 8,96 (d, J = 15,0, 1H), 8,83 (t, J = 10,5, 2H), 8,53 (dt, J = 15,9, 8,0, 2H), 8,23 (d, J = 15,0, 1H), 7,97 (ddd, J = 13,4, 11,9, 7,5, 2H), 4,13 (m, 2H), 3,77 (m, 2H), 3,02 (m, 1H), 2,50 (ddd, J = 26,3, 14,4, 3,7, 2H), 2,31 (m, 3H), 2,13 (dd, J = 19,3, 11,3, 1H), 1,88 (ddd, J = 17,2, 11,0, 7,0, 2H), 1,58 (m, 5H), 1,27 (m, 1H), 0,85 (dt, J = 12,8, 8,7, 1H).
- 270
- [(5-metilpiridin-3-il)metil]({2-[(9R)-9-(piridin2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina 366 δ 8,71 (dd, J = 50,6, 19,3, 3H), 8,37 (m, 2H), 7,85 (m, 2H), 4,20 (d, J = 13,3, 2H), 3,74 (ddd, J = 11,9, 11,1, 5,6, 2H), 3,02 (m, 1H), 2,44 (m, 7H), 2,25 (dd, J = 12,5, 5,0, 1H), 1,84 (m, 2H), 1,57 (tdd, J = 24,6, 15,7, 8,5, 5H), 1,22 (d, J = 9,3, 1H), 0,83 (m, 1H).
- 271
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]deca n-9-il]etil}({[5-(trifluorometil)piridin-3-il]metil })amina 420,1 δ 8,96 (s, 1H), 8,81 (m, 2H), 8,45 (td, J = 8,1, 1,6, 2H), 8,21 (s, 1H), 7,90 (m, 2H), 4,16 (m, 2H), 3,77 (dtd, J = 12,7, 9,5, 5,3, 2H), 3,04 (td, J = 12,2, 5,1, 1H), 2,50 (m, 2H), 2,31 (ddd, J = 21,7, 14,1, 7,0, 3H), 2,12 (d, J = 12,6, 1H), 1,87 (ddd, J = 20,7, 12,7, 7,7, 2H), 1,58 (m, 5H), 1,26 (m, 1H), 0,85 (m, 1H).
- 272
- {[6-cloro-5-(trifluorometil)piri din-3-il]metil}({2-[(9R)-9-(piridin-2-il)-6-oxas piro[4.5]decan-9-il]etil})amina 454,1 δ 8,70(m, 1H), 8,60 (d, J = 2,1, 1H), 8,28 (d, J = 2,2, 1H), 8,16 (td, J = 7,9, 1,8, 1H), 7,73 (d, J = 8,2, 1H), 7,62 (ddd, J = 7,6, 5,3, 1,0, 1H), 4,12 (m, 2H), 3,73 (m, 2H), 3,18 (brs, 1H), 2,99 (td, J = 12,0, 5,1, 2H), 2,49 (td, J = 12,0, 4,4, 1H), 2,35 (dd, J = 14,1, 1,9, 3H), 2,13 (ddd, J = 14,2, 12,1, 5,2, 1H), 1,79 (dd, J = 5,6, 3,7, 2H), 1,62 (dd, J = 7,8, 2,8, 1H), 1,51 (dd, J = 7,9, 4,1, 4H), 1,18 (m, 1H), 0,78 (dt, J = 13,2, 8,9, 1H).
- 273
- {[2-fluoro-5-(trifluorometil)piri din-3-il]metil}({2-[(9R)-9-(piridin-2-il)-6-oxas piro[4.5]decan-9-il]etil})amina 438,1 δ 8,73 (dd, J = 5,3, 1,2, 1H), 8,62 (s, 1H), 8,35 (dd, J = 8,5, 2,3, 1H), 8,22 (td, J = 8,0, 1,6, 1H), 7,78 (d, J = 8,2, 1H), 7,67 (dd, J = 6,9, 5,8, 1H), 4,25 (brs, 1H), 4,13 (m, 2H), 3,74 (ddd, J = 12,3, 11,0, 5,5, 2H), 3,05 (td, J = 11,9, 5,1, 1H), 2,54 (td, J = 12,0, 4,4, 1H), 2,35 (dt, J = 9,7, 5,3, 3H), 2,16 (ddd, J = 9,9, 8,8, 3,8,1H), 2,01 (d, J = 14,1, 1H), 1,80 (m, 2H), 1,62 (m, 1H), 1,49 (m, 4H), 1,19 (m, 1H), 0,79 (dt, J = 13,1, 8,8, 1H).
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 274
- {[6-fluoro-5-(trifluorometil)piri din-3-il]metil}({2-[(9R)-9-(piridin-2-il)-6-oxas piro[4.5]decan-9-il]etil})amina 438,1 δ 8,58 (d, J = 4,0, 1H), 8,45 (s, 1H), 8,35 (d, J = 9,0, 1H), 7,85 (m, 1H), 7,51 (d, J = 8,1, 1H), 7,33 (dd, J = 7,4, 4,9, 1H), 4,12 (m, 2H), 3,70 (dd, J =8,8, 2,9, 2H), 2,98 (m, 2H), 2,47 (dd, J = 12,1, 7,4, 2H), 2,38 (t, J = 11,7, 2H), 2,18 (dd, J = 12,9, 4,8, 1H), 1,90 (d, J = 13,7, 1H), 1,70 (m, 2H), 1,60 (m, 1H), 1,50 (dt, J = 39,4, 20,7, 4H), 1,11 (m, 1H), 0,73 (dt, J = 13,5, 9,1, 1H).
- 275
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]deca n-9-il]etil}({[3-(trifluorometil)piridin-2-il]metil })amina 420,1 δ 9,29 (brs, 1H), 8,90 (s, 1H), 8,86 (d, J = 5,1, 1H), 8,80 (dd, J = 5,7, 1,2, 1H), 8,49 (td, J = 8,0, 1,7, 1H), 7,98 (d, J = 8,2, 1H), 7,91 (ddd, J = 7,6, 5,7, 1,0, 1H), 7,74 (d, J = 5,1, 1H), 4,27 (m, 2H), 3,81 (dt, J = 12,8, 4,6, 1H), 3,72 (m, 1H), 3,13 (td, J = 12,1, 5,1, 1H), 2,60 (td, J = 12,3, 4,1, 1H), 2,49 (m, 1H), 2,33 (m, 3H), 2,10 (d, J = 14,3, 1H), 1,85 (m, 2H), 1,65 (m, 1H), 1,52 (m, 4H), 1,25 (m, 1H), 0,84 (dt, J = 12,8, 8,8, 1H).
- 276
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]deca n-9-il]etil}({[4-(trifluorometil)piridin-3-il]metil })amina 420,1 δ 8,81 (dd, J = 5,5, 1,2, 1H), 8,75 (d, J = 4,4, 1H), 8,32 (td, J = 8,0, 1,7, 1H), 8,16 (dd, J = 8,0, 0,7, 1H), 7,86 (d, J = 8,2,1H), 7,77 (odd, J = 7,6, 5,5, 1,0, 1H), 7,59 (dd, J = 7,5, 5,0, 1H), 4,40 (m, 2H), 3,75 (m, 2H), 3,13 (td, J = 12,0, 5,3,1H), 2,66 (td, J = 12,1, 4,5, 1H), 2,49 (ddd, J = 13,7, 11,9, 4,5, 1H), 2,41 (m, 1H), 2,32 (m, 2H), 2,07 (d, J = 14,0, 1H), 1,85 (ddd, J = 9,3, 7,7, 4,5, 2H), 1,64 (m, 1H), 1,51 (m, 4H), 1,22 (m, 1H), 0,82 (dt, J = 13,1, 8,9, 1H).
- 277
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]deca n-9-il]etil}({[4-(trifluorometil)piridin-2-il]metil })amina 420,1 δ 8,80 (dd, J = 5,5, 1,3, 1H), 8,75 (d, J = 5,0, 1H), 8,31 (td, J = 8,0, 1,7, 1H), 7,84 (d, J = 8,2, 1H), 7,75 (ddd, J = 7,6, 5,5, 0,9, 1H), 7,65 (M, 2H), 4,31 (m, 2H), 3,74 (m, 2H), 3,09 (td, J = 12,0, 5,2, 1H), 2,60 (td, J = 12,1, 4,4, 1H), 2,36 (m, 4H), 2,05 (d, J = 14,1, 1H), 1,82 (m, 2H), 1,64 (m, 1H), 1,50 (m, 4H), 1,20 (m, 1H), 0,81 (dt, J = 12,8, 8,8, 1H).
- 500
- [(4-clorofenil)metil]({2-[4-(4-metoxifenil)-2,2 -dimetiloxan-4-il]etil})amina
- 501
- [(3,4-dimetoxifenil)metil][2-(2,2-dimetil-4-fe niloxan-4-il)etil]amina
- 502
- 2-[({2-[2-etil-2-metil-4-(4metilfenil)oxan-4-il]etil}amino)metil]fenol
- 503
- [2-(2,2-dimetil-4-feniloxan-4-il)etil][(2-fluoro fenil)metil]amina
- Tabla 1: Compuestos con nombre químico y datos de caracterización
- Compuesto.
- Nombre MS (m/z) [M+H]+ 1H NMR
- 504
- 4-[({2-[4-(2-metoxifenil)-2,2-dimetiloxan-4-il ]etil}amino)metil] -N,N-dimetilanilina
- 505
- 2-[({2-[2-etil-4-(4-fluorofenil)-2-metiloxan-4il]etil}amino)metil]fenol
Ejemplo 13: Ligandos de receptores de opioides
Los siguientes compuestos en la Tabla 2 también pueden prepararse de acuerdo con los procedimientos descritos anteriormente a partir de materiales de partida apropiados y reactivos apropiados y se espera que tengan propiedades y efectos terapéuticos similares a los otros compuestos descritos en la presente. Además de la estructura específica mostrada, los otros isómeros o enantiómeros se incluyen con la descripción en la presente. Los compuestos que se han preparado incluyen datos de NMR, mientras que los ejemplos teóricos no incluyen datos de NMR.
Tabla 2: Ejemplos con nombre químico y/o datos de caracterización
- Compuesto
- Nombre Estructura y/o Espectro de NMR
- 506.
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5] decan-9-il]etil}(pirimidin-5-ilmetil)amin a MS: 353,2 1H NMR (400 MHz, CD3CN) δ 9,16 (s, 1H), 8,78 (s, 2H), 8,70 (dd, J = 5,3, 1,1, 1H), 8,16 (td, J = 8,0, 1,8, 1H), 7,74 (d, J = 8,2, 1H), 7,62 (ddd, J = 7,6, 5,4, 0,9, 1H), 4,27 (brs, 1H), 4,04 (t, J = 7,7, 2H), 3,73 (m, 2H), 3,01 (td, J = 12,0, 5,1, 1H), 2,50 (td, J = 12,0, 4,4, 1H), 2,33 (m, 3H), 2,12 (ddd, J = 19,0, 11,7, 5,2, 1H), 1,99 (d, J = 10,1, 1H), 1,78 (m, 2H), 1,61 (m, 1H), 1,48 (m, 4H), 1,17 (m, 1H), 0,78 (dt, J = 13,1, 8,9, 1H).
- 507.
-
[(2-metilpirimidin-5-il)metil]({2-[(9R)-9(piridin-2-il)-6-oxaspiro[4.5]decan-9-il] etil})amina
imagen44
- 508.
-
{2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5] decan-9-il]etil}({[2-(trifluorometil)pirimi din-5-il]metil})amina
imagen45
- Compuesto
- Nombre Estructura y/o Espectro de NMR
- 509.
- [(2-metoxipirimidin-5-il)metil]({2-[(9R)9-(piridin-2-il)-6-oxaspiro[4.5]decan-9il]etil})amina MS: 383,3 1H NMR (400 MHz, CD3CN) δ 8,69 (dd, J = 5,2, 1,1, 1H), 8,54 (s, 2H), 8,10 (td, J = 7,9, 1,7, 1H), 7,69 (d, J = 8,1, 1H), 7,56 (dd, J = 6,7, 5,3, 1H), 3,98 (s, 5H), 3,71 (m, 3H), 3,50 (brs, 1H), 2,98 (td, J = 12,0, 5,0, 1H), 2,47 (td, J = 12,0, 4,3, 1H), 2,37 (m, 2H), 2,27 (m, 1H), 2,10 (m, 1H), 1,77 (m, 2H), 1,62 (m, 1H), 1,47 (dddd, J = 14,1, 12,4, 8,4, 4,9, 4H), 1,17 (m, 1H), 0,77 (dt, J = 13,1, 8,9, 1H).
- 510.
-
(piridazin-4-ilmetil)({2-[(9R)-9-(piridin2-il)-6-oxaspiro[4.5]decan-9-il]etil})ami na
imagen46
- 511.
-
[(6-metilpiridazin-4-il)metil]({2-[(9R)-9(piridin-2-il)-6-oxaspiro[4.5]decan-9-il] etil})amina
imagen47
- 512.
-
{2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5] decan-9-il]etil}({[6-(trifluorometil)pirida zin-4-il]metil})amina
imagen48
- 513.
-
[(6-metoxipiridazin-4-il)metil]({2-[(9R)9-(piridin-2-il)-6-oxaspiro[4.5]decan-9il]etil})amina
imagen49
- Compuesto
- Nombre Estructura y/o Espectro de NMR
- 514.
- (pirazin-2-ilmetil)({2-[(9R)-9-(piridin-2-i l)-6-oxaspiro[4.5]decan-9-il]etil})amina MS: 353,3 1H NMR (400 MHz, CD3CN) δ 8,74 (dd, J = 5,3, 1,1, 1H), 8,60 (d, J = 1,6, 2H), 8,55 (m, 1H), 8,16 (td, J = 7,9, 1,7, 1H), 7,73 (d, J = 8,2, 1H), 7,61 (ddd, J = 7,5, 5,3, 0,8, 1H), 7,13 (brs, 1H), 4,25 (m, 2H), 3,73 (m, 2H), 3,09 (td, J = 11,8, 5,4, 1H), 2,61 (td, J = 11,9, 4,6, 1H), 2,37 (m, 3H), 2,18 (ddd, J = 13,7, 11,6, 5,5, 1H), 1,99 (m, 1H), 1,77 (dd, J = 9,6, 4,4, 2H), 1,62 (m, 1H), 1,48 (m, 4H), 1,18 (m, 1H), 0,79 (dt, J = 13,1, 8,9, 1H).
- 515.
-
[(6-metilpirazin-2-il)metil]({2-[(9R)-9-(p iridin-2-il)-6-oxaspiro[4.5]decan-9-il]eti l})amina
imagen50
- 516.
-
{2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5] decan-9-il]etil}({[6-(trifluorometil)pirazi n-2-il]metil})amina
imagen51
- 517.
-
[(6-metoxipirazin-2-il)metil]({2-[(9R)-9(piridin-2-il)-6-oxaspiro[4.5]decan-9-il] etil})amina
imagen52
- 518.
-
[(5-metilpirazin-2-il)metil]({2-[(9R)-9-(p iridin-2-il)-6-oxaspiro[4.5]decan-9-il]eti l})amina
imagen53
- 519.
-
{2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5] decan-9-il]etil}({[5-(trifluorometil)pirazi n-2-il]metil})amina
imagen54
- 520.
- [(5-metoxipirazin-2-il)metil]({2-[(9R)-9(piridin-2-il)-6-oxaspiro[4.5]decan-9-il]
- Compuesto
- Nombre Estructura y/o Espectro de NMR
- etil})amina
-
imagen55
- 521.
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5] MS: 402,3
- decan-9-il]etil}(quinolin-3-ilmetil)amin a
- 1H NMR (400 MHz, CD3CN) δ 9,90 (brs, 1H), 9,15 (d, J = 1,7,
- 1H), 8,89 (s, 1H), 8,77 (dd, J = 5,6, 1,3, 1H), 8,40 (td, J = 8,0,
- 1,6, 1H), 8,30 (d, J = 8,6, 1H), 8,16 (d, J = 8,2, 1H), 8,08 (ddd,
- J = 8,5, 7,0, 1,3, 1H), 7,90 (m, 2H), 7,81 (m, 1H), 4,36 (m, 2H),
- 3,74 (m, 2H), 3,06 (td, J = 12,0, 5,1, 1H), 2,57 (td, J = 12,2,
- 4,1, 1H), 2,45 (m, 1H), 2,29 (m, 3H), 2,08 (m, 1H), 1,98 (d, J =
- 2,5, 1H), 1,83 (m, 2H), 1,64 (ddd, J = 11,6, 8,7, 3,4, 1H), 1,50
- (m, 4H), 1,23 (ddd, J = 10,4, 4,4, 2,4, 1H), 0,82 (dt, J = 12,9,
- 8,8, 1H).
- 522.
- (1H-pirazol-3-ilmetil)({2-[(9R)-9-(piridi n-2-il)-6-oxaspiro[4.5]decan-9-il]etil})a MS: 341,2
- mina
- 1H NMR (400 MHz, CD3CN) δ 8,76 (dd, J = 5,5, 1,2, 1H), 8,28
- (td, J = 8,0, 1,7, 1H), 7,80 (d, J = 8,2, 1H), 7,73 (ddd, J = 7,6,
- 5,5, 0,9, 1H), 7,61 (d, J = 2,3, 1H), 6,32 (d, J = 2,3, 1H), 5,78
- (brs, 1H), 4,09 (m, 2H), 3,72 (m, 2H), 2,98 (td, J = 12,0, 5,2,
- 1H), 2,47 (td, J = 12,1, 4,3, 1H), 2,36 (m, 3H), 2,16 (m, 1H),
- 2,02 (d, J = 14,2, 1H), 1,79 (m, 2H), 1,62 (m, 1H), 1,49 (m,
- 4H), 1,19 (m, 1H), 0,79 (dt, J = 12,9, 8,8, 1H).
- Compuesto
- Nombre Estructura y/o Espectro de NMR
- 523.
- [(1-metil-1H-pirazol-3-il)metil]({2-[(9R) -9-(piridin-2-il)-6-oxaspiro[4.5]decan-9 MS: 355,3
- -il]etil})amina
- 1H NMR (400 MHz, CD3CN) δ 8,98 (brs, 1H), 8,73 (dd, J =
- 5,3, 1,1, 1H), 8,73 (dd, J = 5,3, 1,1, 1H), 8,16 (m, 2H), 7,72 (d,
- J = 8,2, 1H), 7,72 (d, J = 8,2, 1H), 7,62 (ddd, J = 7,5, 5,4, 0,8,
- 1H), 7,62 (ddd, J = 7,5, 5,4, 0,8, 1H), 7,47 (d, J = 2,2, 1H), 7,47
- (d, J = 2,2, 1H), 6,25 (d, J = 2,2, 1H), 6,25 (d, J = 2,2, 1H), 4,02
- (m, 2H), 3,80 (s, 3H), 3,72 (m, 2H), 2,98 (td, J = 11,8, 5,2, 1H),
- 2,48 (td, J = 11,9, 4,2, 1H), 2,33 (m, 3H), 2,12 (ddd, J = 13,5,
- 11,9, 5,4, 1H), 1,99 (m, 1H), 1,77 (m, 2H), 1,62 (m, 1H), 1,48
- (m, 4H), 1,17 (m, 1H), 0,78 (dt. J = 13,1. 8,9, 1H).
- 524.
- [(5-metil-1H-pirazol-3-il)metil]({2-[(9R) -9-(piridin-2-il)-6-oxaspiro[4.5]decan-9 MS: 355,3
- -il]etil})amina
- 1H NMR (400 MHz, CD3CN) δ 8,78 (dd, J = 5,5, 1,2, 1H), 8,34
- (td, J = 8,0, 1,7, 1H), 7,79 (m, 2H), 6,07 (s, 1H), 5,95 (brs, 1H),
- 4,02 (m, 2H), 3,72 (m, 2H), 2,97 (td, J = 12,0, 5,1, 1H), 2,44
- (ddd, J = 12,1, 10,0, 4,2, 1H), 2,34 (m, 3H), 2,26 (s, 3H), 2,18
- (td, J = 13,1, 5,2, 1H), 2,03 (d, J = 14,2, 1H), 1,81 (ddd, J =
- 8,7, 7,4, 3,8, 2H), 1,63 (ddd, J = 14,6, 10,4, 4,6, 1H), 1,49 (m,
- 4H), 1,20 (m, 1H), 0,81 (dt, J = 12,9, 8,9, 1H).
- 525.
- [(1,5-dimetil-1H-pirazol-3-il)metil]({2-[( MS: 369,3
- 9R)-9-(piridin-2-il)-6-oxaspiro[4.5]dec
- an-9-il]etil})amina
- 1H NMR (400 MHz, CD3CN) δ 12,13 (brs, 1H), 8,77 (dd, J =
- 5,4, 1,2, 1H), 8,28 (td, J = 8,0, 1,7, 1H), 8,00 (brs, 1H), 7,74
- (m, 2H), 6,03 (s, 1H), 3,96 (m, 2H), 3,73 (m, 5H), 2,96 (td, J =
- 12,0, 5,2, 1H), 2,47 (td, J = 12,1, 4,2, 1H), 2,36 (m, 3H), 2,17
- (m, 4H), 2,00 (m, 1H), 1,79 (m, 2H), 1,63 (ddd, J = 8,4, 7,6,
- 3,3, 1H), 1,50 (m, 4H), 1,19 (ddd, J = 10,1, 6,6, 1,8, 1H), 0,81
- (dt, J = 12,9, 8,9, 1H).
- Compuesto
- Nombre Estructura y/o Espectro de NMR
- 526.
- (1H-pirazol-4-ilmetil)({2-[(9R)-9-(piridi n-2-il)-6-oxaspiro[4.5]decan-9-il]etil})a mina MS: 341,2 1H NMR (400 MHz, CD3CN) δ 8,73 (dd, J = 5,3, 1,1, 1H), 8,21 (td, J = 8,0, 1,7, 2H), 7,75 (d, J = 8,2, 1H), 7,66 (m, 3H), 7,56 (s, 1H), 3,96 (s, 2H), 3,73 (m, 2H), 2,91 (m, 1H), 2,32 (m, 4H), 2,08 (m, 1H), 1,99 (m, 1H), 1,78 (m, 2H), 1,62 (m, 1H), 1,49 (m, 4H), 1,19 (m, 1H), 0,78 (dt, J = 13,1, 8,8, 1H).
- 527.
- [(1-metil-1H-pirazol-4-il)metil]({2-[(9R) -9-(piridin-2-il)-6-oxaspiro[4.5]decan-9 -il]etil})amina MS: 355,2 1H NMR (400 MHz, CD3CN) δ 8,78 (dd, J = 5,5, 1,3, 1H), 8,32 (td, J = 8,0, 1,7, 1H), 7,84 (d, J = 8,2, 1H), 7,77 (ddd, J = 7,6, 5,5, 0,9, 1H), 7,71 (brs, 1H), 7,55 (s, 1H), 7,43 (s, 1H), 3,91 (s, 2H), 3,81 (d, J = 11,7, 3H), 3,73 (m, 2H), 2,90 (dt, J = 11,7, 5,8, 1H), 2,35 (m, 4H), 2,14 (ddd, J = 10,8, 10,2, 5,2, 1H), 2,03 (d, J = 14,2, 1H), 1,80 (m, 2H), 1,62 (tdd, J = 8,7, 6,8, 2,7, 1H), 1,49 (m, 4H), 1,20 (m, 1H), 0,80 (dt, J = 12,9, 8,8, 1H).
- 528.
-
[(5-metil-1H-pirazol-4-il)metil]({2-[(9R) -9-(piridin-2-il)-6-oxaspiro[4.5]decan-9 -il]etil})amina
imagen56
- 529.
-
[(1,5-dimetil-1H-pirazol-4-il)metil]({2-[( 9R)-9-(piridin-2-il)-6-oxaspiro[4.5]dec an-9-il]etil})amina
imagen57
- 530.
-
[(5,6-difluoropiridin-3-il)metil]({2-[(9R)9-(piridin-2-il)-6-oxaspiro[4.5]decan-9il]etil})amina
imagen58
- 531.
- [(5-cloro-6-fluoropiridin-3-il)metil]({2-[( 9R)-9-(piridin-2-il)-6-oxaspiro[4.5]dec
- Compuesto
- Nombre Estructura y/o Espectro de NMR
- an-9-il]etil})amina
-
imagen59
- 532.
-
[(5-bromo-6-fluoropiridin-3-il)metil]({2[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]de can-9-il]etil})amina
imagen60
- 533.
-
[(6-fluoro-5-yodopiridin-3-il)metil]({2-[( 9R)-9-(piridin-2-il)-6-oxaspiro[4.5]dec an-9-il]etil})amina
imagen61
- 534.
- [(6-fluoro-5-metilpiridin-3-il)metil]({2-[( 9R)-9-(piridin-2-il)-6-oxaspiro[4.5]dec an-9-il]etil})amina MS: 384,3 1H NMR (400 MHz, CD3CN) δ 8,73 (d, J = 4,4, 1H), 8,36 (s, 1H), 8,20 (d, J = 7,8, 1H), 8,01 (s, 1H), 7,77 (t, J = 7,1, 2H), 7,66 (m, 1H), 4,01 (s, 2H), 3,73 (m, 2H), 2,98 (dd, J = 11,6, 6,9, 1H), 2,36 (m, 5H), 2,26 (s, 3H), 2,16 (dd, J = 13,2, 5,1, 2H), 1,80 (m, 2H), 1,51 (m, 6H), 1,20 (dd, J = 8,7, 4,7, 1H), 0,79 (d, J = 13,3, 1H).
- 535.
-
[(6-fluoro-5-metoxipiridin-3-il)metil]({2[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]de can-9-il]etil})amina
imagen62
- 536.
-
2-fluoro-5-[({2-[(9R)-9-(piridin-2-il)-6-o xaspiro[4.5]decan-9-il]etil}amino)metil ]piridina-3-carbonitrilo
imagen63
- Compuesto
- Nombre Estructura y/o Espectro de NMR
- 537.
- [(6-cloro-5-fluoropiridin-3-il)metil]({2-[( 9R)-9-(piridin-2-il)-6-oxaspiro[4.5]dec an-9-il]etil})amina MS: 404,2 1H NMR (400 MHz, CD3CN) δ 8,68 (dd, J = 5,2, 1,1, 1H), 8,24 (d, J = 1,9, 1H), 8,10 (td, J = 7,9, 1,8, 1H), 7,78 (dd, J = 9,0, 2,0, 1H), 7,69 (d, J = 8,2, 1H), 7,56 (ddd, J = 7,5, 5,3, 0,9, 1H), 4,75 (brs, 1H), 4,07 (m, 2H), 3,72 (m, 2H), 2,99 (td, J = 11,9, 5,2, 1H), 2,48 (td, J = 12,0, 4,5, 1H), 2,32 (m, 3H), 2,11 (m, 1H), 1,77 (m, 2H), 1,62 (m, 1H), 1,49 (m, 4H), 1,17 (m, 1H), 0,77 (dt, J = 13,1, 8,9, 1H).
- 538.
- [(5,6-dicloropiridin-3-il)metil]({2-[(9R)9-(piridin-2-il)-6-oxaspiro[4.5]decan-9il]etil})amina MS: 422,2 1H NMR (400 MHz, CD3CN) δ 8,51 (m, 1H), 8,33 (d, J = 2,1, 1H), 8,12 (d, J = 2,1, 1H), 7,76 (t, J = 7,9, 1H), 7,49 (d, J = 8,1, 1H), 7,23 (dd, J = 7,4, 4,9, 1H), 4,26 (d, J = 1,5, 2H), 3,57 (dd, J = 7,7, 3,0, 2H), 3,09 (td, J = 12,2, 4,6, 1H), 2,55 (td, J = 12,1, 4,6, 1H), 2,27 (dddd, J = 25,5, 17,3, 14,3, 3,4, 4H), 1,77 (m, 1H), 1,59 (m, 2H), 1,34 (m, 6H), 0,98 (dd, J = 11,4, 5,0, 1H), 0,60 (dt, J = 13,4, 9,0, 1H).
- 539.
- [(5-bromo-6-cloropiridin-3-il)metil]({2-[ (9R)-9-(piridin-2-il)-6-oxaspiro[4.5]dec an-9-il]etil})amina MS: 466,1 1H NMR (400 MHz, CD3CN) δ 8,64 (d, J = 5,1, 1H), 8,36 (d, J = 2,1, 1H), 8,24 (d, J = 2,1, 1H), 8,02 (m, 1H), 7,69 (d, J = 8,0, 1H), 7,47 (m, 1H), 3,59 (m, 2H), 3,17 (d, J = 4,7, 1H), 2,63 (d, J = 4,5, 1H), 2,34 (m, 4H), 2,12 (d, J = 4,8, 1H), 1,85 (d, J = 13,8, 1H), 1,66 (m, 2H), 1,35 (m, 6H), 1,02 (m, 1H), 0,66 (s,
- 540.
-
[(6-cloro-5-yodopiridin-3-il)metil]({2-[(9 R)-9-(piridin-2-il)-6-oxaspiro[4.5]deca n-9-il]etil})amina
imagen64
- Compuesto
- Nombre Estructura y/o Espectro de NMR
- 541.
- [(6-cloro-5-metilpiridin-3-il)metil]({2-[(9 R)-9-(piridin-2-il)-6-oxaspiro[4.5]deca n-9-il]etil})amina MS: 400,2 1H NMR (400 MHz, CD3CN) δ 8,70 (dd, J = 5,3, 1,2, 1H), 8,20 (t, J = 2,4, 1H), 8,17 (dd, J = 7,9, 1,7, 1H), 7,74 (t, J = 5,2, 2H), 7,63 (ddd, J = 7,5, 5,3, 0,9, 1H), 5,11 (s, 1H), 4,01 (m, 2H), 3,73 (m, 2H), 2,98 (td, J = 11,9, 5,1, 1H), 2,46 (td, J = 12,0, 4,2, 1H), 2,33 (m, 6H), 2,12 (ddd, J = 14,7, 10,5, 5,3, 1H), 1,99 (d, J = 6,9, 1H), 1,78 (m, 2H), 1,62 (m, 1H), 1,48 (m, 4H), 1,18 (m, 1H), 0,78 (dt, J = 13,1, 8,9, 1H).
- 542.
- [(6-cloro-5-metoxipiridin-3-il)metil]({2-[ (9R)-9-(piridin-2-il)-6-oxaspiro[4.5]dec an-9-il]etil})amina MS: 416,2 1H NMR (400 MHz, CD3CN) δ 8,73 (dd, J = 5,4, 1,2, 1H), 8,26 (td, J = 7,9, 1,6, 1H), 7,93 (d, J = 1,9, 1H), 7,80 (d, J = 8,2, 1H), 7,70 (dd, J = 7,1, 5,9, 1H), 7,52 (d, J = 1,9, 1H), 5,05 (brs, 1H), 4,04 (m, 2H), 3,90 (s, 3H), 3,74 (m, 2H), 2,98 (td, J = 12,0, 5,1, 1H), 2,40 (dddd, J = 19,5, 12,3, 9,6, 4,7, 3H), 2,16 (m, 1H), 1,99 (m, 1H), 1,80 (m, 2H), 1,63 (ddd, J = 14,5, 7,2, 3,0, 1H), 1,49 (m, 4H), 1,20 (m, 1H), 0,80 (dt, J = 12,9, 8,8, 1H).
- 543.
-
2-cloro-5-[({2-[(9R)-9-(piridin-2-il)-6-ox aspiro[4.5]decan-9-il]etil}amino)metil] piridina-3-carbonitrilo
imagen65
- 544
-
3-fluoro-5-[({2-[(9R)-9-(piridin-2-il)-6-o xaspiro[4.5]decan-9-il]etil}amino)metil ]piridina-2-carbonitrilo
imagen66
- 545.
-
3-cloro-5-[({2-[(9R)-9-(piridin-2-il)-6-ox aspiro[4.5]decan-9-il]etil}amino)metil] piridina-2-carbonitrilo
imagen67
- 546.
- 3-bromo-5-[({2-[(9R)-9-(piridin-2-il)-6oxaspiro[4.5]decan-9-il]etil}amino)met
- Compuesto
- Nombre Estructura y/o Espectro de NMR
- il]piridina-2-carbonitrilo
-
imagen68
- 547.
-
3-yodo-5-[({2-[(9R)-9-(piridin-2-il)-6-ox aspiro[4.5]decan-9-il]etil}amino)metil] piridina-2-carbonitrilo
imagen69
- 548.
-
3-metil-5-[({2-[(9R)-9-(piridin-2-il)-6-ox aspiro[4.5]decan-9-il]etil}amino)metil] piridina-2-carbonitrilo
imagen70
- 549.
-
3-metoxi-5-[({2-[(9R)-9-(piridin-2-il)-6oxaspiro[4.5]decan-9-il]etil}amino)met il]piridina-2-carbonitrilo
imagen71
- 550.
-
5-[({2-[(9R)-9-(piridin-2-il)-6-oxaspiro[ 4.5]decan-9-il]etil}amino)metil]piridina -2,3-dicarbonitrilo
imagen72
- 551.
-
5-[({2-[(9R)-9-(piridin-2-il)-6-oxaspiro[ 4.5]decan-9-il]etil}amino)metil]-3-(triflu orometil)piridina-2-carbonitrilo
imagen73
- 552.
-
{[5-fluoro-6-(trifluorometil)piridin-3-il]m etil}({2-[(9R)-9-(piridin-2-il)-6-oxaspiro [4.5]decan-9-il]etil})amina
imagen74
- 553.
-
{[5-cloro-6-(trifluorometil)piridin-3-il]m etil}({2-[(9R)-9-(piridin-2-il)-6-oxaspiro [4.5]decan-9-il]etil})amina
imagen75
- Compuesto
- Nombre Estructura y/o Espectro de NMR
- 554.
- {[5-bromo-6-(trifluorometil)piridin-3-il] metil}({2-[(9R)-9-(piridin-2-il)-6-oxaspi ro[4.5]decan-9-il]etil})amina MS: 498,1 1H NMR (400 MHz, CD3CN) δ 8,74 (dd, J = 5,4, 1,2, 1 H), 8,64 (d, J = 1,6, 1 H), 8,32 (d, J = 1,2, 1 H), 8,26 (td, J = 8,0, 1,6, 1H), 7,81 (d, J = 8,2, 1H), 7,71 (dd, J = 7,1, 6,0, 1H), 4,12 (m, 3H), 3,74 (m, 3H), 3,00 (td, J = 12,0, 5,1, 1H), 2,49 (td, J = 12,1, 4,2, 1H), 2,37 (ddd, J = 14,0, 11,9, 5,0, 3H), 2,16 (m, 1H), 2,02 (m, 1H), 1,81 (m, 2H), 1,63 (ddd, J = 14,4, 8,7, 4,7, 1H), 1,49 (m, 4H), 1,21 (m, 1H), 0,80 (dt, J = 13,0, 8,9, 1H).
- 555.
-
{[5-yodo-6-(trifluorometil)piridin-3-y)]m eti)}({2-[(9R)-9-(piridin-2-il)-6-oxaspiro [4.5]decan-9-il]etil})amina
imagen76
- 556.
-
{[5-metil-6-(trifluorometil)piridin-3-il]m etil}({2-[(9R)-9-(piridin-2-il)-6-oxaspiro [4.5]decan-9-il]etil})amina
imagen77
- 557.
-
{[5-metoxi-6-(trifluorometil)piridin-3-il] metil}({2-[(9R)-9-(piridin-2-il)-6-oxaspi ro[4.5]decan-9-il]etil})amina
imagen78
- 558.
-
5-[({2-[(9R)-9-(piridin-2-il)-6-oxaspiro[ 4.5]decan-9-il]etil}amino)metil]-2-(triflu orometil)piridina-3-carbonitrilo
imagen79
- 559.
-
{[5,6-bis(trifluorometil)piridin-3-il]metil} ({2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5 ]decan-9-il]etil})amina
imagen80
- 560.
- [(5-fluoro-6-metilpiridin-3-il)metil]({2-[( 9R)-9-(piridin-2-il)-6-oxaspiro[4.5]dec an-9-il]etil})amina
- Compuesto
- Nombre Estructura y/o Espectro de NMR
- imagen81
- 561.
-
[(5-cloro-6-metilpiridin-3-il)metil]({2-[(9 R)-9-(piridin-2-il)-6-oxaspiro[4.5]deca n-9-il]etil})amina
imagen82
- 562.
-
[(5-bromo-6-metilpiridin-3-il)metil]({2-[ (9R)-9-(piridin-2-il)-6-oxaspiro[4.5]dec an-9-il]etil})amina
imagen83
- 563.
-
[(5-yodo-6-metilpiridin-3-il)metil]({2-[(9 R)-9-(piridin-2-il)-6-oxaspiro[4.5]deca n-9-il]etil})amina
imagen84
- 564.
-
[(5,6-dimetilpiridin-3-il)metil]({2-[(9R)9-(piridin-2-il)-6-oxaspiro[4.5]decan-9il]etil})amina
imagen85
- 565.
-
[(5-metoxi-6-metilpiridin-3-il)metil]({2-[ (9R)-9-(piridin-2-il)-6-oxaspiro[4.5]dec an-9-il]etil})amina
imagen86
- 566.
-
2-metil-5-[({2-[(9R)-9-(piridin-2-il)-6-ox aspiro[4.5]decan-9-il]etil}amino)metil] piridina-3-carbonitrilo
imagen87
- 567.
-
{[6-metil-5-(trifluorometil)piridin-3-il]m etil}({2-[(9R)-9-(piridin-2-il)-6-oxaspiro [4.5]decan-9-il]etil})amina
imagen88
- Compuesto
- Nombre Estructura y/o Espectro de NMR
- 568.
- [(5-fluoro-6-metoxipiridin-3-il)metil]({2- MS: 400,3
- [(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]de
- can-9-il]etil})amina
- 1H NMR (400 MHz, CD3CN) δ 8,63 (dd, J = 5,3, 1,2, 1H), 8,25
- (s, 1H), 8,12 (td, J = 8,0, 1,6, 1H), 7,83 (d, J = 1,9, 1H), 7,67 (d,
- J = 8,2, 1H), 7,57 (dd, J = 6,8, 5,7, 1H), 7,44 (dd, J = 11,1,2,0,
- 1H), 3,88 (d, J = 6,7, 5H), 3,62 (m, 2H), 2,86 (dd, J = 11,5, 7,1,
- 1H), 2,26 (m, 4H), 2,05 (dd, J = 12,7, 5,0, 1H), 1,69 (ddd, J =
- 9,5, 8,0, 4,4, 2H), 1,69 (ddd, J = 9,5, 8,0, 4,4, 2H), 1,39 (m,
- 5H), 0,68 (d. J = 13,3. 1H).
- 569.
- [(5-cloro-6-metoxipiridin-3-il)metil]({2-[ MS: 416,2
- (9R)-9-(piridin-2-il)-6-oxaspiro[4.5]dec
- an-9-il]etil})amina
- 1H NMR (400 MHz, CD3CN) δ 8,65 (d, J = 5,4, 1H), 8,21 (s,
- 1H), 8,18 (d, J = 8,0, 1H), 7,96 (d, J = 2,1, 1H), 7,72 (m, 2H),
- 7,63 (t, J = 6,4, 1H), 3,87 (m, 5H), 3,62 (m, 2H), 2,85 (dd, J =
- 11,5, 7,2, 1H), 2,27 (m, 4H), 2,07 (d, J = 4,9, 1H), 1,91 (d, J =
- 14,1, 1H), 1,69 (m, 2H), 1,39 (m, 5H), 1,10 (m, 1H), 0,69 (d, J
- = 13,2, 1H).
- 570.
- [(5-bromo-6-metoxipiridin-3-il)metil]({2 MS: 460,2
- -[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]de
- can-9-il]etil})amina
- 1H NMR (400 MHz, CDCl3) δ 8,79 (dd, J = 5,7, 1,3, 1H), 8,43
- (td, J = 8,0, 1,7, 1H), 8,11 (d, J = 2,1, 1H), 7,98 (d, J = 2,1, 1H),
- 7,92 (d, J = 8,2, 1H), 7,86 (ddd, J = 7,6, 5,7, 1,0, 1H), 5,63
- (brs, 1H), 3,97 (m, 5H), 3,75 (m, 2H), 2,96 (m, 1H), 2,42 (dq, J
- = 12,2, 4,1, 2H), 2,33 (d, J = 14,1, 2H), 2,21 (m, 1H), 2,06 (d, J
- = 14,2, 1H), 1,83 (m, 2H), 1,64 (ddd, J = 19,4, 10,1, 4,4, 1H),
- 1,50 (m, 4H), 1,23 (m, 1H), 0,82 (dt, J = 12,9, 8,9, 1H).
- 571.
-
[(5-yodo-6-metoxipiridin-3-il)metil]({2-[ (9R)-9-(piridin-2-il)-6-oxaspiro[4.5]dec an-9-1]etil})amina
imagen89
- Compuesto
- Nombre Estructura y/o Espectro de NMR
- 572.
- [(6-metoxi-5-metilpiridin-3-il)metil]({2-[ (9R)-9-(piridin-2-il)-6-oxaspiro[4.5]dec an-9-il]etil})amina MS: 396,3 1H NMR (400 MHz, CDCl3) δ 8,78 (dd, J = 5,6, 1,3, 1H), 8,38 (td, J = 8,0, 1,7, 1H), 7,96 (d, J = 2,2, 1H), 7,88 (d, J = 8,2, 1H), 7,81 (ddd, J = 7,6, 5,6, 1,0, 1H), 7,49 (d, J = 1,5, 1H), 5,36 (brs, 1H), 3,93 (m, 5H), 3,74 (m, 2H), 2,95 (dd, J = 11,4, 7,7, 1H), 2,39 (m, 4H), 2,21 (dd, J = 13,2, 5,4, 1H), 2,14 (m, 3H), 2,05 (d, J = 14,2, 1H), 1,82 (m, 2H), 1,63 (m, 1H), 1,50 (m, 4H), 1,21 (ddd, J = 10,5, 6,1, 2,5, 1H), 0,81 (dt, J = 12,9, 8,8, 1H).
- 573.
-
[(5,6-dimetoxipiridin-3-il)metil]({2-[(9R )-9-(piridin-2-il)-6-oxaspiro[4.5]decan9-il]etil})amina
imagen90
- 574.
-
2-metoxi-5-[({2-[(9R)-9-(piridin-2-il)-6oxaspiro[4.5]decan-9-il]etil}amino)met il]piridina-3-carbonitrilo
imagen91
- 575.
-
{[6-metoxi-5-(trifluorometil)piridin-3-il] metil}({2-[(9R)-9-(piridin-2-il)-6-oxaspi ro[4.5]decan-9-il]etil})amina
imagen92
Ejemplo 14: Ligandos de receptores de opioides
Los siguientes compuestos en la Tabla 3 también pueden prepararse de acuerdo con los procedimientos descritos anteriormente a partir de materiales de partida apropiados y reactivos apropiados y se espera que tengan
5 propiedades y efectos terapéuticos similares a los otros compuestos descritos en la presente. Además de la estructura específica mostrada, los otros isómeros o enantiómeros se incluyen con la descripción en la presente. Los compuestos que se han preparado incluyen datos de NMR, mientras que los ejemplos teóricos no incluyen datos de NMR.
10 Tabla 3: Ligandos de receptores de opioides
- Compuesto
- Nombre Estructura
- 576
-
[(5-cloropiridin-3-il)metil]({2-[(9R)-9 -fenil-6-oxaspiro[4.5]decan-9-il]etil })amina
imagen93
- 577
-
{2-[(9R)-9-fenil-6-oxaspiro[4.5]dec an-9-il]etil}({[5-(trifluorometil)piridin -3-il]metil})amina
imagen94
- 578
-
{2-[(9R)-9-fenil-6-oxaspiro[4.5]dec an-9-il]etil}({[4-(trifluorometil)piridin -3-il]metil})amina
imagen95
- 579
-
[(3,5-difluorofenil)metil]({2-[(9R)-9fenil-6-oxaspiro[4.5]decan-9-il]etil} )amina
imagen96
- 580
-
[(3-metilfenil)metil]({2-[(9R)-9-fenil6-oxaspiro[4.5]decan-9-il]etil})ami na
imagen97
- 581
-
[(5-cloropiridin-3-il)metil]({2-[(9R)-9 -(4-fluorofenil)-6-oxaspiro[4.5]deca n-9-il]etil})amina
imagen98
- Compuesto
- Nombre Estructura
- 582
-
{2-[(9R)-9-(4-fluorofenil)-6-oxaspir o[4.5]decan-9-il]etil}({[5-(trifluorom etil)piridin-3-il]metil})amin
imagen99
- 583
-
{2-[(9R)-9-(4-fluorofenil)-6-oxaspir o[4.5]decan-9-il]etil}({[4-(trifluorom etil)piridin-3-il]metil})amina
imagen100
- 584
-
[(3,5-difluorofenil)metil]({2-[(9R)-9(4-fluorofenil)-6-oxaspiro[4.5]deca n-9-il]etil})amina
imagen101
- 585
-
[(5-cloropiridin-3-il)metil]({2-[(9R)-9 -[4-(trifluorometoxi)fenil]-6-oxaspir o[4.5]decan-9-il]etil})amina
imagen102
- 586
-
{2-[(9R)-9-[4-(trifluorometoxi)fenil]6-oxaspiro[4.5]decan-9-il]etil}({[5-(t rifluorometil)piridin-3-il]metil})amin a
imagen103
- 587
-
{2-[(9R)-9-[4-(trifluorometoxi)fenil]6-oxaspiro[4.5]decan-9-il]etil}({[4-(t rifluorometil)piridin-3-il]metil})amin a
imagen104
- Compuesto
- Nombre Estructura
- 588
-
[(3,5-difluorofenil)metil]({2-[(9R)-9[4-(trifluorometoxi)fenil]-6-oxaspiro [4.5]decan-9-il]etil})amina
imagen105
- 589
-
[(3-metilfenil)metil]({2-[(9R)-9-[4-(tr ifluorometoxi)fenil]-6-oxaspiro[4.5] decan-9-il]etil})amina
imagen106
- 590
-
[(5-cloropiridin-3-il)metil]({2-[(9R)-9 -(piridin-3-il)-6-oxaspiro[4.5]decan9-il]etil})amina
imagen107
- 591
-
{2-[(9R)-9-(piridin-3-il)-6-oxaspiro[ 4.5]decan-9-il]etil}({[5-(trifluorometi l)piridin-3-il]metil})amina
imagen108
- 592
-
{2-[(9R)-9-(piridin-3-il)-6-oxaspiro[ 4.5]decan-9-il]etil}({[4-(trifluorometi l)piridin-3-il]metil})amina
imagen109
- 593
-
[(3,5-difluorofenil)metil]({2-[(9R)-9(piridin-3-il)-6-oxaspiro[4.5]decan9-il]etil})amina
imagen110
- Compuesto
- Nombre Estructura
- 594
-
[(3-metilfenil)metil]({2-[(9R)-9-(pirid in-3-il)-6-oxaspiro[4.5]decan-9-il]et il})amina
imagen111
- 595
-
[(5-cloropiridin-3-il)metil]({2-[(9R)-9 -(piridin-4-il)-6-oxaspiro[4.5]decan9-il]etil})amina
imagen112
- 596
-
{2-[(9R)-9-(piridin-4-il)-6-oxaspiro[ 4.5]decan-9-il]etil}({[5-(trifluorometi l)piridin-3-il]metil})amina
imagen113
- 597
-
{2-[(9R)-9-(piridin-4-il)-6-oxaspiro[ 4.5]decan-9-il]etil}({[4-(trifluorometi l)piridin-3-il]metil})amina
imagen114
- 598
-
[(3,5-difluorofenil)metil]({2-[(9R)-9(piridin-4-il)-6-oxaspiro[4.5]decan9-il]etil})amina
imagen115
- 599
-
[(3-metilfenil)metil]({2-[(9R)-9-(pirid in-4-il)-6-oxaspiro[4.5]decan-9-il]et il})amina
imagen116
- Compuesto
- Nombre Estructura
- 600
-
[(5-cloropiridin-3-il)metil]({2-[(9R)-9 -(3-metilfenil)-6-oxaspiro[4.5]deca n-9-il]etil})amina
imagen117
- 601
-
{2-[(9R)-9-(3-metilfenil)-6-oxaspiro [4.5]decan-9-il]etil}({[5-(trifluorome til)piridin-3-il]metil})amina
imagen118
- 602
-
{2-[(9R)-9-(3-metilfenil)-6-oxaspiro [4.5]decan-9-il]etil}({[4-(trifluorome til)piridin-3-il]metil})amina
imagen119
- 603
-
[(3,5-difluorofenil)metil]({2-[(9R)-9(3-metilfenil)-6-oxaspiro[4.5]decan -9-il]etil})amina
imagen120
- 604
-
{2-[(9R)-9-(3-metilfenil)-6-oxaspiro [4.5]decan-9-il]etil}[(3-metilfenil)m etil]amina
imagen121
- 605
-
[(5-cloropiridin-3-il)metil]({2-[(9R)-9 -[3-(trifluorometoxi)fenil]-6-oxaspir o[4.5]decan-9-il]etil})amina
imagen122
- Compuesto
- Nombre Estructura
- 606
-
{2-[(9R)-9-[3-(trifluorometoxi)fenil]6-oxaspiro[4.5]decan-9-il]etil}({[5-(t rifluorometil)piridin-3-il]metil})amin a
imagen123
- 607
-
{2-[(9R)-9-[3-(trifluorometoxi)fenil]6-oxaspiro[4.5]decan-9-il]etil}({[4-(t rifluorometil)piridin-3-il]metil})amin a
imagen124
- 608
-
[(3,5-difluorofenil)metil]({2-[(9R)-9[3-(trifluorometoxi)fenil]-6-oxaspiro [4.5]decan-9-il]etil})amina
imagen125
- 609
-
[(3-metilfenil)metil]({2-[(9R)-9-[3-(tr ifluorometoxi)fenil]-6-oxaspiro[4.5] decan-9-il]etil})amina
imagen126
- 610
-
[(5-cloropiridin-3-il)metil]({2-[(9R)-9 -[4-(trifluorometil)fenil]-6-oxaspiro[ 4.5]decan-9-il]etil})amina
imagen127
- 611
-
{2-[(9R)-9-[4-(trifluorometil)fenil]-6oxaspiro[4.5]decan-9-il]etil}({[5-(trif luorometil)piridin-3-il]metil})amina
imagen128
- Compuesto
- Nombre Estructura
- 612
-
{2-[(9R)-9-[4-(trifluorometil)fenil]-6oxaspiro[4.5]decan-9-il]etil}({[4-(trif luorometil)piridin-3-il]metil})amina
imagen129
- 613
-
[(3,5-difluorofenil)metil]({2-[(9R)-9[4-(trifluorometil)fenil]-6-oxaspiro[4 .5]decan-9-il]etil})amina
imagen130
- 614
-
[(3-metilfenil)metil]({2-[(9R)-9-[4-(tr ifluorometil)fenil]-6-oxaspiro[4.5]de can-9-il]etil})amina
imagen131
- 615
-
[(5-cloropiridin-3-il)metil]({2-[(9R)-9 -(3-fluorofenil)-6-oxaspiro[4.5]deca n-9-il]etil})amina
imagen132
- 616
-
{2-[(9R)-9-(3-fluorofenil)-6-oxaspir o[4.5]decan-9-il]etil}({[5-(trifluorom etil)piridin-3-il]metil})amina
imagen133
- 617
-
{2-[(9R)-9-(3-fluorofenil)-6-oxaspir o[4.5]decan-9-il]etil}({[4-(trifluorom etil)piridin-3-il]metil})amina
imagen134
- Compuesto
- Nombre Estructura
- 618
-
[(3,5-difluorofenil)metil]({2-[(9R)-9(3-fluorofenil)-6-oxaspiro[4.5]deca n-9-il]etil})amina
imagen135
- 619
-
{2-[(9R)-9-(3-fluorofenil)-6-oxaspir o[4.5]decan-9-il]etil}[(3-metilfenil) metil]amina
imagen136
- 620
-
[(5-cloropiridin-3-il)metil]({2-[(9R)-9 -[3-(trifluorometil)fenil]-6-oxaspiro[ 4.5]decan-9-il]etil})amina
imagen137
- 621
-
{2-[(9R)-9-[3-(trifluorometil)fenil]-6oxaspiro[4.5]decan-9-il]etil}({[5-(trif luorometil)piridin-3-il]metil})amina
imagen138
- 622
-
{2-[(9R)-9-[3-(trifluorometil)fenil]-6oxaspiro[4.5]decan-9-il]etil}({[4-(trif luorometil)piridin-3-il]metil})amina
imagen139
- 623
-
[(3,5-difluorofenil)metil]({2-[(9R)-9[3-(trifluorometil)fenil]-6-oxaspiro[4 .5]decan-9-il]etil})amina
imagen140
- Compuesto
- Nombre Estructura
- 624
-
[(3-metilfenil)metil]({2-[(9R)-9-[3-(tr ifluorometil)fenil]-6-oxaspiro[4.5]de can-9-il]etil})amina
imagen141
- 625
- [(5-cloropiridin-3-il)metil](metil){2-[( 9R)-9-(piridin-2-il)-6-oxaspiro[4.5]d ecan-9-il]etil}amina MS: 400,2 1H NMR (400 MHz, CD3CN) δ 8,77 (dd, J = 5,6, 1,3, 1H), 8,67 (d, J = 2,0, 1H), 8,53 (s, 1H), 8,41 (td, J = 8,0, 1,6, 1H), 7,93 (m, 2H), 7,85 (m, 1H), 4,18 (s, 2H), 3,76 (ddd, J = 12,4, 11,3, 5,5, 2H), 3,09 (d, J = 5,1, 1H), 2,65 (s, 3H), 2,55 (m, 2H), 2,33 (m, 3H), 2,08 (d, J = 14,2, 1H), 1,84 (m, 2H), 1,53 (m, 5H), 1,21 (m, 1H), 0,77 (d, J = 13,2, 1H).
- 626
- metil({2-[(9R)-9-(piridin-2-il)-6-oxa spiro[4.5]decan-9-il]etil}){[5-(trifluor ometil)piridin-3-il]metil}amina MS: 434,3 1H NMR (400 MHz, CD3CN) δ 8,99 (s, 1H), 8,84 (s, 1H), 8,77 (m, 1H), 8,40 (td, J = 8,0, 1,6, 1H), 8,23 (s, 1H), 7,91 (d, J = 8,2, 1H), 7,84 (dd, J = 6,9, 6,3, 1H), 4,26 (s, 2H), 3,77 (m, 2H), 3,11 (d, J = 4,8, 1H), 2,65 (s, 3H), 2,57 (ddd, J = 17,4, 12,8, 8,9, 2H), 2,34 (dd, J = 19,0, 9,6, 3H), 2,09 (d, J = 14,2, 1H), 1,86 (m, 2H), 1,54 (m, 5H), 1,20 (dd, J = 9,5, 3,8, 1H), 0,77 (dd, J = 9,0, 4,1, 1H).
- Compuesto
- Nombre Estructura
- 627
- [(5-cloropiridin-3-il)metil-(2H2)]{2-[( MS: 388,2
- 9R)-9-(piridin-2-il)-6-oxaspiro[4.5]d
- ecan-9-il]etil}amina
- 1H NMR (400 MHz, CD3CN) δ 9,51 (s, 1H), 8,48 (d, J = 1,9, 1H),
- 8,45 (d, J = 2,3, 1H), 8,42 (ddd, J = 4,8, 1,8, 0,8, 1 H), 8,06 (m,
- 1H), 7,64 (td, J = 7,8, 1,8, 1H), 7,33 (d, J = 8,1, 1H), 7,12 (ddd, J
- = 7,4, 4,8, 0,7, 1H), 3,57 (m, 2H), 2,74 (td, J = 12,0, 4,7, 1H), 2,21
- (m, 4H), 1,96 (dt, J = 12,4,6,1, 1H), 1,76 (d, J = 13,8, 1H), 1,63
- (dd, J = 9,9, 5,9, 1 H), 1,40 (m, 6H), 0,95 (m, 1H), 0,59 (m, 1H).
- 628
- ({2-[(9R)-9-(piridin-2-il)-6-oxaspiro[ MS: 422,3
- 4.5]decan-9-il]etil}){[5-(trifluorometi
- l)piridin-3-il]metil-(2H2)}amina
- 1H NMR (400 MHz, CD3CN) δ 9,44 (s, 1H), 8,82 (d, J = 1,9, 1H),
- 8,78 (d, J = 1,2, 1H), 8,40 (ddd, J = 4,8, 1,8, 0,9, 1H), 8,31 (m,
- 1H), 7,61 (m, 1H), 7,31 (m, 1H), 7,09 (ddd, J = 7,4, 4,8, 1,0, 1H),
- 3,57 (m, 2H), 2,74 (m, 1H), 2,24 (m, 3H), 2,10 (m, 1H), 1,95 (dd, J
- = 12,5, 4,7, 1H), 1,75 (d, J = 13,6, 1H), 1,44 (m, 7H), 0,96 (s, 1H),
- 0,59 (m, 1H).
- 629
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[ MS: 420,2
- 4.5]decan-9-il]etil}({[6-(trifluorometi
- l)piridin-2-il]metil})amina
- 1H NMR (400 MHz, CD3CN) δ 8,70 (dd, J = 5,2, 1,1, 1H), 8,53
- (brs, 1H), 8,11 (td, J = 7,9, 1,7, 1H), 8,05 (t, J = 7,9, 1H), 7,80 (d,
- J = 7,8, 1H), 7,70 (d, J = 8,2, 1H), 7,57 (ddd, J = 8,3, 7,5, 4,4, 2H),
- 6,58 (brs, 1H), 4,29 (m, 2H), 3,73 (m, 2H), 3,09 (td, J = 11,8, 5,2,
- 1H), 2,60 (td, J = 11,9, 4,8, 1H), 2,36 (m, 3H), 2,16 (m, 1H), 1,99
- (m, 1H), 1,77 (ddd, J = 14,0, 9,0, 5,1, 2H), 1,62 (m, 1H), 1,48 (m,
- 4H), 1,16 (ddd, J = 8,5, 7,0, 3,5, 1H), 0,78 (dt, J = 13,1, 8,9, 1H).
- Compuesto
- Nombre Estructura
- 630
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[ MS: 420,2
- 4.5]decan-9-il]etil}({[5-(trifluorometi
- l)piridin-2-il]metil})amina
- 1H NMR (400 MHz, CD3CN) δ 8,86 (d, J = 0,8, 1H), 8,77 (dd, J =
- 5,4, 1,2, 1H), 8,20 (m, 1H), 8,11 (dd, J = 8,3, 1,9, 1H), 7,77 (d, J =
- 8,2, 1H), 7,66 (ddd, J = 7,6, 5,4, 0,9, 1H), 7,53 (d, J = 8,3, 1H),
- 4,31 (m, 2H), 3,73 (m, 2H), 3,09 (td, J = 11,9, 5,4, 1H), 2,60 (td, J
- = 11,9, 4,6, 1H), 2,39 (m, 3H), 2,21 (ddd, J = 13,6, 11,8, 5,4, 1H),
- 2,02 (d, J = 14,0, 1H), 1,80 (ddd, J = 9,5, 8,3, 4,6, 2H), 1,63 (m,
- 1H), 1,49 (qdd, J = 13,9, 8,5, 3,5, 4H), 1,19 (m, 1H), 0,80 (dt, J =
- 13,1, 8,8, 1H).
- 631
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[ 4.5]decan-9-il]etil}(piridin-2-ilmetil) MS: 352,3
- amina
- 1H NMR (400 MHz, CD3CN) δ 10,49 (s, 1H), 8,81 (dd, J = 5,5,
- 1,2, 1H), 8,55 (dd, J = 3,7, 0,8, 1H), 8,30 (td, J = 8,0, 1,7, 1H),
- 7,91 (td, J = 7,8, 1,7, 1H), 7,83 (d, J = 8,2, 1H), 7,75 (ddd, J = 7,6,
- 5,5, 1,0, 1H), 7,45 (dd, J = 11,3, 6,5, 2H), 4,24 (m, 2H), 3,73 (m,
- 2H), 3,06 (td, J = 12,0, 5,2, 1H), 2,57 (td, J = 12,1, 4,4, 1H), 2,39
- (m, 3H), 2,24 (m, 1H), 2,04 (d, J = 14,0, 1H), 1,82 (m, 2H), 1,63
- (m, 1H), 1,50 (m, 4H), 1,19 (m, 1H), 0,81 (dt, J = 12,9, 8,8, 1H).
- 632
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[ 4.5]decan-9-il]etil}(piridin-3-ilmetil) MS: 352,3
- amina
- 1H NMR (400 MHz, CD3CN) δ 8,81 (s, 1H), 8,74 (m, 2H), 8,32 (d,
- J = 8,1, 1H), 8,26 (td, J = 8,0, 1,7, 1H), 7,80 (m, 2H), 7,70 (m,
- 1H), 4,18 (m, 2H), 3,73 (m, 2H), 3,02 (td, J = 12,0, 5,1, 1H), 2,51
- (td, J = 12,1, 4,3, 1H), 2,36 (m, 3H), 2,15 (m, 1H), 2,01 (d, J =
- 14,1, 1H), 1,80 (ddd, J = 9,8, 8,2, 4,7, 2H), 1,62 (m, 1H), 1,48 (m,
- 4H), 1,19 (m, 1H), 0,80 (dt, J = 13,0, 8,8, 1H).
- Compuesto
- Nombre Estructura
- 633
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[ 4.5]decan-9-il]etil}(piridin-4-ilmetil) MS: 352,3
- amina
- 1H NMR (400 MHz, CD3CN) δ 8,73 (m, 3H), 8,20 (td, J = 8,0, 1,7,
- 1H), 7,82 (d, J = 6,5, 2H), 7,76 (d, J = 8,2, 1H), 7,65 (m, 1H), 4,22
- (m, 2H), 3,73 (m, 2H), 3,03 (td, J = 12,0, 5,1, 1H), 2,53 (td, J =
- 12,1, 4,4, 1H), 2,37 (m, 3H), 2,16 (m, 1H), 2,00 (d, J = 14,2, 1H),
- 1,79 (m, 2H), 1,63 (ddd, J = 12,2, 8,8, 4,0, 1H), 1,49 (m, 4H), 1,19
- (m, 1H), 0,80 (dt, J = 13,1, 8,9, 1H).
- 634
- (1H-imidazol-4-ilmetil)({2-[(9R)-9-( piridin-2-il)-6-oxaspiro[4.5]decan-9 MS: 341,2
- -il]etil})amina
- 1H NMR (400 MHz, CD3CN) δ 8,75 (dd, J = 5,4, 1,2, 1H), 8,54 (d,
- J = 1,0, 1H), 8,22 (td, J = 8,0, 1,6, 1H), 7,77 (d, J = 8,2, 1H), 7,67
- (dd, J = 6,8, 5,6, 1H), 7,47 (s, 1H), 4,18 (s, 2H), 3,72 (m, 2H),
- 2,92 (td, J = 12,1, 5,0, 1H), 2,38 (m, 4H), 2,13 (m, 1H), 2,00 (m,
- 1H), 1,79 (m, 2H), 1,63 (m, 1H), 1,48 (m, 4H), 1,19 (m, 1H), 0,82
- (dt, J = 13,1, 8,9, 1H).
- 635
- [(2-metilpiridin-4-il)metil]({2-[(9R)-9 MS: 366,3
- -(piridin-2-il)-6-oxaspiro[4.5]decan
- 9-il]etil})amina
- 1H NMR (400 MHz, CD3CN) δ 8,71 (d, J = 1,9, 1H), 8,65 (dd, J =
- 5,1, 1,0, 1H), 8,18 (dd, J = 8,2, 2,1, 1H), 8,02 (td, J = 7,9, 1,8,
- 1H), 7,64 (d, J = 8,1, 2H), 7,49 (dd, J = 6,7, 5,2, 1H), 4,13 (m,
- 2H), 3,71 (m, 2H), 3,00 (td, J = 11,8, 5,1, 1H), 2,71 (s, 3H), 2,50
- (td, J = 11,9, 4,6, 1H), 2,37 (m, 2H), 2,23 (m, 1H), 2,06 (dd, J =
- 12,0, 5,1, 1H), 1,76 (ddt, J = 14,1, 9,4, 3,8, 3H), 1,61 (dd, J =
- 16,6, 9,7, 1H), 1,49 (m, 4H), 1,16 (d, J = 11,3, 1H), 0,76 (dt, J =
- 13,1, 8,9, 1H).
- Compuesto
- Nombre Estructura
- 636
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[ MS: 420,2
- 4.5]decan-9-il]etil}({[2-(trifluorometi
- l)piridin-4-il]metil})amina
- 1H NMR (400 MHz, CD3CN) δ 8,75 (d, J = 5,1, 2H), 8,30 (td, J =
- 8,1, 1,4, 1H), 7,84 (m, 2H), 7,74 (m, 1H), 7,63 (d, J = 4,7, 1H),
- 4,13 (m, 2H), 3,73 (m, 2H), 3,01 (td, J = 11,9, 5,0, 1H), 2,45 (m,
- 4H), 2,22 (td, J = 13,0, 5,0, 1H), 2,03 (d, J = 14,1, 1H), 1,81 (m,
- 2H), 1,63 (m, 1H), 1,49 (m, 4H), 1,21 (dd, J = 9,4, 5,1, 1H), 0,81
- (dt, J = 12,8, 8,8, 1H).
- 637
- [(6-cloropiridin-3-il)metil]({2-[(9R)-9 MS: 386,2
- -(piridin-2-il)-6-oxaspiro[4.5]decan
- 9-il]etil})amina
- 1H NMR (400 MHz, CD3CN) δ 8,69 (m, 1H), 8,38 (m, 1H), 8,12
- (m, 1H), 7,81 (m, 1H), 7,70 (m, 1H), 7,58 (m, 1H), 7,45 (m, 1H),
- 4,43 (s, 1H), 4,06 (d, J = 13,9, 2H), 3,72 (m, 2H), 2,98 (td, J =
- 11,9, 5,1, 1H), 2,48 (td, J = 12,0, 4,4, 1H), 2,32 (m, 3H), 2,10 (m,
- 1H), 1,98 (d, J = 2,4, 1H), 1,77 (m, 2H), 1,61 (ddd, J = 15,0, 8,2,
- 4,0, 1H), 1,48 (m, 4H), 1,16 (ddd, J = 8,7, 7,1, 4,1, 1H), 0,77 (dt, J
- = 13,2, 8,9, 1H).
- 638
- [(1-metil-1H-imidazol-2-il)metil]({2- MS: 355,3
- [(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]
- decan-9-il]etil})amina
- 1H NMR (400 MHz, CD3CN) δ 8,71 (ddd, J = 5,3, 1,7, 0,6, 1H),
- 8,14 (td, J = 8,0, 1,8, 1H), 7,73 (d, J = 8,2, 1H), 7,60 (ddd, J = 7,6,
- 5,3, 1,0, 1H), 7,43 (d, J = 1,9, 1H), 7,35 (d, J = 1,9, 1H), 4,33 (s,
- 2H), 3,80 (m, 3H), 3,72 (ddt, J = 15,3, 9,3, 3,1, 2H), 3,03 (td, J =
- 12,0, 4,9, 1H), 2,59 (td, J = 12,0, 4,6, 1H), 2,36 (m, 3H), 2,15 (m,
- 1H), 1,99 (m, 1H), 1,80 (m, 2H), 1,63 (ddd, J = 14,4, 9,9, 5,5, 1H),
- 1,49 (m, 4H), 1,19 (m, 1H), 0,83 (dt, J = 13,1, 8,9, 1H).
- Compuesto
- Nombre Estructura
- 639
- (naftalen-2-ilmetil)({2-[(9R)-9-(pirid in-2-il)-6-oxaspiro[4.5]decan-9-il]et MS: 401,3
- il})amina
- 1H NMR (400 MHz, CD3CN) δ 8,57 (dd, J = 5,0, 1,0, 1H), 7,90
- (m, 5H), 7,59 (m, 2H), 7,54 (d, J = 8,1, 1H), 7,48 (dd, J = 8,5, 1,7,
- 1H), 7,34 (m, 1H), 4,19 (s, 2H), 3,69 (dt, J = 8,9, 5,1, 3H), 3,48
- (brs, 1H), 3,02 (s, 1H), 2,52 (s, 1H), 2,33 (m, 2H), 2,19 (m, 1H),
- 2,02 (m, 1H), 1,89 (t, J = 9,4, 1H), 1,70 (dq, J = 9,2, 5,1, 2H), 1,59
- (m, 1H), 1,44 (m, 4H), 1,10 (m, 1H), 0,69 (dt, J = 13,1, 8,8, 1H).
- 640
- [(6-bromo-5-fluoropiridin-3-il)metil] MS: 448,2
- ({2-[(9R)-9-(piridin-2-il)-6-oxaspiro[
- 4.5]decan-9-il]etil})amina
- 1H NMR (400 MHz, CD3CN) & 8,68 (dd, J = 5,2, 1,2, 1H), 8,24
- (d, J = 1,5, 1H), 8,12 (td, J = 7,9, 1,7, 1H). 7,71 (m, 2H), 7,58 (dd,
- J = 7,1, 5,7, 1H), 4,88 (s, 1H), 4,08 (d, J = 14,0, 2H), 3,72 (m, 2H),
- 2,98 (td, J = 11,9, 5,1, 1H), 2,48 (td, J = 12,0, 4,4, 1H), 2,32 (m,
- 3H), 2,11 (m, 1H), 1,98 (d, J = 2,5, 1H), 1,77 (m, 2H), 1,61 (m,
- 1H), 1,48 (m, 4H), 1,17 (m, 1H), 0,77 (dt, J = 13,1, 8,9, 1H).
- 641
- [(5-metanosulfonilpiridin-3-il)metil]( MS: 430,2
- {2-[(9R)-9-(piridin-2-il)-6-oxaspiro[
- 4.5]decan-9-il]etil})amina
- 1H NMR (400 MHz, CD3CN) δ 9,10 (d, J = 2,0, 1H), 8,87 (d, J =
- 1,8, 1H), 8,71 (dd. J = 5,3, 1,1, 1H), 8,37 (t, J = 2,0, 1H), 8,18 (td,
- J = 8,0, 1,8, 1H), 7,75 (d, J = 8,2, 1H), 7,63 (ddd, J = 7,6, 5,4, 0,9,
- 1H), 4,16 (m, 2H), 3,73 (m, 2H), 3,14 (s, 3H), 3,02 (td, J = 12,0,
- 5,2, 1H), 2,52 (m, 1H), 2,33 (m, 3H), 2,14 (m, I H), 2,01 (m, 1H),
- 1,79 (m, 2H), 1,62 (m, 1H), 1,48 (m, 4H), 1,19 (m, 1H), 0,79 (dt, J
- = 13,1, 8,9, 1H).
- Compuesto
- Nombre Estructura
- 642
-
[2-(3-metilfenil)etil]({2-[(9R)-9-(piri din-2-il)-6-oxaspiro[4.5]decan-9-il] etil})amina
imagen142
- 643
-
[2-(3-clorofenil)etil]({2-[(9R)-9-(piri din-2-il)-6-oxaspiro[4.5]decan-9-il] etil})amina
imagen143
- 644
-
[2-(3-bromofenil)etil]({2-[(9R)-9-(pir idin-2-il)-6-oxaspiro[4.5]decan-9-il] etil})amina
imagen144
- 645
-
[2-(3-fluorofenil)etil]({2-[(9R)-9-(piri din-2-il)-6-oxaspiro[4.5]decan-9-il] etil})amina
imagen145
- 646
-
{2-[(9R)-9-(piridin-2-il)-6-oxaspiro[ 4.5]decan-9-il]etil}({2-[3-(trifluorom etil)fenil]etil})a mine
imagen146
- 647
-
[2-(3-metoxifenil)etil]({2-[(9R)-9-(pi ridin-2-il)-6-oxaspiro[4.5]decan-9-il ]etil})amina
imagen147
- 648
-
[2-(4-metilfenil)etil]({2-[(9R)-9-(piri din-2-il)-6-oxaspiro[4.5]decan-9-il] etil})amina
imagen148
- Compuesto
- Nombre Estructura
- 649
-
[2-(4-clorofenil)etil]({2-[(9R)-9-(piri din-2-il)-6-oxaspiro[4.5]decan-9-il] etil})amina
imagen149
- 650
-
[2-(4-bromofeny)etil({2-[(9R)-9-(piri din-2-il)-6-oxaspiro[4.5]decan-9-il] etil})amina
imagen150
- 651
-
[2-(4-fluorofenil)etil]({2-[(9R)-9-(piri din-2-il)-6-oxaspiro[4.5]decan-9-il] etil})amina
imagen151
- 652
-
{2-[(9R)-9-(piridin-2-il)-6-oxaspiro[ 4.5]decan-9-il]etil}({2-[4-(trifluorom etil)fenil]etil})a mine
imagen152
- 653
-
[2-(4-metoxifenil)etil]({2-[(9R)-9-(pi ridin-2-il)-6-oxaspiro[4.5]decan-9-il ]etil})amina
imagen153
- 654
-
[2-(2-metilfenil)etil]({2-[(9R)-9-(piri din-2-il)-6-oxaspiro[4.5]decan-9-il] etil})amina
imagen154
- 655
-
[2-(2-clorofenil)etil]({2-[(9R)-9-(piri din-2-il)-6-oxaspiro[4.5]decan-9-il] etil})amina
imagen155
- Compuesto
- Nombre Estructura
- 656
-
[2-(2-bromofenil)etil]({2-[(9R)-9-(pir idin-2-il)-6-oxaspiro[4.5]decan-9-il] etil})amina
imagen156
- 657
-
[2-(2-fluorofenil)etil]({2-[(9R)-9-(piri din-2-il)-6-oxaspiro[4.5]decan-9-il] etil})amina
imagen157
- 658
-
{2-[(9R)-9-(piridin-2-il)-6-oxaspiro[ 4.5]decan-9-il]etil}({2-[2-(trifluorom etil)fenil]etil})a mine
imagen158
- 659
-
[2-(2-metoxifenil)etil]({2-[(9R)-9-(pi ridin-2-il)-6-oxaspiro[4.5]decan-9-il ]etil})amina
imagen159
Ejemplo 15: Síntesis de [(3-metoxitiofen-2-il)metil]({2-[(9R)-9-(piridin-2-il)-6-oxaspiro[4.5]decan-9-il]etil})amina (Compuesto 140).
2-Ciano-2-[6-oxaspiro[4.5]decan-9-ilideno]acetato de metilo (mezcla de isómeros E y Z)
Una mezcla de 6-oxaspiro[4.5]decan-9-ona (13,74 g, 89,1 mmol), metilcianoacetato (9,4 ml, 106,9 mmol), acetato de amonio (1,79 g, 26,17 mmol) y ácido acético (1,02 ml, 17,8 mmol) en benceno (75 ml) se calentó a reflujo en un matraz de fondo redondo de 250 ml equipado con un Dean-Stark y un condensador de reflujo. Después de 3h, la TLC (25% de EtOAc en hexano, mancha de PMA) mostró que la reacción se había completado. Después de enfriar, se 10 agregó benceno (50 ml) y la capa se separó, el producto orgánico se lavó con agua (120 ml) y la capa acuosa se extrajo mediante CH2Cl2 (3 x 120 ml). El producto orgánico combinado se lavó con NaHCO3 saturado, salmuera, se secó y se concentró y el residuo se purificó mediante cromatografía instantánea (columna de gel de sílice de 340 g, elución mediante EtOAc en hexano: 5% de EtOAc, 2CV; 5-25%, 14CV; 25-40%,8 CV) lo que proporcionó una mezcla de isómeros E y Z: 2-ciano-2-[6-oxaspiro[4.5]decan-9-ilideno]acetato de metilo (se observó: 18,37 g, 87,8 % de
15 rendimiento, m/z 236,0 [M + H]+) como un aceite claro.
2-Ciano-2-[9-(piridin-2-il)-6-oxaspiro[4.5]decan-9-il]acetato de metilo
Claims (1)
-
imagen1 imagen2 imagen3 imagen4 imagen5 imagen6
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161466809P | 2011-03-23 | 2011-03-23 | |
US201161466809P | 2011-03-23 | ||
US201261596808P | 2012-02-09 | 2012-02-09 | |
US201261596808P | 2012-02-09 | ||
PCT/US2012/030327 WO2012129495A1 (en) | 2011-03-23 | 2012-03-23 | Opioid receptor ligands and methods of using and making same |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2632009T3 true ES2632009T3 (es) | 2017-09-07 |
Family
ID=46877853
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES17173483T Active ES2857549T3 (es) | 2011-03-23 | 2012-03-23 | Ligandos de receptores de opioides y métodos para utilizar y obtener los mismos |
ES12760456.9T Active ES2632009T3 (es) | 2011-03-23 | 2012-03-23 | Ligandos de receptores de opioides y métodos para utilizar y obtener los mismos |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES17173483T Active ES2857549T3 (es) | 2011-03-23 | 2012-03-23 | Ligandos de receptores de opioides y métodos para utilizar y obtener los mismos |
Country Status (22)
Country | Link |
---|---|
US (8) | US8835488B2 (es) |
EP (3) | EP2688403B1 (es) |
JP (6) | JP5912169B2 (es) |
KR (3) | KR101991326B1 (es) |
CN (1) | CN103702561B (es) |
AU (2) | AU2012230761B2 (es) |
CA (1) | CA2830742C (es) |
CY (1) | CY1119057T1 (es) |
DK (2) | DK2688403T3 (es) |
EA (1) | EA025456B1 (es) |
ES (2) | ES2857549T3 (es) |
HK (1) | HK1250984A1 (es) |
HR (1) | HRP20171021T1 (es) |
HU (2) | HUE054055T2 (es) |
IL (4) | IL228506A (es) |
LT (1) | LT2688403T (es) |
ME (1) | ME02754B (es) |
PL (2) | PL2688403T3 (es) |
PT (2) | PT3290415T (es) |
RS (1) | RS56111B1 (es) |
SI (1) | SI2688403T1 (es) |
WO (1) | WO2012129495A1 (es) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA025456B1 (ru) * | 2011-03-23 | 2016-12-30 | Тревена, Инк. | Лиганды опиоидных рецепторов и способы их применения и получения |
JP6205354B2 (ja) | 2011-07-06 | 2017-09-27 | ギリアード サイエンシーズ, インコーポレイテッド | Hivの処置のための化合物 |
TWI706945B (zh) | 2013-03-01 | 2020-10-11 | 美商基利科學股份有限公司 | 供治療反轉錄病毒科病毒感染之治療性化合物 |
US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
EP3350166A4 (en) | 2015-09-16 | 2019-05-01 | Metacrine, Inc. | FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF |
EP3350158A4 (en) | 2015-09-16 | 2019-05-08 | Metacrine, Inc. | X FARNESOID RECEPTOR AGONISTS AND USES THEREOF |
EP3350165B1 (en) | 2015-09-16 | 2023-07-26 | Organovo, Inc. | Farnesoid x receptor agonists and uses thereof |
EP3354649B1 (en) * | 2015-10-15 | 2019-12-04 | Jiangsu Hengrui Medicine Co., Ltd. | Oxa spiro derivative, preparation method therefor, and applications thereof in medicines |
CN106588899B (zh) * | 2015-10-15 | 2019-11-15 | 江苏恒瑞医药股份有限公司 | 吡啶基取代的6-氧杂螺[4.5]癸烷类衍生物、其制备方法及其在医药上的应用 |
JP6991993B2 (ja) * | 2015-12-14 | 2022-01-13 | トレベナ・インコーポレイテッド | 痛覚過敏を治療する方法 |
WO2017105881A1 (en) * | 2015-12-15 | 2017-06-22 | NeuForm Pharmaceuticals, Inc. | Deuterated compounds for treating pain |
AU2016370860A1 (en) * | 2015-12-17 | 2018-07-12 | Trevena, Inc. | Combinations of opioid receptor ligands and cytochrome P450 inhibitors |
CN107098876B (zh) * | 2016-02-23 | 2021-04-06 | 江苏恒瑞医药股份有限公司 | 苯基丙酰胺类衍生物、其制备方法及其在医药上的应用 |
WO2018006077A1 (en) | 2016-07-01 | 2018-01-04 | NeuForm Pharmaceuticals, Inc. | Deuterated compounds for treating pain |
KR102180740B1 (ko) | 2016-08-19 | 2020-11-20 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물 |
US20200010457A1 (en) * | 2016-12-16 | 2020-01-09 | Esteve Pharmaceuticals, S.A. | Tetrahydropyran and tetrahydrothiopyran amide derivatives having multimodal activity against pain |
WO2018152286A1 (en) * | 2017-02-17 | 2018-08-23 | Trevena, Inc. | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same |
BR112019016827A2 (pt) | 2017-02-17 | 2020-04-07 | Trevena Inc | compostos moduladores de receptor delta-opioide contendo aza-heterocíclico com 5 membros, métodos de uso e produção dos mesmos |
US10961198B2 (en) | 2017-03-15 | 2021-03-30 | Metacrine, Inc. | Farnesoid X receptor agonists and uses thereof |
IL269065B (en) | 2017-03-15 | 2022-09-01 | Metacrine Inc | Paranoid x receptor agonists and uses thereof |
CN108727347B (zh) * | 2017-04-14 | 2020-06-16 | 江苏恒瑞医药股份有限公司 | 一种阿片样物质受体(mor)激动剂的晶型及其制备方法 |
WO2018188641A1 (zh) * | 2017-04-14 | 2018-10-18 | 江苏恒瑞医药股份有限公司 | 一种mor激动剂与kor激动剂的药物组合物及其用途 |
RS61193B1 (sr) * | 2017-04-14 | 2021-01-29 | Jiangsu hengrui medicine co ltd | So agonista opijatnog receptora (mor), kristalni oblik i fumaratne soli iste i postupak za njihovo dobijanje |
CN115124520A (zh) * | 2017-07-04 | 2022-09-30 | 四川海思科制药有限公司 | 阿片受体激动剂及其应用 |
AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
AR112413A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas sólidas de un inhibidor de la cápside del vih |
EP3686198B1 (en) * | 2017-09-18 | 2022-12-14 | Shanghai Synergy Pharmaceutical Sciences Co., Ltd | Mu-opioid receptor agonist and preparation method therefor and use thereof in field of medicine |
CA3076395A1 (en) * | 2017-09-28 | 2019-04-04 | Jiangsu Hengrui Medicine Co., Ltd. | Method for preparing oxaspirocycle derivative, and intermediate thereof |
CN115093428B (zh) * | 2017-10-13 | 2023-09-22 | 山东绿叶制药有限公司 | 2,6-二氧杂螺[4,5]癸烷类衍生物、其制备方法及其在医药上的应用 |
US11471503B2 (en) | 2017-12-06 | 2022-10-18 | Jiangsu Hengrui Medicine Co., Ltd. | Use of KOR agonist in combination with MOR agonist in preparing drug for treating pain |
SG11202007422QA (en) | 2018-02-05 | 2020-09-29 | Alkermes Inc | Compounds for the treatment of pain |
CA3089590C (en) | 2018-02-15 | 2022-12-06 | Gilead Sciences, Inc. | Pyridine derivatives and their use for treating hiv infection |
AR114631A1 (es) | 2018-02-16 | 2020-09-30 | Gilead Sciences Inc | Métodos e intermedios para preparar compuestos de piridina |
WO2019205983A1 (zh) * | 2018-04-28 | 2019-10-31 | 四川科伦博泰生物医药股份有限公司 | 氧杂螺环类化合物及其制备方法和用途 |
TW202015678A (zh) * | 2018-05-14 | 2020-05-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種mor受體激動劑醫藥組成物 |
KR20210033492A (ko) | 2018-07-16 | 2021-03-26 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료를 위한 캡시드 억제제 |
MA53665A (fr) | 2018-09-18 | 2021-07-28 | Metacrine Inc | Agonistes du récepteur farnésoïde x et leurs utilisations |
CN112638906B (zh) * | 2018-10-12 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法 |
CN112638907B (zh) * | 2018-10-12 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法 |
WO2020147848A1 (zh) * | 2019-01-17 | 2020-07-23 | 上海海雁医药科技有限公司 | 三环取代的氧杂螺环衍生物、其制法与医药上的用途 |
CN111662284B (zh) * | 2019-03-06 | 2021-08-10 | 上海海雁医药科技有限公司 | 双杂环取代的氧杂螺环衍生物、其制法与医药上的用途 |
JP2023502530A (ja) | 2019-11-26 | 2023-01-24 | ギリアード サイエンシーズ, インコーポレイテッド | Hiv予防のためのカプシド阻害剤 |
AU2021208113B2 (en) | 2020-01-17 | 2023-11-30 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Azabicyclic substituted oxaspiro derivative, preparation method therefor and medical use thereof |
WO2021143803A1 (zh) | 2020-01-17 | 2021-07-22 | 上海海雁医药科技有限公司 | 光学纯的氧杂螺环取代的吡咯并吡唑衍生物、其制法与医药上的用途 |
CN113214264B (zh) * | 2020-01-21 | 2022-08-09 | 上海海雁医药科技有限公司 | 二氢吡咯并五元杂芳基取代的氧杂螺环衍生物、其制法与医药上的用途 |
WO2021262990A1 (en) | 2020-06-25 | 2021-12-30 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
EP4089088A4 (en) * | 2020-08-10 | 2023-09-13 | Chengdu Easton Biopharmaceuticals Co., Ltd. | MOR RECEPTOR AGONIST COMPOUND, METHOD FOR PREPARATION THEREOF AND USE THEREOF |
CN112694485B (zh) * | 2020-09-10 | 2023-04-07 | 四川海品信医药科技有限公司 | 一种阿片受体激动剂噻吩类化合物及其制备方法 |
EP4265604A1 (en) | 2020-12-29 | 2023-10-25 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd | Oxaspiro substituted pyrrolopyrazole derivative, intermediate thereof, and preparation method therefor |
EP4361154A1 (en) | 2021-07-13 | 2024-05-01 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Pharmaceutically acceptable salt of mor receptor agonist, and polymorph thereof and use thereof |
IL310506A (en) * | 2021-08-02 | 2024-03-01 | Shujing Biopharma Co Ltd | An oxaspiro derivative, a method for its preparation and use |
CN116075505A (zh) * | 2021-08-31 | 2023-05-05 | 天地恒一制药股份有限公司 | 阿片受体激动剂及其制备方法和用途 |
US11787825B2 (en) | 2021-12-03 | 2023-10-17 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
CN116041336A (zh) * | 2022-01-21 | 2023-05-02 | 成都苑东生物制药股份有限公司 | 一种6-氧杂螺[4,5]癸烷类化合物的新晶型、用途及其制备方法 |
CN116589451A (zh) * | 2022-02-11 | 2023-08-15 | 成都苑东生物制药股份有限公司 | 一种6-氧杂螺[4,5]癸烷类化合物的新晶型、用途及其制备方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5825980B2 (ja) | 1976-02-12 | 1983-05-31 | ヤマサ醤油株式会社 | サイクリックヌクレオチドの定量法 |
US4602035A (en) * | 1983-12-07 | 1986-07-22 | Hoechst-Roussel Pharmaceuticals Inc. | Antidepressant (3-aryl-2,3-dihydrobenzofuran-3-yl)alkylamines |
US5223530A (en) | 1990-07-31 | 1993-06-29 | Sri, International | Arylcycloalkanepolyalkylamine ligands |
US5401629A (en) | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
WO1996005166A1 (fr) * | 1994-08-11 | 1996-02-22 | Yamanouchi Pharmaceutical Co., Ltd. | Derive d'amine substitue et composition medicamenteuse le contenant |
DE69635048T2 (de) | 1995-06-12 | 2006-02-16 | G.D. Searle & Co. | Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor |
US6071918A (en) | 1999-07-21 | 2000-06-06 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
GB0130261D0 (en) * | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Lactams as tachykinin antagonists |
TW200307539A (en) * | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
CA2499690C (en) * | 2002-09-19 | 2011-05-24 | Eli Lilly And Company | Diaryl ethers as opioid receptor antagonist |
AU2004278414B2 (en) * | 2003-10-01 | 2012-05-24 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
US20100022637A1 (en) * | 2005-09-29 | 2010-01-28 | The Trustees Of Columbia University In The City Of New York | Identification of anti-cancer compounds and compounds for treating huntington's disease and methods of treatment thereof |
WO2007081966A2 (en) * | 2006-01-09 | 2007-07-19 | University Of Southern California | Small molecules for treating cancer and abnormal cell proliferation disorders |
US7645767B2 (en) | 2006-08-31 | 2010-01-12 | Trinity Laboratories, Inc. | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
US8067447B2 (en) * | 2006-11-01 | 2011-11-29 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
EP2099767A1 (en) * | 2006-11-01 | 2009-09-16 | Brystol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1, and/or nf- b activity and use thereof |
US20090028873A1 (en) | 2007-07-27 | 2009-01-29 | Auspex Pharmaceuticals, Inc. | Substituted cyclohexanols |
DK2260042T3 (da) * | 2008-03-27 | 2011-10-31 | Gruenenthal Gmbh | Substituerede spirocykliske cyklohexan-derivater |
FR2939136B1 (fr) * | 2008-12-02 | 2010-12-03 | Galderma Res & Dev | Nouveaux composes 4-(heterocycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique |
EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
FR2967672B1 (fr) * | 2010-11-22 | 2012-12-28 | Sanofi Aventis | Derives de nitrobenzothiazoles, leur preparation et leurs applications therapeutiques |
EA025456B1 (ru) * | 2011-03-23 | 2016-12-30 | Тревена, Инк. | Лиганды опиоидных рецепторов и способы их применения и получения |
JP6991993B2 (ja) | 2015-12-14 | 2022-01-13 | トレベナ・インコーポレイテッド | 痛覚過敏を治療する方法 |
-
2012
- 2012-03-23 EA EA201391332A patent/EA025456B1/ru unknown
- 2012-03-23 LT LTEP12760456.9T patent/LT2688403T/lt unknown
- 2012-03-23 ES ES17173483T patent/ES2857549T3/es active Active
- 2012-03-23 ES ES12760456.9T patent/ES2632009T3/es active Active
- 2012-03-23 DK DK12760456.9T patent/DK2688403T3/en active
- 2012-03-23 ME MEP-2017-129A patent/ME02754B/me unknown
- 2012-03-23 PT PT171734833T patent/PT3290415T/pt unknown
- 2012-03-23 PT PT127604569T patent/PT2688403T/pt unknown
- 2012-03-23 HU HUE17173483A patent/HUE054055T2/hu unknown
- 2012-03-23 EP EP12760456.9A patent/EP2688403B1/en active Active
- 2012-03-23 PL PL12760456T patent/PL2688403T3/pl unknown
- 2012-03-23 SI SI201231000T patent/SI2688403T1/sl unknown
- 2012-03-23 EP EP17173483.3A patent/EP3290415B1/en active Active
- 2012-03-23 AU AU2012230761A patent/AU2012230761B2/en active Active
- 2012-03-23 JP JP2014501273A patent/JP5912169B2/ja active Active
- 2012-03-23 WO PCT/US2012/030327 patent/WO2012129495A1/en active Application Filing
- 2012-03-23 CA CA2830742A patent/CA2830742C/en active Active
- 2012-03-23 KR KR1020187025108A patent/KR101991326B1/ko active IP Right Grant
- 2012-03-23 KR KR1020197016977A patent/KR102129247B1/ko active IP Right Grant
- 2012-03-23 PL PL17173483T patent/PL3290415T3/pl unknown
- 2012-03-23 HU HUE12760456A patent/HUE032948T2/en unknown
- 2012-03-23 US US13/428,849 patent/US8835488B2/en active Active
- 2012-03-23 EP EP20217112.0A patent/EP3872076A1/en active Pending
- 2012-03-23 CN CN201280021050.7A patent/CN103702561B/zh active Active
- 2012-03-23 DK DK17173483.3T patent/DK3290415T3/da active
- 2012-03-23 RS RS20170630A patent/RS56111B1/sr unknown
- 2012-03-23 KR KR1020137027288A patent/KR101991327B1/ko active IP Right Grant
-
2013
- 2013-08-12 US US13/964,505 patent/US9044469B2/en active Active
- 2013-09-17 IL IL228506A patent/IL228506A/en active IP Right Grant
-
2015
- 2015-05-15 US US14/712,974 patent/US9309234B2/en active Active
- 2015-12-27 IL IL243318A patent/IL243318B/en active IP Right Grant
-
2016
- 2016-03-30 JP JP2016067208A patent/JP6243949B2/ja active Active
- 2016-04-07 US US15/093,315 patent/US9642842B2/en active Active
-
2017
- 2017-02-03 AU AU2017200745A patent/AU2017200745B2/en active Active
- 2017-03-29 US US15/472,345 patent/US9849119B2/en active Active
- 2017-07-04 CY CY20171100716T patent/CY1119057T1/el unknown
- 2017-07-04 HR HRP20171021TT patent/HRP20171021T1/hr unknown
- 2017-11-09 JP JP2017216012A patent/JP6649341B2/ja active Active
- 2017-12-01 US US15/828,695 patent/US11077098B2/en active Active
-
2018
- 2018-08-14 HK HK18110440.5A patent/HK1250984A1/zh unknown
-
2019
- 2019-07-25 US US16/522,008 patent/US10588898B2/en active Active
-
2020
- 2020-01-15 JP JP2020004039A patent/JP6923683B2/ja active Active
- 2020-01-21 IL IL272165A patent/IL272165B/en unknown
-
2021
- 2021-06-27 IL IL284407A patent/IL284407B2/en unknown
- 2021-07-02 US US17/367,021 patent/US11931350B2/en active Active
- 2021-07-28 JP JP2021122940A patent/JP7248750B2/ja active Active
-
2023
- 2023-03-15 JP JP2023040218A patent/JP2023075282A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2632009T3 (es) | Ligandos de receptores de opioides y métodos para utilizar y obtener los mismos | |
ES2623491T3 (es) | Estimuladores de GCs | |
ES2572803T3 (es) | Estimuladores de GCs | |
ES2957383T3 (es) | Compuestos de piridazinona y usos de estos | |
ES2244231T3 (es) | Derivados de aminopirazol. | |
ES2958954T3 (es) | Compuestos de piridazinona y usos de los mismos | |
ES2609578T3 (es) | Amino-quinolinas como inhibidores de quinasa | |
KR20180094938A (ko) | 오피오이드 수용체 리간드와 시토크롬 p450 억제제의 결합 | |
AU2016372028B2 (en) | Methods of treating hyperalgesia | |
ES2899000T3 (es) | Benzamidas | |
BR112013021566B1 (pt) | composto, composição farmacêutica e uso de um composto de fórmula (i) | |
AU2020368392A1 (en) | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases | |
CN114375193B (zh) | 甲状腺激素受体β激动剂化合物 | |
WO2022216717A1 (en) | Citron kinase inhibitors |